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LIST of ABBREVIATIONS 
AEP auditory evoked potentials 
BIS bispectral index 
Ce effect-site concentration 
Ce50 effect-site concentration for 50% effect 
Cl clearance 
Cp plasma concentration 
EEG electro encephalography 
Emax maximal possible drug effect 
IQR interquartile range 
IV intravenous 
Ke0 effect-site concentration equilibration constant 
LBM lean body mass 
LOC loss of consciousness 
LORNC loss of respone to name calling 
MDAPE median of absolute values of performance errors 
MDPE median performance error 
NONMEM non linear mixed effects modeling 
OBJFN objective function 
PD pharmacodynamics 
PE performance/prediction error 
PK pharmacokinetics 
PWT population median weight 
ROC return of consciousness 
SD standard deviation 
SE standard error 
TCI target controlled infusion 
TIVA total intravenous anaesthesia 
TTPE time to peak effect 
ɀ steepness of the concentration-versus-response curve 
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CHAPTER 1 OUTLINE AND AIMS OF THE THESIS 
The goal of administering propofol as a hypnotic drug  is to obtain and maintain a desired time course of clinical and thera-
peutic effect as accurately as possible: e.g. loss of response to name calling (LORNC) or predefined bispectral index values 
(BIS).  The specific effect-site  drug concentrations  to evoke this effect, can be obtained through different dosing regimens.
The key question remains which dosing regimen provides optimal control of the time course of the effect of  propofol.  
Standard dosing guidelines ignore the large inter-individual variability in dose-response relationship. Pharmacokinetic-
pharmacodynamic (PK-PD) models used in TCI (target controlled infusion) systems reduce this variability by incorporating 
different co-variates but still model inaccuracy limits universal application of a specified PK-PD model. This thesis discusses
several sources of model inaccuracy. 
The dose-response relationship can be divided into three parts. The first part involves the relationship between the adminis-
tered dose and the plasma concentration (pharmacokinetics) and the second part the relationship between plasma or effect 
site concentration and clinical effect (pharmacodynamics). The final part is the coupling between PK and PD. Additionally, 
it is important to recognize that these relationships are subject to population variability. It has been proven that incorporating 
PK-PD information as an additional input to guide clinical anaesthesia can result in better patient care
1-8
. As such, it is im-
portant that anaesthetists learn and understand basic anaesthetic pharmacological principles and apply the available pharma-
cology-based technology into their daily clinical practice
9
.
Optimized patient-individual dosing may be achieved by the application of pharmacokinetic and pharmacodynamic models 
with real-time estimation of the dose-response relationship online. For intravenous anesthetics such as propofol, target-
controlled infusion (TCI) techniques based on compartmental models have been developed and are used frequently in daily 
clinical practice. A target controlled infusion (TCI) aims to achieve a user-GHILQHGGUXJFRQFHQWUDWLRQLQD³ERG\FRPSDUt-
PHQW´RILQWHUHVWXVLQJDFRPSXWHURUPLFURSURFHVVRU7KHVHV\VWHPVXVHPXOWL-compartmental PK-PD models to calculate 
the infusion rates required to achieve the specific target concentration. A clinician using a TCI system to administer an intra-
YHQRXVK\SQRWLFLVWKXVDEOHWRVHWDGHVLUHG³WDUJHW´GUXJFRQFHQWUDWLRQDQGWKHQDGMXVWLWEDVHGRQFOLQLFDOUHVSRQVHRU
measurements of drug effect. A computer or microprocessor performs the complex calculations, and controls the infusion 
pump. Classically, plasma or effect-site concentrations are targeted
10
 .
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The development of target-controlled infusion (TCI) technology, has enabled clinicians to  manage more pre-
cisely the complex relationship between dose, blood-concentration, effect-site concentration and clinical effect. 
One of the most important components of TCI is an accurate PK-PD model  describing the time course of drug 
plasma concentration and effect-site concentration. The search for the optimal PK-PD model has a long stand-
ing history and is continuously developing. Investigators are still searching for the optimal PK-PD model pre-
dicting the time course of propofol concentrations and hence hypnotic effect.  
This thesis aims at guiding the clinician who makes  use of target ±controlled infusion (TCI) in daily clinical 
practice through different PK-PD models. The choice of  the model is crucial as an inaccurate model choice can 
result in a lack of effect or too much effect. However, (possible known) various sources of modeling inaccura-
cies may bias the TCI concept and may therefore be relevant for clinical practice. As these are not well docu-
mented in the literature we aimed to investigate the impact of these inaccuracies. 
1) We hypothesized that especially during the first minutes following bolus administration of propofol the pre-
diction error using three compartmental PK models may be large. Due to failure to describe the very early drug 
distribution in the central compartment: the mixing within the vascular volume, blood flow and subsequently 
the distribution of the drug to both active and inactive tissues. We tested the hypothesis that different injection 
rates of propofol correspond with different ke0¶V ,QLWLDOO\HVWLPDWHGEORRGFRQFHQWUDtions were used, in a se-
cond stage we performed frequent arterial blood sampling (and measure propofol concentrations) during the 
first minutes following propofol bolus administration.  
2) We hypothesized that available PK-PD models for propofol would be able to accurately estimate the effect-
site concentration of propofol at loss-of-consciousness and consequently that the effect would remain stable 
once this concentration is maintained. We tested this hypothesis comparing clinically applied compartmental 
PK-PD models for propofol. 
3) We hypothesized that the estimation of the PD model, using published PK models, does not ensure accurate 
estimates for PK and PD parameters. An accurate estimation of ke0, linking the kinetic and dynamic model, 
demands an integrated PK-PD study, combining measurement of blood concentrations and drug effect which 
are then used to construct a PK-PD model within the same specific population. This results in an overall model 
describing the dose-response behavior of the drug, with an accurate estimation of the ke0. We tested this hy-
pothesis by constructing a PK-PD model in a pediatric patient-population based on measured blood concentra-
tions and BIS values. In a second step we used published PK models to re-estimate the PD model. We tested 
the hypothesis that these predicted PK parameters would be able to identify the best-performing PK model and 
to provide accurate estimations for the true PD parameters. 
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CHAPTER 2 BASIC PRINCIPLES AND REVIEW OF THE LITERATURE
 
2.1. Controlling  the dose-response relationship 
The main drugs used to provide general anaesthesia are hypnotics, analgesics and muscle relaxants. These 
drugs induce unconsciousness, analgesia, suppression of the hemodynamic response and suppression of reflex 
movements
11
. This thesis will focus mainly on pharmacological properties of propofol as the hypnotic compo-
nent of anaesthesia.  
Controlling the time course and the degree of hypnotic drug effect is a very important goal in anaesthetic prac-
tice. The patient should loose consciousness rapidly during induction and the level of consciousness should be 
easily titrated to the level of surgical stimulation.  
2QWKHRQHKDQGXQGHUGRVLQJWKHK\SQRWLFFRPSRQHQWRIDQDHVWKHVLDPLJKWUHVXOWLQµDZDUHQHVV¶RUDQDFFi-
dental awakening
12-14
 of the patient during surgery, which is a very distressing event for both the patient and 
anaesthetist and is to be absolutely avoided.  
On the other hand, excessive doses of hypnotic will increase the incidence and the degree of side effects and 
possibly accounts for long-term morbidity and mortality
15
.
Once the surgical procedure is finished the drug effect should dissipate so that the patient wakes up as rapidly 
as possible. From this moment on any residual hypnotic or sedative effect is deemed as µDGYHUVHHIIHFW¶ WKDW
delays early recovery and transit times from high dependency to low care units. In ambulatory anaesthesia any 
UHVLGXDOVHGDWLRQLVXQZDQWHGDVLWQHJDWLYHO\LQIOXHQFHVµKRPH-UHDGLQHVV¶16 (Table 1).  
Optimal patient-individual dosing may be achieved by the application of pharmacokinetic-pharmacodynamic 
principles. Using the dose-response relationship, drug titration should be done as close as possible to the drug 
effect. Titrating a specific effect or, if not possible, a specific effect-site concentration offers advantages. As the 
effect-site or plasma concentrations are not continuously measurable on-line for most intravenous drugs used 
during anaesthesia (in contrast to inhaled anaesthetics
17-19
), it requires a pharmacokinetic and/or pharmacody-
namic drug model and a computer continuously updating the administration rate to maintain an estimated drug 
effect or drug concentration. If a specific plasma or effect-site concentration is titrated, this technique is called 
target-controlled infusion (TCI). TCI is an infusion controlled in such a manner as to achieve a user-defined 
estimated drug concentration in a body compartment or tissue of interest. A clinician using a TCI system to 
administer an anaesthetic agent is thus able to set and adjust a desired drug concentration, usually referred to as 
WKH³WDUJHWFRQFHQWUDWLRQ´EDVHGRQFOLQLFDOREVHUYDWLRQRI WKHSDWLHQWRUPHDVXUHPHQWRIGUXJHIIHFW0XOWL-
compartmental pharmacokinetic-dynamic models are used by TCI systems to calculate the infusion rates re-
10
  
quired to achieve the target concentration. A computer or microprocessor is required to perform the complex 
calculations, and to control the infusion pump. Classically, plasma or effect-site concentrations are targeted. 
When the effect-site is targeted, the classical multi-compartmental pharmacokinetic model has to be extended 
with an effect-site compartment.  
In experimental conditions it is already possible to quantitate expiratory propofol concentrations. These tech-
niques range from discontinuous techniques to fast and very fast analysing techniques. As these very fast tech-
niques result in analytical times within seconds to milliseconds, on-line detection of expiratory propofol con-
centration will possibly become available in the future. Several authors have shown good correlation between 
propofol concentration in the brain, blood and exhaled breath.
20-23
 
Advantages and disadvantages of Total Intravenous Anesthesia with propofol 
Advantages  Disadvantages  
Induction is very rapid in onset Pain during injection of propofol 
Rapid onset of action independent from alveolar 
ventilation
Need sophisticated infusion pumps with algorithms 
for the TCI software 
Improved quality of emergence from anesthesia Greater pharmacokinetic and pharmacodynamic 
interindividual variability 
Very smooth and peaceful recovery Difficult to estimate blood concentration of propofol 
in real time at the moment 
No risk of environmental pollution Propofol infusion syndrome  
Reduction in the incidence of postoperative nausea 
and vomiting 
Method of choice in patients at risk of malignant 
hyperthermia 
Method of choice in some patients with congenital 
myopathies 
Can be reliably administered to maintain anesthesia 
in patients undergoing airway procedures 
Table 1. Advantages and disadvantages of TIVA with propofol 
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2.2 Developing  a compartmental kinetic model for TCI.   
‘Like paintings pharmacokinetic models range from the completely abstract to the naturalistic.’
24
In order to target a specific plasma concentration of propofol one must know what happens when a specific 
amount of drug is administered to a patient in a specific time frame. For this, one needs pharmacokinetics de-
scribing the time course of the plasma concentration, or stated otherwise  “what does the body with the drug ?” 
Typically a bolus or short-lasting infusion can be given and than blood samples are taken to describe the time 
course of the plasma concentration. With this information one can try to predict what will probably be the 
plasma concentration when  a certain amount of propofol is injected.  
If the human body was one single compartment, it would be easy to describe the time course of the concentra-
tion of a hypothetical drug. A basic assumption of the concept of a one-compartment representation of distribu-
tion is that equilibration of drug between tissues and blood occurs spontaneously and immediately. Knowing 
the volume of that compartment would enable us to know the concentration of a given amount (dose) of a spe-
cific drug (equation 1). 
࡯૙ ൌ 
࢞૙
ࢂ
         equation 1 
Where C0 is the concentration at time 0, x0 is the initial dose of drug, V is the volume of the compartment. 
The clearance of a drug is typically a first-order process. The rate of change for a first-order process is : 
ࢊ࢞
ࢊ࢚
ൌ െ࢑Ǥ ࢞         equation 2 
x is the amount of drug,  k is the rate constant for drug elimination, the unit of k is time
-1
.
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If  a value of x at time t is needed, x(t), it can be found as: 
x(t)=x0.e
-kt
        equation 3 
x0 is the amount of drug concentration at t=t0 or the initial dose,   x(t) is the amount of drug  at time t, 
by using equation 1 the plasma concentration can be found as: 
 
C(t)= C0 . e
 -kt
        equation 4 
 
 
However in reality drug distributes from the plasma to different groups of tissues, a process that takes time. A 
multi-compartmental model is needed to describe this phenomenon. The time required for distribution depends 
on tissue perfusion, permeability characteristics of tissue membranes for the drug, lipid solubility and its parti-
tioning between tissues and blood. The drug is also distributed to eliminating organs, so clearance starts imme-
diately.
When the anaesthetist injects a given amount of drug, e.g. propofol, the drug will initially dilute in a certain 
volume, the central volume of distribution (V1 or Vc) (fig1). This volume reflects the volume of the heart, great 
vessels and the venous volume of the upper arm. The drug passes through the lungs and eventually meets the 
arterial circulation. Immediately however propofol fades to peripheral tissues away from the plasma. Two 
groups of tissues, compartments, receive propofol from the central volume of distribution.  
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Fig 1 A three compartmental pharmacokinetic model. The drug is administered in the central compartment (small container in the 
middle), from which it is eliminated and distributed to a rapid equilibrating peripheral compartment (right hand container) and a 
slow equilibrating peripheral compartment (left hand, largest container). In the y axis the log (plasma concentration) is plotted
against time in the x axis. Figure from S. Shafer25
2QHJURXSRIWLVVXHVWKHµYHVVHOULFKJURXS¶RULJLQDOO\UHFHLYHVDORWRISURSRIROIURPWKHFHQWUDOFRPSDUWPHQW
and hence is called the second compartment (V2) and  rapidly equilibrates with the central volume.  
7KHGUXJHYHQWXDOO\PRYHVWRDQRWKHUJURXSRIWLVVXHVWKHµYHVVHOSRRU¶JURXSFKDUDFWHUL]HGE\DVORZHTXLOi-
EUDWLRQZLWKWKHFHQWUDOYROXPHWKHµLQIORZ¶RISURSRIROLQWKLVWKLUGFRPSDUWPHQW93) is much slower.  
The volumes and equilibration constants of a three-compartmental pharmacokinetic (PK) model can be esti-
mated by administering an amount of propofol in a standardized population. Subsequently  blood samples are 
drawn at specific time-points for measuring propofol plasma concentrations. The results are depicted in a log 
(plasma concentration) over time graph. Three distinct phases can be distinguished (fig1). The initial distribu-
tion phase following bolus injection describes distribution from plasma to the rapidly equilibrating tissues. A 
slower second distribution phase is explained by a movement of the drug into more slowly equilibrating tissues 
and a return of the drug from the most rapidly equilibrating tissue. The terminal phase is a straight line when 
plotted on a semi logarithmic graph and  is often called the elimination phase because the primary mechanism 
for decreasing drug concentration during the terminal phase is elimination from the body. 
The rates of drug metabolism and distribution can be interchangeably described by rate constants or clearances.  
A rate constant describes a proportion of drug in a compartment undergoing a process during a unit of time, and 
14
  
is thus reported with the units min
-1
 or hr
-1
. By convention k10 is used to denote the rate constant for metabo-
lism or elimination. The symbols k12, k21, k13, k31 are used to denote the rate constants for drug transfer from V1
to V2, from V2 back to V1, from V1 to V3, and from V3 back to V1 respectively.
Clearances describe a YROXPHRIDFRPSDUWPHQWWKDWLVµFOHDUHG¶IURPGUXJGXULQJDXQLWRIWLPH7KHXQLWV
are thus ml/min or ml/hr. 
For a three-compartmental model it is more difficult to calculate the inter-compartmental rate constants. Anal-
ogous to equation 2 and 3 the equations for a three-compartmental model are: 
dx1/dt = I ± dx2/dt ± dx3/dt ± x1k10     equation 5
dx2/dt = x1k12 ± x2k21        equation 6 
dx3/dt = x1k13 ± x3k31 equation 7
Integration of equations 6 and 7 in equation 5 and rearrangement yields equation 8 
dx1/dt = I + x2k21 + x3k31 ± x1k10 - x1k12 - x1k13   equation 8 
  
Where I is the rate of drug input, x is the amount of drug for a specific compartment and k is a micro-rate con-
stant
The dataset gives rise to a pharmacokinetic model, a mathematical fitting of measured concentrations. The 
model not only describes the time course of drug concentration in a studied population but subsequently it can 
be used to predict the blood concentration profile of a drug after a bolus dose or an infusion of varying duration 
in a subject that corresponds to the typical patient of the original study population.  
We developed our own pharmacokinetic model for propofol in children
26
. In this example (table 2) V1  is the 
central volume for propofol in a 20 kg child. V2 and V3 are the volumes of the second and third compartment. 
Cl is the elimination clearance, the amount of the central volume that is cleared from propofol per min. Q2 is an 
intercompartmental clearance, the amount of V2 that is cleared from propofol per min. Q3  is the amount of V3
that is cleared from propofol per min. 
15
  
Table 2 The Coppens PK model for propofol as an example. Values are calculated for a 20 kg child 
Parameter Units Typical value 
V1 L 3,5 
V2 L 4,7 
V3 L 19 
Cl l * min
-1
 0,79 
Q2 l * min
-1
2
Q3 l * min-1 0,67 
16
  
Fig 2  BIS Range guidelines. as included in the user guide of BIS XP® (Aspect Medical, MA, USA) 
 
2.3  Measuring cerebral drug effect as a pharmacodynamic end-point 
The hypnotic effect of propofol can be measured with bispectral index monitoring (BIS)
27,28
. BIS measures a 
selected part of a classical EEG signal that is highly associated with sedation/hypnosis, regardless of which 
type of agent is used to produce that clinical state.  BIS index is a processed EEG parameter derived from mul-
tiple advanced signal processing techniques.  The BIS algorithm provides a reliable processed EEG parameter 
of anaesthetic and sedative effect
29-31
. BIS generates a figure from 0 to 100. The awake patient typically has a 
BIS CLINICAL ENDPOINTS & 
SEDATION RANGES 
CLINICAL SITUATION 
100 ---------- AWAKE -------------------------------------- ------------------------------------------------
Sedated

- Awake or resting state 
- Sedated for special  procedures; conscious 
sedation
- Response to vigorous stimulation during 
surgery
- Emergence from general anesthesia 
----------------- LIGHT HYPNOTIC EFFECTS--------- 
Very Low Probability of Recall 

-----------------------------------------------
- Short surgical procedures requiring deep 
sedation or light anesthesia 
- Results from a multi-center study demon-
strated when the BIS was below 70 there 
was very low probability of recall
------------------ MODERATE HYPNOTIC EFFECTS- 
Unconscious

-----------------------------------------------
- Maintenance range during general surgi-
cal procedures 
- Results from a multi-center study demon-
strated when the BIS was below 60 subjects 
were unconscious
40------------ DEEP HYPNOTIC EFFECTS----------- 

-----------------------------------------------
- High dose opioid anesthesia 
- Surgical procedures where deep anesthe-
sia is required 
- Barbiturate coma 
- Profound hypothermia
0 ----------- EEG SUPPRESSION---------------------- ------------------------------------------------
70
60
17
  
BIS value of 100. The value drops as the patient falls asleep. BIS values between 60 and 40 are associated with 
an appropriate anaesthetic level. Values lower than 40 are deemed as a too deep level of anaesthesia (fig 2). 
Anesthetic depth is the result of hypnosis, amnesia, anti-nociception and reflex suppression. Soon after BIS 
monitoring was developed many studies appeared in the literature to validate the technique. Correlation studies 
try to link depth of anesthesia to specific BIS values. Sebel et al.
32
 performed a multicenter trial where two 
groups of patients were included; in the control group patients were only monitored with BIS, in the treatment 
group anesthesia was titrated to a BIS value below 60. Primary endpoint of the study was the rate of patient 
movement as response to skin incision. In the control group, the mean BIS value was 66 (±19) and 43% of 
patients moved. In the treatment group the mean BIS value was 51 ±19 and only 13% of patients moved on 
skin incision. Movement on skin incision is a very rudimentary surrogate of depth of anesthesia. So other au-
thors tried to correlate BIS values with levels of consciousness.  
With increasing sedation
33
 there was a progressive decrease in BIS during sedation with midazolam; Observ-
HU¶VDVVHVVPHQWRIDOHUWQHVVDQGVHGDWLRQVFRUHV2$$62ZHUHFRUUHODWHGWR%,6YDOXHVOAAS/O scores of 5 
mean an awake state. OAAS/O of 1 means no response to tactile stimulation. OAAS/O scores of 5 correlated to 
BIS values of 95.4 ±2.3, scores of 4 to BIS values of 90.3 ±4.5, scores of 3 to BIS values of 86.6 ±4.6,scores of 
2 to BIS values of 75.6 ±9.7 and an OAAS/O score of 1 corresponded with BIS values of 69.2 ±13. During 
recovery from midazolam sedation BIS values increased together with OAAS/O scores.  
34
 compared measured propofol concentrations with BIS in volunteers. The mean propofol concen-
tration to suppress learning by 50% was 0.66 µg/ml. BIS decreased linearly as propofol blood concentration 
increased. (r=0.69). Doi et al
35
 also found a good correlation of BIS values with propofol blood concentrations. 
2WKHUVWXGLHVXVHGWRYDOLGDWHµ'HSWKRI$QHVWKHVLD¶PRQLWRUVORRNDWUHFRYHU\WLPHV$PXOWLFHQWHUUDQGRm-
ized trial
36
 (302 patients) studied patients under routine care versus patients guided under BIS monitoring. BIS 
monitoring led to a reduction in propofol requirements and earlier recovery. A meta-analysis of trials
37
 (1383 
day surgery patients) concluded that use of BIS monitoring significantly reduced anaesthetic consumption by 
19%, reduced the incidence of nausea and vomiting by 23%, and reduced recovery time by 4 min.  
A third kind of studies look at WKHDELOLW\RIµ'HSWKRI$QHVWKHVLD¶PRQLWRUVWRSUHYHQWPHPRU\IRUPDWLRQRU
awareness during anesthesia. For most anesthetists this remains a major objective. Ekman et al
38
. did a before 
and after comparison of the use of BIS monitoring (4945 patients undergoing general anesthesia with muscle 
relaxation, BIS monitored versus 7826 patients not BIS monitored). They found a 5-fold reduction in risk of 
awareness, 0.04% vs 0.18%. Myles et al
39
. found a reduced risk of awareness by 82% in a study of 2643 adult 
patients at high risk of awareness. However in an effectiveness study
40
 (three hospitals, 21.601 patients) no 
significant difference in intraoperative awareness with explicit recall was detected between bispectral index and 
anesthetic concentration protocols. It concerned an unselected surgical population.  
A Cochrane analysis
41
 included 31 trials. In studies using clinical signs as control, the analysis demonstrates a 
significant effect of the BIS-guided anaesthesia: a risk reduction of intraoperative recall, a risk reduction of 
18
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awareness among surgical patients with high risk of awareness (2493 participants; OR 0.24). This effect was 
not demonstrated in studies using end tidal anaesthetic gas monitoring as standard practice (1981 participants; 
OR 1.01). BIS-guided anaesthesia reduced the requirement for propofol by 1.44 mg/kg/hr (662 participants), 
and for volatile anaesthetics (desflurane, sevoflurane, isoflurane) by 0.14 minimal alveolarconcentration equiv-
alents (MAC) in 928 participants. Irrespective of the anaesthetics used, BIS reduced the following recovery 
times: time for eye opening (2446 participants; by 2.14 min), response to verbal command (777 participants; by 
2.73 min), time to extubation (1488 participants; by 2.87 min) and orientation (316 participants; by 2.57 min). 
BIS shortened the duration of postanaesthesia care unit stay by 7.63 min in 1940 participants. 
2.4   Linking kinetics and dynamics using the concept of the effect-site concentration : 
 
The standard pharmacokinetic model assumes that after bolus injection there is a complete mixing within the 
central compartment resulting in the peak plasma concentration occurring at time 0. Following bolus admin-
istration it takes 30 to 45 seconds for the drug to pass from the venous circulation to the arterial site.  
However a hypnotic drug like propofol does not exert its effect in the arterial circulation. Propofol exerts its 
effect in the brain and so additional time is required for the drug to reach the target organ, penetrate the tissue 
and induce an intracellular process which will lead to the onset of drug effect (i.e. unconsciousness). This delay 
between peak plasma concentration and peak concentration in the brain is called hysteresis (fig 3). 
The concentration of propofol in the brain can not be measured in every day clinical practice. In experimental 
conditions microdialysis techniques can be used when brain tissue becomes or is made accessible. 
Microdialysis probes measure free drug concentrations, which from a pharmacodynamic point of view is the 
concentration surrounding receptors
42
.
However we can measure the hypnotic effect of propofol, and hence the time course of drug effect can be char-
acterized. Knowing the time course of drug effect, the apparent rate of drug inflow into and from the effect site 
can be characterized. The time course of drug effect is a reflection of the time course of the effect site concen-
tration.
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Fig 3 Hysteresis. The anaesthetic effect is measured continuously. Estimated effect-site concentration, Ce  is calculated from the 
estimated plasma concentration and different ke0¶V:LWKDNe0 of 0.38 min-1 there is a collapse of the hysteresis loop.  Figure from 
Absalom et al43
The effect site
44,45
 is the hypothetical compartment that mathematically links the time course of plasma drug 
concentration to the time course of drug effect and ke0 is the rate constant of drug elimination from the effect 
site (fig 4). The ke0 defines the proportional change in each unit of time of the concentration gradient between 
plasma and effect-site. The effect-site compartment is assumed to have negligible volume. Hence uptake of 
drug into the effect-site should have negligible influence on the plasma concentration of a drug, so that the 
calculated plasma concentration profile following an infusion of drug is identical for any value of ke0.
 
Fig 4. A three compartmental pharmacokinetic-pharmacodynamic model extended with an effect-site compartment. Figure from 
Mani46
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An accurate estimation of ke0 demands an integrated pharmacokinetic-dynamic study combining blood sam-
pling with frequent measurement of drug effect, resulting in an overall model for the dose response behavior of 
the drug. 
Mathematically the effect-site concentration is the convolution of an input function (in this case, the plasma 
concentration over time) and the disposition function of the effect-site.  
Ceffect-site(t)=Cplasma(t) * Deffect-site(t)     equation 9 
The disposition function of the biophase is typically modeled as a single exponential decay: 
Deffect-site(t)=ke0 e
-ke0t
        equation 10
The mono-exponential disposition function is simply an additional compartment that is connected to the central 
compartment. 
We cannot measure directly the Ceffect-site or Deffect-site but we can measure the drug effect. Knowing that the 
observed drug effect is a function of the drug concentration in the effect-site, it is possible to predict the drug 
effect as: 
Effect=fPD (Cplasma(t)*Deffect-site(t), PPD, ke0)     equation 11 
Where fPD is a pharmacodynamic model (typically sigmoidal in shape), PPD represents the parameters of the 
pharmacodynamic (PD) model and ke0 is the rate constant for equilibration between plasma and the effect-site. 
Nonlinear regression programs are used to link values of PPD and ke0 that best predicts the time course of drug 
effect. This method is called loop collapsing (fig 5). 
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If no integrated pharmacokinetic-dynamic model exists, the time to peak effect after a bolus injection can be 
used to recalculate ke0 using the pharmacokinetic model to yield the correct time to peak effect. After a 
propofol bolus there is a rapid increase in plasma concentration followed by a tri-exponential decline. As long 
as the plasma concentration of propofol is greater than the concentration in the effect-site, the effect-site con-
centration increases. After a bolus dose the maximum effect site concentrations occurs at the point where the 
plasma and effect-site concentration curves cross (fig 6). As the hypnotic effect of propofol is determined by 
the effect-site concentration, the time delay between a bolus dose injection and the time at which the plasma 
and effect-VLWHFRQFHQWUDWLRQVLQWHUVHFWVLVUHIHUUHGWRDVµWKHWLPHWRSHDNHIIHFW¶ (TTPE).  
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Fig 5 : Hysteresis loop collapsing: broken lines represent calculated effect-site concentrations, circles are observed measures of 
effect, full lines are plasma concentrations, an effect-site concentration vs effect hysteresis loop is generated by plotting each 
observed effect against the effect-site concentration predicted for the same time and connecting these points (by line segments) in 
time order; an effect versus effect ±site concentration curve is obtained for the trial ke0. The final ke0 estimate is the value that best 
collapses the hysteresis loop in the effect versus effect-site concentration curve with superimposition of both limbs of the curve. 
Figure from Bührer47
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Constructing curves for estimated effect-site concentrations with different ke0 and comparing them with the 
curve for the measured effect allows to choose the ke0 value that best predicts the time course of effect.
Fig 6  Estimation of ke0  using TTPE methodology. Estimated plasma concentrations and a measure of anaesthetic effect are plot-
ted over time. The estimated effect-site concentrations resulting from different ke0 values are then calculated and plotted, to de-
termine which ke0  value is associated with a peak effect-site concentration that matches the peak clinical effect. Figure from 
Absalom43
When targeting the effect site, the TCI system manipulates the plasma concentration to achieve the effect-site 
concentration as rapidly as possible, but without an overshoot at this effect-site level. The magnitude of the 
plasma concentration overshoot estimated by the system depends critically on the ke0 and also on the estimated 
rate of decline in the plasma concentration. If a slower ke0 is used, a greater overshoot in the peak plasma con-
centration will be required to produce a larger concentration gradient between the blood and effect-site and 
thereby to hasten plasma-effect-site equilibration.(Fig 7) 
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Fig 7  Effect-site targeted TCI for propofol (Marsh model), showing the effect of the choice of ke0. If a slow ke0 is used, then a 
large overshoot in plasma concentration will result when the target concentration is increased. Figure from Absalom43
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2.5   Non Linear Mixed Effects Modeling 
Basically this thesis handles the time course of propofol concentrations in plasma or effect site in different 
study populations. Also the nature and magnitude of drug effect in relation to the concentration is being inves-
tigated.
Classical pharmacology tends to describe the dose-response relationship in a group of patients without taking 
into account the intra-individual and/or inter-individual physiological and pharmacological variation. Starting 
from measured plasma concentrations, data are pooled together as if all doses and all observations describe a 
VLQJOHVXEMHFW7KLVUHVXOWVLQµDYHUDJH¶VWDWLVWLFVZLWKPHDQYDOXHDQGVWDQGDUGHUURUV(TXDOZHLJKWLVDVVLJQHG
to every individual subject; sample values from significant outliers will have a significant effect on one or more 
of the average parameters in the final model. This approach suggests  that many samples are taken in a large 
study population. 
Population pharmacokinetics study the variability in drug concentrations among individuals who are the target 
patient population receiving clinically relevant doses of a drug of interest. Certain patient demographics (e.g. 
body weight, gender, height, hair color
48
 (!?)«SK\VLRORJLFDOfunctions (e.g. cardiac output, liver and kidney 
IXQFWLRQ« WKHUDSHXWLF IHDWXUHV DQG WKH SUHVHQFH RI RWKHU WKHUDSLHV FDQ UHJXODUO\ DOWHU GRVH-concentration 
relationships.
An advantage of population pharmacokinetic modeling is its ability to analyze sparse data sets (sometimes only 
one concentration measurement per patient is available). Basically, there are two approaches to population 
modeling, defined as the standard two stage approach and the non-linear mixed effect approach.  
In the standard two stage approach, as a first step, the individual concentration-time profile is appreciated to 
generate parameters as volumes and clearances.  In a second step, these parameters are summarized by calculat-
ing the mean, median and the variability between subjects (SE or IQR). A major drawback of this approach is 
that it requires a relatively high number of samples in each individual, while each patient has to contribute 
roughly the same number of samples. Moreover it is more difficult to distinguish between inter-individual (var-
iability between subjects) and intra-individual or residual variability (variability within one subject, measure-
ment error and model misspecification) and as a result inter-individual variability is often overestimated.  
The population approach using non-linear mixed effects modeling to obtain pharmacokinetic parameters is the 
preferred approach, because the analysis is based on simultaneous analysis of all data of the entire population 
while still taking into account that different observations come from different patients
49
. Both the inter-
individual and intra-individual variability are separately estimated in the dataset using this approach. The term 
µPL[HG¶LQQRQ-linear mixed effects modeling represents a mixture of fixed and random effects. For the fixed 
effects, a structural model describing the PK or PD is chosen (eg a three compartmental model for PK or an 
Emax model for PD). The random effects quantify the variability that is not explained by the fixed effects. These 
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random effects include inter-subject and intra-subject random variability, which are both simultaneously and 
separately estimated.  
In general model building requires three different steps: 
A structural model (fixed effects) has to be designed 
A  statistical sub-model (random effects) has to be developed 
A covariate sub-model has to be identified 
 
Fixed effects 
The structural model contains descriptors of a process (disposition of propofol in the body, elimination, clear-
ance, volume of distribution ) (e.g. a three compartmental model for PK or an Emax model for PD) that vary 
among individuals. The population values for these parameters are called typical values and are expressed as 
ș¶V7KHNQRZQREVHUYDEOHSURSHUWLHVRI individuals that cause these parameters to vary across the population 
DUHFDOOHGµIL[HG¶HIIHFWVRUFRYDULDWHV&RYDULDWHVDUHVSHFLILFSUHGLFWRUVRI3.DQG3'YDULDELOLW\ZLWKLQWKH
population. Covariates can be demographic (age, body weight, gender), pathophysiological (renal or hepatic 
function) and genetic/environmental.  For example, if we know that clearance is proportional to weight, then 
we simply express clearance in the model as a scalar times weight. Weight has a fixed effect on clearance. 
Random effects 
After selecting the structural model, the statistical sub-model, which accounts for the inter-individual as well as 
the residual variability is chosen and tested. The random effects quantify the variability that is not explained by 
the fixed efIHFWV7KHVHHIIHFWVDUHFDOOHGµUDQGRP¶EHFDXVHWKH\FDQQRWEHSUHGLFWHGLQDQ\ZD\7KHUHDUHWZR
sources of random variability when dealing with biological data. 
One kind of random effects is the unexplained differences between individuals. This is called inter-individual 
or between subject variability. It is often assumed that the variability between subjects follows a normal distri-
EXWLRQZLWKDPHDQRI]HURDQGYDULDQFHȦ
șI șTV  . eȘi         equation 12
:KHUHși LVWKHSDUDPHWHUYDOXHLQWKHLWKSDWLHQWșTV is the typical value of the parameter in the population and 
Și LVDUDQGRPYDULDEOHLQWKHLWKSDWLHQWZLWKDPHDQRI]HURDQGDYDULDQFHRIȦ2.
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The second source of variability is the residual error RUµQRLVH¶ This is the difference between the prediction of 
WKHPRGHO IRU WKH LQGLYLGXDODQG WKHPHDVXUHGREVHUYDWLRQ7KLV LVFDOOHG µLQWUD-LQGLYLGXDO¶RUwithin-subject
variability. This is the result of noise in the dataset, error in the assay, errors in drug dose, etc (fig 8). 
Yobs  7<ȯ       equation 13
Where Yobs is the observed value of Y, TY is the true value of Y and ȯ is the error, a normally distributed 
random variable with a mean of zero and a variance of ı2.
Fig 8  In a, the inter-individual variability among three individuals who received the same dose is shown. b presents the intra-
individual or residual variability by showing the concentration±time profile after repeated administration. Figure from De Cock49
In this thesis NONMEM was used to explore the pharmacokinetic-dynamic relationship between BIS meas-
urements (measures of cerebral hypnotic drug effect (=dependent variable)) and the calculated effect-site con-
centration of propofol (= independent variable). This relationship classically is described  by a sigmoidal Emax
model.  
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This model is determined by four variables: the baseline effect (E0 ), the maximum effect (Emax), the effective 
dose compatible with 50% of the maximal effect (ED50 ), and the slope of the sigmoidal curve (Ȗ). 
Effect = E0 + (Emax – E0 )
࡯ࢋࢽ
࡯ࢋࢽା࡯ࢋ૞૙
ࢽ      equation 14
Additionally we quantified the intra- and inter-individual variability, by estimating the respective variances for 
these random effects. Finally NONMEM provides a tool (‘objective function’) that allows to compare several 
estimated models on the same dataset, in order to determine the most optimal parameter estimation. Greatly 
simplified, the ‘objective function’ value should be decreased or minimized, as it reflects the mathematical 
process that aims to minimize the -2 log likelihood of the fit of the model to the observed dataset. We used this 
method in our studies to find the optimal set of parameters for describing a sigmoidal Emax  model with our 
dataset.
2.6  Accuracy analysis of a TCI model 
Acceptance of target-controlled drug delivery of propofol requires evaluation of both accuracy and outcome 
among patients in whom TCI has been used. Sources of inaccuracy with pharmacokinetic model-driven devices 
include software and  hardware problems, and pharmacokinetic variability. Problems with software and hard-
ware became rather exceptional. Biologic variability still is the  major source of inaccuracy. Firstly, the phar-
macokinetic model may be inaccurate, resulting in a difference between the predicted and the observed concen-
trations in an individual (residual error, noise). Individuals are far more complex than implied by simple com-
partmental models, and thus no such model can precisely predict the concentrations. Secondly the pharmacoki-
netic parameters of a patient may differ from the model, simply as a result of ‘between-subject’ variability, due 
to intrinsic biological inter-individual differences.
Accounting for as much as possible specific patients characteristics, i.e. covariates, is an attempt to compensate 
for biologic variability. The ultimate model still has to be developed
50
.
The variability with TCI technology will always be less than the variability observed after a single manual 
bolus injection, or a continuous infusion at a fixed rate. The mechanism by which a TCI device decreases bio-
logic variability is by incorporating patient covariates such as weight, height, sex, liver function, cardiac out-
put,…The patient-specific model is subsequently used to control the drug administration according to the char-
acteristics of the patient. Another mechanism by which TCI decreases variability is by accounting for drug 
accumulation in peripheral tissues. Targeting a specific concentration typically results in a steady concentra-
29
tion. The choice for a fixed infusion rate results in increasing plasma concentrations over time. Hu
51
 et al. simu-
lated a 10 mg bolus of propofol, a continuous infusion of 10 mg/min or a TCI regimen with a target of 1µg/ml. 
Plasma propofol concentrations were simulated with the Schnider model. Hu showed that the variability in 
estimated concentrations following bolus administration was twice the variability of concentration achieved 
with conventional infusion or TCI administration. 
Performance of a pharmacokinetic model  is the ability to estimate a specific drug plasma concentration. Nu-
merically, the primary concern is how far the measured concentration deviates from the predicted concentra-
tion. A classical graphical representation of model performance is an XY plot depicting predicted versus meas-
ured plasma drug concentrations or the relationship measured/predicted drug concentration ratio versus time. 
The most straightforward measure of good performance would be to simply estimate the size of the typical 
miss of the measured concentration from the targeted or predicted concentration. The smaller the size of the 
typical miss, the greater the accuracy of the TCI system, and the closer the predicted concentration is to the 
measured concentration.  
The basis for quantification of performance is: the percentage performance error (PE): 
ࡼࡱ࢏࢐ ൌ
࡯࢓࢏࢐ି࡯࢖࢏࢐
࡯࢖࢏࢐
ൈ ૚૙૙        equation 15
Where Cpij is the jth prediction of the plasma drug concentration in the ith patient and Cmij  the jth measure-
ment of the plasma concentration in the ith patient. 
Subsequently four measures are used to quantify the predictive performance of TCI systems and PK/PD mod-
els: median absolute performance error (MDAPE), median performance error (MDPE), divergence and 
wobble
52.
The first measure of TCI/model performance, reflecting the inaccuracy, is the median absolute performance 
error 
ࡹࡰ࡭ࡼࡱ࢏ ൌ ࢓ࢋࢊ࢏ࢇ࢔൛หࡼࡱ࢏࢐หǡ ࢐ ൌ ૚ǡǥ ǡࡺ࢏ൟ      equation 16
Where Ni  is the number of performance errors in the ith individual. 
Another characteristic of TCI performance is whether the device produces measured drug concentrations that 
are systematically above or below the targeted concentrations, this is termed ‘bias’. Bias is measured by the 
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median prediction error (MDPE). MDPE is a signed (positive or negative) value and thus represents the direc-
tion (over- or underprediction) of the performance error. 
ࡹࡰࡼࡱ࢏ ൌ ࢓ࢋࢊ࢏ࢇ࢔൛ࡼࡱ࢏࢐ǡ ࢐ ൌ ૚ǡǥ ǡࡺ࢏ൟ      equation 17 
Some individuals may differ from the general patient population and show a gradual worsening (or improve-
ment) of TCI performance over time. This is ‘divergence’, the performance of the TCI deteriorates (or im-
proves) systematically with time. 
Divergence is calculated for each individual as the slope of the linear regression of that individual’s absolute 
performance errors over time. A negative value indicates that the measured concentrations are converging with 
the predicted values over time. A positive value indicates the opposite. 
Wobble is a measure of the variability of the PEij in ith individual. Wobble measures the total intra-individual 
variability in performance error. 
Wobblei =median absolute deviation of ൛ࡼࡱ࢏࢐ǡj=1,…,Ni } from MDPEi equation 18 
As an example of how PK model performance is expressed an article by Sepulveda is discussed. Sepulveda
53
and colleagues investigated the performance of different currently available PK models for propofol in chil-
dren. In a group of 41 children (3-26 months), they administered  a bolus of 2,5 mg propofol, followed by an 
infusion of 8 mg/kg/h. Arterial blood samples were collected at regular intervals (fig.9 a.). For different PK 
models plasma concentrations were estimated by simulation using each individual weight and dose profile. For 
each measured plasma concentration the corresponding estimated plasma concentration was used to calculate 
the PE. For any individual this results in an MDPE and MDAPE. Overall for the whole group of patients this 
results in an MDPE and MDAPE for the model. One of the models investigated was the Coppens model. 
MDPE and MDAPE was calculated after bolus administration, during infusion and recovery. The Coppens 
model resulted in a MDPE of -13,-11,-32, and in a MDAPE of 23, 15 and 36, after bolus administration, during 
infusion and recovery respectively. MDPE and MDAPE  during the test period for the model was -16,47 and 
21,01 (fig 9). The negative value for MDPE reflects an overestimation of the model.  
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Fig. 9 a. Measured arterial propofol concentration versus time for each individual. 
Fig 9 b.  Time profile of the measured/predicted (with Coppens) propofol plasma concentrations for each individual. The dotted 
lines represent an acceptable range. The bold line indicates perfect prediction. MDPE = median performance error, MDAPE = 
median absolute performance error. Figure from Sepulveda53 
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2.7  ǣǮǯǣ 
For propofol various multi-compartmental pharmacokinetic-dynamic models have been published. Coetzee et 
al.
54
 compared the accuracy of some of the models published before 1995 and found that propofol TCI using 
the model published by Marsh resulted in acceptable performance (MDPE -7%; MDAPE18%). 
The Marsh
55
 model for propofol was first published in 1991. Compartmental volumes (V1 , V2 and V3 ) and 
clearances are proportional to body weight, whereas rate constants for redistribution are fixed. The Marsh mod-
el was adapted from the Gepts
56
 three-compartmental model, developed from a study involving three groups of 
six patients who each received constant rate infusions of propofol at either 3,6 or 9 mg kg
-1
 h
-1
.
The Marsh model was incorporated in the first commercially available TCI system. This device, the 
Diprifusor®, was originally developed for targeting plasma concentration of propofol. Early models only dis-
played the target and the estimated plasma concentration. The Diprifusor®  microprocessor controlled a syringe 
recognition system that only  allowed  the use of glass pre-filled 50 ml syringes of 1% or 2% propofol 
(Diprivan® 1%TM or Diprivan® 2%TM, AstraZeneca). The major drawback of the Marsh model is the lack of 
effect compartmental information and the fact that weight is the only covariate. 
A  ke0 value of 0.26 min
-1
 was  used with the Marsh  model in first generation TCI pumps, to enable effect-site 
estimations to be made and displayed as additional information. The data on which this ke0 was based were 
never published in the literature, although it is quite similar to the value of 0.2 min
-1
 found by Billard et al.
57
Struys and colleagues published evidence that a ke0 of 1.2 min
-1
 used in conjunction with the Marsh pharmaco-
kinetic parameters more accurately predicted the time course of clinical effect (BIS) than the ke0 of 0.26 min
-1
 . 
A ke0 of 1.2 min
-1
 used with the Marsh model results in an estimated time to peak effect of approximately 1.6 
min, which is consistent with the findings of other groups. This combination is used in the Base Primea TCI 
system
4
 and results in more gentle manipulations of the plasma concentration when effect-site targeting mode 
is used. In the pump, it is defined as the µPRGLILHG0DUVKPRGHO¶
Schnider
58
 et al. evaluated age, height, weight and lean body mass (LBM) as covariates in a new combined 
pharmacokinetic-dynamic three-compartmental model. The large variability of the study population (18-81 
years and 44-123 kg)  provides a wide applicability of the model. 
The Schnider model has fixed values for V1,V3,k13, and k31, adjusts V2, k12, k21, for age and adjusts k10, accord-
ing to total body weight, lean body mass (LBM), and height. In plasma targeting mode, the small, fixed V1
results in very small initial doses on starting the system. The Schnider model however also describes the dose-
effect relationship for propofol and hence has a pharmacodynamic component.   
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Schnider used semi-OLQHDU FDQRQLFDO FRUUHODWLRQ WR FDOFXODWH WKH µFDQRQLFDO XQLYDULDWH SDUDPHWHU¶ IURP((*
data recorded from the volunteers in his study, and used this to track the time course of the pharmacodynamic 
effect of propofol. The median TTPE of a propofol bolus, determined by this parameter, was 1.69 min. Based 
on visual inspection of the EEG the TTPE ranged from 1.0 to 2.4 min (median 1.6 min). When a TTPE of 1.6 
min was used to calculate the keo for each of their volunteers, the median keo was 0.456 min
-1
. The authors con-
cluded that a keo of 0.456 min
-1
 used with the pharmacokinetic parameters determined in the same group of 
volunteers provided the best description of the time course of clinical effect of propofol.  
Most pediatric anaesthetists still prefer inhalation anaesthetics for both the induction and maintenance of anaes-
thesia because of the ease of use and the rapid reversibility
59
. Although, propofol is infrequently used in chil-
dren, propofol anaesthesia may present some clinical advantages: reduced incidence of postoperative nausea 
and vomiting
60,61
, decrease in emergence agitation compared to volatile agents
62,63
. Total Intravenous Anaes-
thesia (TIVA) has demonstrated advantages in ambulatory surgery for short procedures but also for sedation 
and spontaneous breathing procedures. In some procedures where the airway is manipulated by the surgeon or 
pediatrician, the use of intravenous anaesthesia is obligatory as administration of inhalational anaesthetic is not 
possible such as in situations where jet ventilation is performed or intermittent manual ventilation by face 
mask
64
.
In patients who are at risk of malignant hyperthermia propofol is the only safe option
65,66
. Environmental issues 
could convince the anesthesiologist to use intravenous anesthesia: inhalational anesthetics are detrimental for 
the ozon layer
67
. Nitrous oxide is partially responsible for the greenhouse effect
68
.
Unfortunately intravenous induction of anesthesia with propofol causes pain, apnea and occasionally hypoten-
sion in children. Prolonged administration of propofol has resulted in severe life threatening side-effects and 
death associated with rhabdomyolysis, lactic acidosis, myocardial toxicity and malignant dysrythmias (propofol 
infusion syndrome)
69-75
. This unpredictable and potentially lethal complication of propofol resulted in some 
reluctance towards the use of propofol for long term sedation in children. 
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Table 3  Pharmacokinetic models for propofol in adults: Marsh and Schnider  
Two pharmacokinetic models for propofol in children are available in clinical TCI systems.  
In 1999 Kataria
76
 et al. published a three compartmental model in a healthy pediatric population  between 3 and 
11 years. 658 venous plasma samples were taken. In this model compartmental volumes are a linear function of 
body weight, while rate constants are fixed. They incorporated in their model various covariates (age, weight, 
gender and body surface area) to investigate the improvement of its accuracy. Weight adjusting the volumes 
and clearances significantly improved the accuracy of the pharmacokinetics. Age as an additional covariate for 
the volume of the rapid distribution compartment only slightly improved the model and therefore was ultimate-
ly left out the final model. The weight proportional model predicts that children will need infusion rates 50-
100% higher than adults to maintain any desired propofol concentration during the first 30 minutes. 
Murat
77
 et al found that the pharmacokinetics of propofol in children aged 1-3 years of age differ from those 
reported in older children and adults. They reported poor prediction of the Kataria model in small children.  
 Marsh Schnider 
 General  
model 
70 kg 
 individual 
General 
model 
70 kg male 
170 cm 
height 
V1 
V2 
V3 
K10 min
-1
 
K12 min
-1
 
K13 min
-1
 
K21 min
-1
 
K31 min
-1
 
Ke0 min
-1
 
TTPE min 
0.228 litre kg
-1 
0.463 litre kg
-1 
2.893 litre kg
-1 
0.119 
 
0.112 
0.042 
0.055 
0.0033 
0.26 
4.5 min 
15.9 litre 
32.4 litre 
202.0 litre 
0.119 min
-1 
0.112 
0.042 
0.055 
0.0033 
0.26 
4.5 
4.27 litre 
ϭϴ͘ϵоϬ͘ϯϵϭп;ĂŐĞоϱϯͿůŝƚƌĞ 
238 litre  
Ϭ͘ϰϰϯнϬ͘ϬϭϬϳп;ǁĞŝŐŚƚоϳϳͿоϬ͘Ϭϭϱϵп;>DоϱϵͿнϬ͘ϬϬϲϮп;ŚĞŝŐŚƚоϭϳϳͿ
Ϭ͘ϯϬϮоϬ͘ϬϬϱϲп;ĂŐĞоϱϯͿ 
0.196 
[1.29ʹϬ͘ϬϮϰп;ĂŐĞоϱϯͿ΁ͬ΀ϭϴ͘ϵʹϬ͘ϯϵϭп;ĂŐĞоϱϯͿ΁ 
0.0035 
0.456 
1.69   
4.27 litre 
24.0 litre 
238 litre 
0.384 min
-1 
0,375 min
-1 
0.196 
0.067 
0.004 
0.0456 
1.69 
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The larger central compartment together with the higher clearance explain the increased requirements for 
propofol for both induction and maintenance of anaesthesia in young children compared to older children; the 
latter will also require more propofol than adults. Age-related pharmacokinetic differences may explain why 
adult pharmacokinetic model-driven algorithms systematically overpredict the measured blood concentrations 
in children aged 2-10 years. Our group was the first to prospectively validate the Kataria model.  
In 1991 Marsh et al. studied the accuracy of their adult pharmacokinetic model (as used in Diprifusor®) in 20 
children
55
. They found a consistent overprediction of the blood concentrations; measured blood concentrations 
were significantly less than those predicted by the model. The Marsh model was then revised to produce a 
model specific for children: the size of the central volume was increased approximately by 50%, but remained a 
linear function of body weight. The clearance of propofol was found 25% higher compared to adults.  The ini-
tial bolus should be increased by 50% compared to adults and maintenance infusion at equilibrium should also 
be increased by 25%. This new model performed better when tested prospectively in 10 children. Marsh and 
FROOHDJXHV¶ILQGLQJVZHUHFRQVLVWHQWZLWKWKRVHRIRWKHUJURXSVRIZRUNHUVZKRIRXQGWKDWWKHSKDUPDFRNLQHt-
ics of propofol differ between children and adults. 
Marsh adult Marsh pediatric 
Vc ml kg
-1 228 343 
K10 min
-1 0,119 0,1 
K12 min
-1 0,112 0,0855 
K13 min
-1 0,0419 0,021 
K21 min
-1 0,055 0,033 
K31 min
-1 0,0033 0,0033 
Table 4 Marsh adult versus pediatric PK model for propofol 
Short et al
78
 evaluated prospectively the Marsh model in 10 Chinese children aged 4-10 yr and found a lower 
precision and a large negative bias. In their revised model (20 Chinese children) the volume of the central com-
partment is larger than that of Marsh et al. 
Schüttler
79
 analyzed 4112 propofol plasma concentrations of 270 individuals (age 2-88 years). The data came 
from 9 studies covering  pediatric, adult and geriatric patients. Propofol was administered as a bolus or infu-
sion, and venous or arterial blood samples were drawn. The effect of age, weight, type of administration and 
sampling site were investigated. The inclusion of age and weight as covariates improved their model. 
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Weight was found to be a significant covariate for elimination clearance (fig 10), the two inter-compartmental 
clearances and the volumes of the central compartment and the volume of V2. Nearly all parameters were found 
to alter with bolus administration compared to infusion data. The model described more accurately the pharma-
cokinetics when sampling site was accounted for in the equation for Cl2 . Also  V1, V2, and Cl2 were larger after 
bolus then after infusion. Cl3 was decreased. 
Fig 10 elimination clearance as a function of body weight Figure from Schüttler79
The final Schüttler model was able to describe the pharmacokinetics with sufficient precision for concentra-
tions below 8 µg/ml. At higher concentrations the model underestimates the plasma concentration; the meas-
ured concentrations are systematically higher. This underestimation may indicate nonlinear pharmacokinetics 
of propofol, in the sense that the total body clearance decreases with increasing concentration.  The authors 
suggest that this may be explained by the fact that propofol reduces liver blood flow, particularly at high con-
centrations such as shortly after bolus administration. This also reflects the problem of the assumption of in-
stantaneous mixing of propofol in the initial distribution volume. 
The Paedfusor is a prototype target-controlled infusion system developed by Absalom
80
 et al in 1998 using a 
preliminary model developed by Schüttler before the publication of his final model. In the Paedfusor the central 
compartment volume and clearance have a nonlinear correlation with weight, and the size of the central com-
partment is quite larger compared to Marsh pediatric and Schüttler model. To validate the model 29 children 
aged 1-15 years were investigated. As the children were scheduled for cardiac surgery or cardiac catheteriza-
tion, the researchers were able to obtain arterial samples (9 per patient). The predictive indices of median per-
formance error (MDAPE) of the Paedfusor system, and median absolute performance error were found to be 
4.1% and 9.7% respectively and the median value for wobble was 8.3%. 
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All the pediatric models listed in table 5 show distribution volumes two times greater than in adult models with 
a wide inter-individual variability and a moderate increase in the metabolic clearance with moderate inter-
individual variability
81
 Marsh Kataria Short Schüttler Paedfusor Schnider 
V1 litre 
V2 litre 
V3 litre 
Cl1 l . min
-1
 
Cl2 l . min
-1
 
Cl3 l . min
-1
 
K10 min
-1 
K12 min
-1
 
K13 min
-1
 
K21 min
-1
 
K31 min
-1
 
6.8 
17.6 
40.68 
0.68 
0.58 
0.14 
0.1 
0.0855 
0.021 
0.033 
0.00351 
7.6 
17.4 
122.34 
0.74 
1.26 
0.5 
0.097 
0.166 
0.066 
0.072 
0.0041 
8.6 
11.13 
68.8 
0.83 
1.22 
0.34 
0.0967 
0.1413 
0.0392 
0.1092 
0.0049 
7.6 
20 
266 
0.56 
1.04 
0.46 
0.073 
0.135 
0.059 
0.052 
0.0017 
9.2 
19 
117.1 
0.58 
1.05 
0.39 
0.063 
0.114 
0.042 
0.055 
0.0033 
4.27 
37.3 
238 
0.37 
2.42 
0.83 
0.086 
0.565 
0.196 
0.065 
0.0035 
Table 5 Comparison between the variables calculated with the different pediatric models and the Schnider model for a 6 year 
old child (20 kg)
The original analyses leading to the derivation of the Kataria and Paedfusor models were based on pharmaco-
kinetic data only. However, values for ke0 and the blood-brain equilibration rate constant have been retrospec-
tively generated for both models using the time to peak effect technique. 
Traditionally target-controlled infusion in children was limited to plasma targeted infusion. Targeting the effect 
site concentration may offer advantages. In adults several studies have demonstrated that a TCI device control-
ling the concentration at the effect site, produces a desired time course of drug effect more efficiently than a 
device that only controls plasma concentration
2,4,82
.
Muñoz
83
 et al. determined the tpeak of propofol in children. As Schnider found that tpeak is higher with increasing 
age, Muñoz hypothesized a shorter tpeak in children. Additionally they calculated plasma effect site equilibra-
tion rate constant, ke0, for propofol both in children and adults, using the time to peak effect method published 
by Minto
84
 et al. The authors used auditory evoked potentials (AEP) as a measure of the hypnotic effect of 
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propofol. $(3¶VDUHHOHFWULFDOSRWHQWLDOVUHFRUGHGIURPWKHcentral nervous system (cerebral cortex). $(3¶VDUH
generated as a response to an acoustic signal or sound through the ascending auditory pathway. This has been 
extensively investigated as another measure of anaesthetic effect of hypnotics.  
The pharmacokinetic parameters were based on the Kataria and Paedfusor (Schüttler preliminary) model for the 
pediatric patients and the Schnider model for the adult patients. 
They observed a tpeak of 80 s in adults and 132 s in children.Using the corresponding PK model they estimated a 
median ke0 of 0.56 min
-1
 in adults (Schnider) and a median ke0 of 0.41 min
-1
 (Kataria) or 0.91 min
-1
 (Paedfusor) 
in children. This results in a predicted peak effect of propofol occurring significantly later in children compared 
with adults: the mean tpeak  after a submaximal dose of propofol in adults is 82 ± 2s versus 131 ± 25s (Kataria) 
or 128 ± 3s (Paedfusor) in children. There is a good correlation between observed and estimated tpeak¶V.
Fig 11.  A-Line ARX index (AAI) values after propofol (thick line) of an adult (upper graph) and child (lower graph). AAI re-
cordings have been turned upside-GRZQWRGLVSOD\JUDSKLFDOO\ WKH³LQFUHDVH´ LQ WKHHIIHFW7KH WKLQGDVKHGOLQHV UHSUHVHQW WKH
plasma (Cp) and effect site (Ce) concentration of propofol after 100-mg and 60-mg bolus doses in the adult and child, respective-
ly. In the adult, Cp and Ce have been estimated with the parameters of Schnider and the individual plasma effect site equilibration
rate constant (0.502 min-1). In the child, Cp and Ce have been estimated with the parameters of Kataria and the individual plasma 
effect site equilibration rate constant (0.229 min-1). Ce¶s peak 6 s earlier than time to peak effect measured from the AAI record-
ing because we subtracted the 6-s delay in the signal of the monitor for calculation of Ce peak. Figure from Munoz 83
Rigouzzo
85
 et al. tried to identify the best model to describe pharmacokinetics and pharmacodynamics of 
propofol in children. Children were treated with plasma target controlled infusion based on the Kataria model, 
adults with the Schnider model. They also measured BIS values during induction. They simulated several 
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pharmacokinetic models in children: Kataria, pediatric Marsh, Schüttler and Schnider. The relationschip be-
tween BIS values and the predicted concentrations were analyzed as the basis for pharmacodynamic variables: 
the time to peak effect, Tpeak, ke0, Ce50 . 
They identified the Schnider model for adults as the model that best predicted concentration/effect relationships 
in prepubertal children. The Schnider model is unique in that both age and lean body mass are included as co-
variates, thus allowing a more precise tailoring of individual predicted propofol concentrations. In the same 
study, puberty as a covariate, further improved the model. The time to peak effect is shorter in children (0.71 
min vs 1.73 min in adults).The ke0 is higher in children than in adults (1.17 vs 0.375). The Ce50 is approximately 
20% higher in children. This could reflect the fact that there is a lower sensitivity for propofol in children ver-
sus adults. Venous blood samples were drawn to analyse the pharmacokinetic performance. The pharmacoki-
netic predictive performances of Kataria and Schnider model in children were low.  
Jeleazcov et al
86
. also found PD parameters to be age dependent: ke0 decreased with age, tpeak increased with 
age. Indeed growth and maturation are likely to induce changes on PK and PD characteristics. Also in adults it 
has been shown that the required propofol concentration decreases with increasing age
87
. However in the previ-
ous studies PD parameters were calculated, starting from estimated in stead of measured plasma concentrations 
with possible bias in resulting parameters. 
We performed our own PK/PD model for propofol in children and compared its performance to the existing 
models
26
. We made use of blood samples and BIS to correlate propofol dose to effect and for that reason our 
PD parameters possibly may be more accurate. Results are shown in chapter 5. 
40
  
Dataset N  sampling Age yr Weight kg ref 
Coetzee Validation study 30 patients arterial 21-58 42-38 54 
Gepts 16 patients arterial 25-65 48-84 56 
Kataria 53 patients venous 3-11 15-60 76 
Schnider 24 volunteers arterial 18-81 44-123 58 
Coppens 28 patients venous 3-11 15-54 26 
Marsh 37 patients venous 2-17 12-54 55 
Billard 51 patients venous 26-69 40-89 57 
Struys 10 volunteers arterial 22-48 51-86 102 
Short 10 patients  4-10  78 
Short revised 20 patients    78 
Schüttler 270 pat/vol art/venous 2-88 12-100 79 
Absalom 29 patients arterial 1-15 5-53 80 
Table 6 PK models for propofol
 
2.8   Front-end kinetics and re-circulatory models 
The drugs we use in anesthesia typically have a rapid onset of effect ( e.g. hypnotics, opiates ) and have a low 
margin of safety (depression of the cardiovascular and respiratory system !). Furthermore there is a large inter-
individual variability both on a pharmacokinetic and pharmacodynamic base. The effects appear rapidly (se-
conds to minutes after injection) but in contrast traditional pharmacokinetic models are based on blood samples 
that are drawn after maximal or peak effect occurred. Understanding the pharmacokinetics of early drug distri-
bution is essential for explaining the variability in response. 
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Multi-compartmental PK models are based on the simplifying assumption that intravenously administered 
drugs mix instantaneously and completely within the initial distribution volume (central compartment, Vc) that 
includes, at a minimum, the intravascular space. Conventional PK models overestimate Vc because they ignore 
the complexity of intravascular mixing.
88
 When PK models in which Vc is overestimated are used to design 
target-controlled infusions, drug concentrations not only greatly exceed the target concentrations in the first 
minutes after starting the infusion but also long thereafter. Conventional PK models estimate Vc by dividing the 
dose by the hypothetical concentration at time zero, which is determined by back extrapolation of the concen-
tration-versus-time relation. (fig 12 and 13). When the first blood sample is taken very early, i.e. high on the 
decreasing part of the concentration curve, the back-extrapolated value at time zero is high. When the first 
blood sample is taken later, i.e. lower on the decreasing part of the curve, then the back-extrapolated concentra-
tion at time zero will be lower (fig 14). A lower concentration at time zero will result in a higher estimate of Vc.
In vivo the concentration at time zero is not maximal, in contrast to the back-extrapolated value. In reality the 
first part of the concentration vs. time curve shows a rapid increase to the maximal value
25
. Back-extrapolation 
from the first blood sample to concentration at time zero ignores the information available from the first-pass 
concentration versus time relation, i.e. the real in vivo plasma concentration versus time curve during the first 
minutes. This first part should be a reflection of the fact that there is a temporal lag between the time of intra-
venous drug administration and the time drug appears at an arterial sampling site, furthermore there may be 
significant drug uptake by the lung and washout
89
 from it, and the mixing of drug and blood, even within what 
might be considered the true Vc is not instantaneous.
90
Fig 12 The central volume is based on the fundamentally flawed assumption that drug is instantaneously and completely mixed 
and hence that the concentration peaks at time 0. Figure from S Shafer25
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Fig 13 More realistic representation of the concentration vs time curve (solid line). The dashed line represents an estimation by 
back-extrapolation. Figure from S Shafer25
Fig 14 The influence of study design on the estimate of the concentration at time 0 and hence the estimate of V1. Studies with 
rapid early sampling typically have smaller estimates of V1 than studies in which the first samples are drawn many minutes after 
drug administration. Figure from S. Shafer25
Front-end kinetics were more accurately described by Masui et al
91
. He used a conventional  two compart-
mental PK model extended with a LAG and TRANSIT model, describing the time required for the venously 
injected drug to reach the sampling site of arterial blood. He showed that propofol administration rate influ-
ences the early phase kinetics but not the dynamics, resulting in equal keo¶VIRUWKHGLIIHUHQWUDWHRIDGPLQLVWUa-
tion.
The mixing period may be better described with physiologic pharmacokinetic models that account for cardiac 
output, and hence drug distribution, among tissues with similar perfusion and drug solubility characteristics. 
Physiological PK models  analyze volumes and clearances for each organ in the body, assuming that blood 
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flows throughout the system according to zero-order processes and that blood transfer between blood and tis-
sues occurs according to first-order processes.  
The recirculatory pharmacokinetic model also addresses concerns about traditional mammillary 
multicompartmental analysis. The model fits early arterial drug concentrations of samples frequently obtained 
soon after rapid intravenous input that resemble a drug concentration profile resulting from a zero-order infu-
sion. In the fit of the model to the data, the concentration is 0 at time 0, and there is a delay between the time 
drug is administered and its appearance at the sampling site. Pulmonary drug uptake is an integral part of the 
model. Intravascular mixing is characterized, as is the role of cardiac output in drug distribution. Finally, the 
model accounts for arterial-mixed venous concentration differences.  
The lungs are pharmacologically active organs and affect the blood concentrations of drugs given intravenous-
ly.  The lungs can take up, retain, metabolize and delay the release of many drugs. It has been shown that the 
first-pass pulmonary retention of a single dose of propofol is 28%.  There probably is no extra hepatic 
propofol metabolism in the human lung. 
Upton and Lundbrook developed a physiologically based re-circulatory (fig 15) model of propofol kinetics in a 
sheep model , later extended to humans . In the model particular attention was paid to representing those 
physiologic features that influence propofol bolus kinetics (vascular mixing during cardiac output) and 
propofol dynamics (cerebral kinetics, cerebral blood flow, cerebral concentration effect relationships). The 
incorporation of blood flow terms into the model was considered important because surgery and anesthetic 
management affects the state of the circulation, which may affect the disposition of propofol (Fig 16). 
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Fig 15 A taxonomy of pharmacokinetic models Compartmental mammillary models are just one approach; an over-simplification 
of a complex biological process. Other models account for more physiological phenomena but at the expense of more complicated 
mathematical descriptions and the requirement of large amount of data. Figure from  Stoeckel24
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Fig 16 A schematic representation of the physiologically based recirculatory model (Upton model). The compartments of the 
model each have defined apparent distribution volumes (V) and associated blood flows (Q). The lungs were represented as a 3-
FRPSDUWPHQW³WDQNLQVHULHV´VXEPRGHODQGWKHEUDLQDQG³VORZ´WLVVXHVDVPHPEUDQHOLPLWHGVXEPRGHOV36UHSUHVHQWVSHUPHa-
bility terms for  linking 2 compartments of these membrane-limited submodels. Delay(pre) and Delay(post) are delay terms ac-
counting for intravascular transport. Vmix is a vascular mixing compartment. The symbols used are: Cpa =  pulmonary artery drug 
concentration; Cart ven = mixed venous propofol concentration; Qco = cardiac output; Qbrn = 
brain blood flow; Qhep= liver and gut blood flow; Qfast = fast tissues blood flow; Qslow = slow tissues blood flow; PSdeep= permea-
bility term for slow tissues; Elng=propofol extraction across the lungs; Ehep= propofol extraction across the liver and gut; 
Efast=propofol extraction across the fast tissues (includes kidney). Figure from Upton
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Influence of Administration Rate on Propofol Plasma-
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Introduction
Classic multicompartmental mammillary models assume that drug added to the central compartment is instan-
taneously and completely mixed both at the venous and arterial site of the circulation. The biological phenome-
non is more complex and classic models have difficulties to describe the time course of arterial drug concentra-
tions in the very first minutes after intravenous drug administration. 
When using estimated drug concentrations for a combined PK-PD model to describe the complete dose rela-
tionship, misspecification of the PK model over the first minutes could lead to misspecification of the pharma-
codynamics and a less accurate interpretation of the plasma effect-site equilibration. PK-PD modeling without 
blood-sampling can be a source of error. 
.
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time). Anesthesiology 2007; 107:367±8.
ABSTRACT 
Background:  The authors hypothesized a difference in plasma±effect site equilibration, depicted by a 
first-order constant ke0, depending on the injection rate of propofol. 
Methods:  Sixty-one patients received 2.5 mg/kg propofol given as a bolus or as a 1-, 2-, or 3-min infu-
sion. The Bispectral Index was used to monitor drug effect. Propofol predicted plasma concentration was 
calculated using a three-compartment model and the effect site concentration over time as the convolu-
tion between the predicted plasma concentration and the disposition function of the effect site concentra-
tion. The authors evaluated the influence of the infusion rate on the ke0 by comparing the model with one 
ke0 for all groups with models estimating different ke0 values for each group. The authors also assessed 
the accuracy of two pharmacokinetic models after bolus injection. 
Results: 7KHEHVWPRGHOEDVHGZDVD IL[HG %LVSHFWUDO ,QGH[SOXVVLJPRLGDOPRGHO %LVSHFWUDO
Index < 90) with two values of ke0, one for the bolus (t½ ke0 = 1.2 min) and one for the infusions (t½ ke0 = 
2.2 min). However, the tested pharmacokinetic models poorly predicted the arterial concentrations in the 
first minutes after bolus injection. Simulations showed the requirement for two ke0 values for bolus and 
infusion was mostly a compensation for the inaccurate prediction of arterial concentrations after a bolus. 
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Conclusion:  Propofol plasma±effect site equilibration occurs more rapidly after a bolus than after rapid 
infusion, based on the electroencephalogram as a drug effect measure, mostly because of misspecifica-
tion of the pharmacokinetic model in the first minutes after bolus. 
PROPOFOL transfer between the plasma and effect site can be modeled as a first-order process char-
acterized by ke0.
1,2 The standard model of ke0 assumes that the rate of equilibration between the plas-
ma and the site of drug effect is independent of the rate of drug administration. However, there are 
conflicting data on the rate of equilibration between the plasma and the site of propofol drug effect. 
In a study involving both bolus injections and intravenous infusions, Schnider et al.3 found that the 
rate of equilibration was rapid, with a half-time of equilibration, t½ ke0, of 1.5 min, and a peak effect, 
tpeak, of 1.7 min. Schnider's finding of rapid equilibration was subsequently validated by Struys et al.
4
However, using continuous infusions of propofol, Doufas et al.5 found a much slower rate of plasma±
effect site equilibration, with a t½ ke0 of 4.1 min, and a tpeak of 2.7 min. They also found that infusion 
rate had no influence on ke0.
5
The maximum propofol infusion rate in the study of Doufas et al.5 was 60 mg/min, far lower than the 
maximum rate of approximately 500 mg/min required for Schnider et al. to give a 2.5-mg bolus over 
20 s. Doufas et al.5 proposed that there could be a fundamental difference in plasma±effect site equi-
libration depending on whether propofol was given as a bolus or continuous infusion. We 
investigated this hypothesis.
Materials and Methods 
Clinical Protocol 
After institutional ethics committee approval, written informed consent was obtained from 61 female 
patients with American Society of Anesthesiologists physical status I, aged 18±45 yr, scheduled to un-
dergo ambulatory gynecologic surgery. Exclusion criteria included weight less than 70% or more than 
130% of ideal body weight, neurologic disorder, and recent use of psychoactive medication, including 
alcohol.
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All patients were randomly assigned to one of four groups to receive 2.5 mg/kg propofol (Diprivan 1%; 
AstraZeneca, London, United Kingdom) given as a bolus (within 10 s) (group 1) or given as a continu-
ous infusion over 1, 2, or 3 min (groups 2, 3, and 4, respectively). Bolus administration was performed 
manually. The continuous infusions were administered using a Fresenius Modular DPS Infusion Pump 
connected to a Fresenius Base A (Fresenius Vial Infusion Systems, Brézins, France). To ensure synchro-
nized data recording, all monitor and infusion data were continuously captured by a computer running 
RUGLOOP II (Demed, Temse, Belgium) via multiple RS 232 interfaces. By tracking the infused 
propofol volume continuously in groups 2, 3, and 4, RUGLOOP II calculated the corresponding plasma 
concentration using the three-compartment model previously published by Schnider et al.6 This model 
was selected because of its optimal performance in previous studies.5 For group 1, the plasma concentra-
tion was calculated post hoc using RUGLOOP II simulation mode and the Schnider propofol pharmaco-
kinetic model.6
Propofol was infused via a large left forearm vein. Every patient received approximately 100 ml crystal-
loid fluid during the study period. No fluid load was given before induction. No patient received 
preanesthetic medication. No other drugs were given. All patients maintained spontaneous ventilation 
via a facemask delivering 100% O2. Before starting the drug administration, all patients were asked to 
close their eyes and relax for 2 min. Thereafter, baseline measures were taken. The operating room was 
kept silent to avoid noise-related stimulation and artifact. 
Propofol drug effect was continuously monitored using the Bispectral Index (BIS; version 4.0; Aspect 
Medical Systems, Inc., Newton, MA). The BIS was derived from the frontal electroencephalogram and 
calculated by the A-2000 BIS® monitor using the four BIS®-Sensor electrodes. Electrode impedance 
ZDVOHVVWKDQNȦ7KHVPRRWKHQLQJWLPHRIWKH%,6PRQLWRUZDVVHWDWV7KH%,6GDWDZHUHFDp-
tured in real time on a laptop computer using RUGLOOP II. Heart rate, noninvasive blood pressure, 
oxygen saturation measured by pulse oximetry, and capnography were recorded at 1-min time intervals 
using an S-5 monitor (Datex-Ohmeda, Helsinki, Finland) and were also captured electronically using 
RUGLOOP II. Averaging of the data was performed using 10-s intervals. All patients were monitored 
until return of consciousness after propofol administration, defined as spontaneous eye opening (without 
a stimulus). 
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Pharmacodynamic Modeling and Estimation of ke0. 
In our initial approach, the effect site was assumed to be linked to the plasma by a compartment of trivial 
volume with a first-order equilibrium constant of ke0. The relation between propofol effect site concen-
tration (Ce) and the electroencephalographic measures of anesthetic drug effect was described using a 
classic sigmoid Emax model: 
Effect = E0 + (Emax ± E0)
where Effect is the electroencephalographic effect (e.g., the measured BIS), E0 is the baseline measure-
ment when no drug is present, Emax is the maximum possible drug effect, Ce is the calculated effect site 
concentration of propofol, Ce50 is the Ce associated with 50% maximal drug effect, and  is the steepness 
of the concentration-versus-response relation. The model parameters were estimated using NONMEM V 
(GloboMax LLC, Hanover, MD). For Ce50 and ke0, interindividual variability was permitted using a log-
normal distribution: 
Pi = PTV e
- i
where Pi is the parameter value in the i
th patient, PTV is the typical value of the parameter in the popula-
tion, and LVDUDQGRPYDULDEOHZLWKDPHDQRIDQGDYDULDQFHRIȦ2. Individual variability is reported 
DVȦWKH6'RI  in the log domain, which is approximately the coefficient of variation in the standard 
domain. Residual intraindividual variability was modeled using a standard additive error model. 
After visual inspection of the BIS data above 90, and initial attempts to find a value of ke0 that fit all of
the observations to a single pharmacodynamic model, we concluded that no model could be fit to the 
data. The raw BIS data showed an abrupt (< 15 s) transition from a BIS greater than 90 to a very low 
BIS, suggesting a nearly instantaneous state change. Therefore, we investigated the relation between 
propofol Ce and BIS using separate models for periods before and after the state change. The combined 
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PRGHOGHVFULEHGDOO%,6GDWDDERYHE\DVLQJOHYDOXHPRGHO³RQHVL]HILWVDOO´DQGDOOdata of 90 or 
less using the classic sigmoid Emax model. 
For both model approaches (classic sigmoidal model or the combined fixed plus sigmoidal model), we 
assumed that the underlying sigmoidal model which describes the relation between the effect site con-
centration and the drug effect is not influenced by the method of drug administration. Indeed, this is a 
fundamental assumption underlying the standard model of the effect site. Therefore, we concurrently 
estimated the model parameters for all four groups, only permitting the value of ke0 to differ between 
groups. We evaluated the influence of the administration rate on the ke0 by comparing the log likelihood 
between a model with one ke0 for all administration rates with models estimating different ke0 values for 
each group. The addition of infusion rate specific values of ke0 was considered statistically significant 
when the log likelihood decreased by at least 6.63 (P < 0.01, chi-square test with 1 degree of freedom).7
NONMEM had difficulty simultaneously estimating the parameters of the structural model (e.g., the ș
parameters) and the variance model (the parameters). Specifically, estimating both the structural and 
variance models simultaneously produced highly biased estimates of the parameters, as demonstrated by 
WKHREVHUYDWLRQWKDWWKHSRVWKRFHVWLPDWHVRIWKHȘSDUDPHWHUZHUHXQLIRUPO\HLWKHUSRVLWLYHRUQHJDWLYH
Therefore, we chose the best model using the naive pooled data method as described by Kataria et al.8
After identifying the best structural model, we fixed the parameters of the structural model at the naive 
pooled data estimates and estimated the parameters of the intersubject and intrasubject variability mod-
els. This approach comes very close to the generalized least-squares method. The generalized least-
VTXDUHV DSSURDFK LQYROYHV WKUHH VWHSV ,Q WKH ILUVW VWHS WKH LQWHUVXEMHFW YDULDELOLW\ LHȦ LV IL[HG DW
]HURDQGWKHW\SLFDOYDOXHVRIWKHVWUXFWXUDOPRGHOLHșDUHHVWLPDWHG,QWKHVHFRQGVWHSWKHW\SLFDO
values of WKHVWUXFWXUDOPRGHOLHșDUHIL[HGDWWKHHVWLPDWHVIURPWKHILUVWVWHSDQGWKHLQWHUVXEMHFW
YDULDELOLW\LHȦ@LVHVWLPDWHG,QWKHWKLUGVWHSWKHLQWHUVXEMHFWYDULDELOLW\LHȦLVIL[HGDWWKHYDOXH
from step 2, and the typical values of the structural model (i.e., ) are estimated for the last time. Our 
approach was to implement the first two steps of the generalized least-squares method. 
The effect site concentrations over time were calculated as the convolution of the predicted plasma con-
centrations over time with the disposition function of the effect site, ke0 e
-ke0t. The convolution was based 
RQD³FRQQHFW-the-GRWV´DSSURDFKSUHYLRXVO\XVHGE\6FKQLGHUHWDO3 In brief, increasing plasma concen-
59
 trations were modeled using a linear interpretation between adjacent plasma concentrations. As such, 
when concentrations are increasing, the slope in the concentration from time t1 to time t2 can be modeled 
as 
 ൌ
ܥ݌ሺݐଶሻ െ ܥ݌ሺݐଵሻ
ݐଶ െݐଵ
where Cp is the plasma concentration, and thus the plasma concentrations from time t1 to time t2 are 
described by the formula 
ܥሺݐሻ ൌ ܥሺݐଵሻ ൅ ݏ݈݋݌݁ ൈ ሺݐ െݐଵሻ
The convolution of this with ke0 e
-ke0t  calculates the effect site concentration at time t2 as a function of
the effect site concentration at time t1 and the plasma concentrations over the interval 
ܥ݁ሺݐଶሻ ൌ ܥ݁ሺݐଵሻ݁ି௞೐బሺ௧మି௧భሻ ൅ ሺݐଶ െ ݐଵሻݏ݈݋݌݁ ൅
ሺ݇௘଴ܥሺݐଵሻ െ ݏ݈݋݌݁ሻሺͳ െ ݁ି௞೐బሺ௧మି௧భሻሻ
݇௘଴
Similarly, when concentrations are decreasing, the slope of the log of the concentrations from time t1 to 
time t2 can be modeled as 
ݏ݈݋݌݁ ൌ
ܮ݋݃൫ܥ݌ሺݐଶሻ൯ െ ܮ݋݃ሺܥ݌ሺݐଵሻሻ
ݐଶ െݐଵ
and thus the plasma concentrations from time t1 to time t2 are described by the formula 
ܥሺݐሻ ൌ ܥሺݐଵሻ݁௦௟௢௣௘ൈሺ௧ି௧భሻ
The convolution of this with ke0 e
-ke0t calculates the effect site concentration at time t2 as a function of the 
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 effect site concentration at time t1 and the plasma concentrations over the interval 
ܥ݁ሺݐଶሻ ൌ ܥ݁ሺݐଵሻ݁ି௞೐బሺ௧మି௧భሻ ൅
ܥሺݐଵሻ݇௘଴ሺ݁௦௟௢௣௘ൈሺ௧మି௧భሻ െ ݁ି௞೐బሺ௧మି௧భሻሻ
݇௘଴ ൅ ݏ݈݋݌݁
The observed BIS value has a time delay for the measurement, which we fixed at 10 s and defined as lag 
time. This lag time is approximately the sum of half of the smoothing interval within the BIS® monitor 
and the time for the automated data collection. 
We assessed the model performance by calculating the prediction error (PE) between measured (BISmeas)
and post hoc Bayesian predicted BIS (BISpred) values, as 
ܲܧ ൌ ሺܤܫܵ௠௘௔௦ െ ܤܫܵ௣௥௘ௗሻ ൊ ܤܫܵ௣௥௘ௗ
We also calculated median prediction error (MDPE) and absolute median prediction error, (MDAPE), 
for each patient.9 Differences among groups for MDPE and MDAPE were tested using a Student t test 
with Bonferroni correction for multiple testing. 
To observe whether the model reflects reality, we compared the observed time of maximum BIS re-
sponse (tmax,BIS) with the time to reach maximum Ce (tmax,Ce) after the specific administration of propofol 
in each group. 
Bolus Validation Study 
The three-compartment pharmacokinetic model published by Schnider et al.6 was used to predict the 
time course of the propofol plasma concentration in our study. For slowly administered continuous infu-
sion of propofol, Doufas et al.5 found that the pharmacokinetic model published by Schnider et al.6 accu-
rately predicted the propofol plasma concentrations in arterial blood. However, the accuracy of this 
model in the first 3 min after bolus injection is not described in the literature. 
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We therefore performed a study to validate the pharmacokinetics after bolus injection. In this study, we 
collected propofol arterial blood samples from 10 additional patients to evaluate the accuracy of the 
pharmacokinetic models published by Schnider et al.6 and by Marsh et al.10 in the first 5 min after intra-
venous propofol bolus. After additional ethics committee approval and written informed consent, 10 
patients received a bolus dose of propofol (2.5 mg/kg) within 10 s in a large forearm vein. Propofol arte-
rial blood samples were collected (contralateral from the injection of propofol) at 0, 30, 60, 120, 180, 
240, and 300 s after injection. Propofol (bound and free) plasma concentrations were analyzed using a 
validated gas chromatographic±mass spectrometric method with solid-phase micro extraction. The time 
course of the propofol plasma concentration as predicted by both pharmacokinetic models (Schnider and 
Marsh) was simulated using RUGLOOP II. We calculated the PE of the predicted concentration and the 
MDAPE for both models for the first 5 min after injection. 
The arterial concentrations in the first 5 min after bolus injection were compared with the predictions 
based on the pharmacokinetics reported by Schnider et al.6 and by Marsh et al.10 As described in the 
Results, neither pharmacokinetic parameter set accurately predicted the concentrations in the first 5 min 
after bolus injection. To see whether this misspecification might affect the estimation of ke0, we calculat-
ed the effect site concentrations over time after bolus injection as a convolution of the median concentra-
tions in these 10 individuals with ke0 e
-ke0t, the disposition function of the effect site. We then calculated 
the value of ke0 that predicted the observed time of peak BIS response. 
Validation of the Applied Lag Time in the BIS Measurement 
 
We fixed the lag time of the BIS at 10 s. Based on literature reports,11 a longer lag time might be more 
appropriate. Therefore, we applied a post hoc analysis on our final selected model in an attempt to ex-
plore whether longer lag times would result in a better model for both the sigmoidal model and the fixed 
BIS plus sigmoidal model. Lag times between 10 and 25 s were evaluated, and the NONMEM objective 
functions were compared. 
Validation of the Modeling Methods Using Another Data Set 
We validated our final model results against the data previously published by Doufas et al.5 In brief, 
62
  
Doufas et al. analyzed the pharmacokinetics and pharmacodynamics of propofol in 18 healthy volunteers 
receiving five consecutive target-controlled propofol infusions. During each infusion, predicted Ce in-
creased linearly at a rate of 0.1, 0.3, 0.5, 0.7, or 0.9 µg · ml-1 · min-1 based on the Schnider pharmacoki-
netic±pharmacodynamic model. BIS was collected continuously during the infusions. Doufas et al.5 fit a 
combined pharmacokinetic±dynamic model to their data. To describe the pharmacodynamics of
propofol, a classic sigmoid Emax model was used. No lag time in the BIS was included in the model. The 
study results can be seen in the original publication.5
We validated four models: (1) a sigmoid Emax model without a lag time (same as the model used in the 
Doufas article; (2) a sigmoidal Emax model with a 10-s lag time (equivalent to our sigmoidal Emax model); 
(3) a model consisting of a fixed estimate of BIS values of 90 or greater and a sigmoidal Emax model for 
BIS values less than 90, with no lag time; and (4) a model consisting of a fixed estimate of BIS values of 
90 or greater and a sigmoidal Emax model for BIS values less than 90, with a 10-s lag time (equivalent to 
our best model). We encountered identical problems with concurrent identification of the structural and 
variance models that we described when fitting our own data, and so we used the naive pooled data ap-
proach to identify the best model among the four structural models considered. After identification of the 
best structural model, we fixed the structural parameters and estimated the interindividual variability. 
We assessed the performance of the optimal model by calculating the PE between BISmeas and BISpred
values, as well as the MDPE and MDAPE for each patient.9   
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Results 
Model Estimation and Validation 
All recorded data were used. No patients experienced hemodynamic or respiratory instability during the 
study. The demographics for patient in the four groups are shown in table 1. The amount of propofol 
given and the infusion rates are shown in table 2. 
Figures 1A±D show the relation between the measured BIS and calculated plasma concentrations, Cp, 
versus time for the four groups, respectively. The dashed line shows the cutoff value of 90 used in the 
combined fixed plus sigmoidal model approach. Figures 1E±H show the relation between BIS and plas-
ma concentration, revealing the hysteresis in the plasma concentration±versus±response relation. 
Table 3 shows the NONMEM objective function (-2 log likelihood) for all investigated models. The 
NONMEM objective function improved by 46 points (P << 0.001) when the bolus group (group 1) was 
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given a ke0 distinct from the ke0 used for the three infusion groups (groups 2, 3, and 4). There was no 
significant benefit to adding distinct values of ke0 for the three infusion groups. Therefore, we selected 
the model with two values of ke0, one for the bolus (t½ ke0 = 1.2 min) and one for the infusions (t½ ke0 = 
2.2 min). 
Our final model included estimates of interindividual variability on ke0 and Ce50. In our final model, BIS 
values of 90 or greater were typically 95.6. BIS values less than 90 were described by a sigmoidal curve 
with ranging from a maximum value of 74 to a minimum of 25. The Ce50 for the sigmoidal portion was 
JPOZLWKDȖRI7KH6'VLQWKHORJGRPDLQRI&H50 and ke0 were 0.27 and 0.83, respectively, 
which approximately correspond to the coefficient of variation in the standard domain. Additive residual 
intraindividual error was 7.2. 
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Fig. 1 Relation between the measured Bispectral Index (BIS) and propofol plasma concentration (Cpprop)  versus time (s) for the
four groups, in A-D. The dashed line shows the cutoff value for modeling when the two consecutive model approach was used 
(fixed  90, sigmoidal < 90), fixed at a BIS of 90. E-H  show the relation between BIS and Cp, thereby revealing the hysteresis in 
the relation.
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Fig. 2 Results from the best-fitting model (including estimates of interindividual variability on ke0 and effect site concentration
associated with 50% maximal drug effect (Ce50). Individual measured Bispectral Index (BIS) values and the calculated Ce  
versus time for the four groups, in A-D. E-H show the BIS versus Ce, based on the ke0 estimate by NONMEM. To visualize the 
source data and results for the fixed number model, we showed the measured BIS data  90 as black circles. The second part (the 
sigmoid Emax model using BIS < 90) data are shown as straight lines. 
Figures 2A±D show the raw BIS values and the calculated effect site concentration, Ce, versus time, 
showing the parallel between the time course of BIS and Ce. Figures 2E±H show the BIS versus Ce. 
BIS values of 90 or greater are depicted as black circles. BIS values less than 90 are shown as connect-
ed lines. Two individuals receiving the bolus injection had baseline BIS values below 90 (fig. 2E), 
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which escaped our efforts to censor the initial unresponsive portion of the BIS response. We did not 
decrease our censoring value (90) to censor these data because we did not wish to lose informative BIS 
values in other subjects. 
Table 4 shows the median (range) results for the post hoc Bayesian estimates of Ce50 and t½ ke0 for each 
individual in the four groups. Table 4 also shows the time of maximum BIS change (tmax,BIS), the time 
of maximum Ce (tmax,Ce) after the specific propofol infusion, and the absolute value of the difference 
between these times (terror). The difference in the time of maximum BIS change and the time of the 
highest Ce can be used to assess the performance of the model. The median terror was 0.6 min or less for 
all groups. For all patients, the individual results for the post hoc Bayesian estimates of Ce50 and t½ ke0
in the four groups, tmax,BIS and tmax,Ce after the specific propofol infusion, and the absolute value of the 
difference between these times (tabs,error) can be found in a supplement on the Anesthesiology Web site 
(http://www.anesthesiology.org). 
The performance accuracy for the final model was assessed by calculating the PE. Figures 3A±D show 
the individual PE versus time for the four groups, respectively. Median (range) MDPE and MDAPE 
for each group was calculated as shown in table 4. The MDAPE was 18% or less for all groups. No 
group showed significant bias (MDPE). All individual MDPE and MDAPE calculations can be found 
on the Anesthesiology Web site (http://www.anesthesiology.org). 
Bolus Validation Study 
Ten female patients were included, and all blood samples were analyzed. Demographics were similar 
68
  
in study groups 1 through 4 (age, 34 ± 8 yr; weight, 63 ± 10 kg; height, 163 ± 7 cm). For both models, 
measured versus predicted propofol plasma concentrations and individual PE% versus time are plotted 
in figure 4. The mean (SD) PEs were -40.50 (53.08) and -25.90 (36.80)% for the Marsh and Schnider 
models, respectively. The mean MDAPEs were 60.22 (28.24) and 39.45 (21.38)% for the Marsh and 
Schnider models, respectively. 
Figure 5 shows the median arterial concentrations from the bolus. The effect site concentrations were 
computed based on a t½ ke0 of 2.0 min and predict a peak effect site concentration of 1.9 min, consistent 
with the time of peak BIS effect in our bolus study (table 4, group 1). All data can be found on the 
Anesthesiology Web site (http://www.anesthesiology.org). 
Validation of the Applied Lag Time in the BIS Measurement 
 
Table 5 shows the -2 log likelihood values (the NONMEM objective function) when applying different 
lag times. The best result is obtained when implementing a 10-s lag time in the combined fixed plus 
sigmoidal model approach. 
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Fig. 3 Individual prediction errors (PEs)  versus time for the four groups, in A-D. 
Method Validation 
All data from the 18 volunteers in the original publication by Doufas et al. were included in the model 
validation. Figure 6A shows the relation between BIS and Cp for the Doufas validation data set. Table 
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6 shows the -2 log likelihood values (the NONMEM objective function) and the typical values for all 
investigated models. Doufas' data were best described by a single estimate for those BIS observations 
of 90 or greater, and a sigmoidal Emax model for BIS values less than 90, with a 10-s delay, exactly as 
was the case for our data. Most critically, this model estimated a t½ ke0 of 2.1 min, very close to our 
estimate of 2.2 min for infusions. The SDs in the log domain of Ce50 and ke0 were 0.31 and 1.29, re-
spectively. Additive residual intraindividual error was 9 (i.e., residual variance = 81). 
Figure 6B shows the relation between BIS and Ce for each individual, based on the best model and the 
post hoc Bayesian estimates of Ce50 and ke0. The individual PEs are shown in figure 6C. 
The median (range) post hoc Bayesian parameter estimates for all subjects in the validation data set 
are shown in table 7, as well as the individual MDPE and MDAPE. The model performed well, with 
an MDAPE less than 9% and minimal bias (5%). The Ce50 in the validation set is less than in our data 
set (3.6 vs. 5.1 µg/ml) but is similar to that seen in our bolus group (3.7 µg/ml; table 4).
Fig. 4 The bolus injection validation set. The relation between the individual measured propofol plasma concentration (Cp) 
and the plasma concentration predicted by the Marsh and Schnider pharmacokinetic models ( A). The time course of the 
prediction error (PE%) for both applied models (B). 
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7KHHVWLPDWHRIȖLQWKHYDOLGDtion set is less than in our data set (1.3 vs. 3.4). For all patients, individ-
ual data can be found on the Anesthesiology Web site (http://www.anesthesiology.org). 
Fig. 5 The median plasma concentrations (Cp) from the 10 patients in the bolus validation study, and the effect site concen-
trations (Ce) predicted by a t1/2 ke0 of 2.0. The time of peak effect, 1.9 min, matches the median time of peak Bispectral 
Index in the bolus study ( table 4). 
Discussion 
Our goal was to determine whether the equilibration rate between plasma and effect site was influ-
enced by rate of propofol administration. If so, this must be considered when designing drug infusions, 
and is particularly relevant for target-controlled infusion systems. We tested this by examining the 
time course of electroencephalographic (BIS) response to a bolus and three infusion rates. The appar-
ent plasma±effect site equilibration for bolus injections is faster than for infusions. This is consistent 
with the hypothesis of Doufas et al.5  who speculated that this might be the explanation for the differ-
ence between plasma±effect site equilibration in their study versus the study by Schnider et al.3  The 
accuracy of the pharmacodynamic models is demonstrated by the reasonable values of MDAPE and 
the agreement between the observed time to maximum BIS changes and the calculated time to the 
highest effect site concentration after a specific propofol administration (depending on the group). 
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Because this study aimed at answering the question of why different ke0s are found in the literature, 
even when using the same pharmacokinetic model, we wanted to explore bolus injections (as used by 
Schnider et al.3) and various infusion rates covering published work and clinical practice. Our bolus 
was 2.5 mg/kg given over 10 s. Our slowest administration was an infusion of 2.5 mg/kg given over 3 
min, which is 50 mg kg-1 h-1. This is lower than the critical infusion rate of 80 mg kg-1 h-1 that Kazama 
et al.12 postulate causes incomplete mixing in the central compartment. 
Classically, the sigmoid Emax model has been applied successfully for pharmacodynamic modeling of
propofol. However, when observing our raw BIS data, we found that the BIS values showed no 
change during the initial increase in effect site propofol concentration, until there was an abrupt de-
crease. This may reflect an acute change in BIS with loss of consciousness, although the article by 
Doufas et al. examined BIS at loss of consciousness and did not detect any abrupt state change. This 
might be due to the fact that they used an Observers' Assessment of Anesthesia/Sedation score of less 
than 2 (= loss of responsiveness to shaking and shouting) as their endpoint.5  Alternatively, this delay 
may reflect the combination of the averaging algorithm to calculate BIS (i.e., smoothing rate) and the 
delay in adaptation of one of the artifact rejection preprocessing steps, that rejects large changes in the 
electroencephalogram as artifact until those changes persist for approximately 5 s (Scott Greenwald, 
Ph.D., Vice President of Research, Aspect Medical Systems, Newton, MA, verbal personal communi-
cation, April 2005). We found that the inclusion of a lag time of 10 s into our model resulted in the 
best fit. Longer lag times resulted in worse fits of the model to the data. Regardless, the initial obser-
vations when the BIS was unambiguously unresponsive to changing propofol concentrations (figs. 
1E±H) were censored from the sigmoidal model by introducing a separate model for BIS values of 90 
or greater and BIS values less than 90. This model significantly improved the quality of the fit with 
our data (P << 0.001 for the 2 ke0 model; table 3) and with the validation data set from Doufas et al.
5
(P << 0.001 for the models with 10-s delays; table 6). 
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Fig. 6 The validation data set. A shows the relation between the measured Bispectral Index (BIS) and propofol plasma con-
centration (Cpprop). B shows BIS versus effect site concentration (Ceprop), based on ke0 estimate by NONMEM. To visual-
ize the source data and results for the fixed number model, we showed the measured BIS data  90 as black circles. The 
second part (the sigmoid Emax model using BIS<90) data are shown as straight lines. C shows the individual prediction error 
(PE) from the best fitting model (fixed  90, sigmoidal <90, 10 s delay; including estimates of interindividual variabililty on 
ke0 and Ce50).
If propofol administration rate is influencing the time course of drug effect, a model incorporating 
different estimates of ke0 for different infusion rates would yield a better model fit than a model 
whereby one ke0 was used to describe the time course of effect site concentration independent of drug 
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administration rate. We found that the model discriminating the bolus injection group from the three 
continuous infusion groups yielded a significantly better fit than a model with a single ke0 for all four 
groups. In our bolus group, the value of t½ ke0 was 1.2 min, very close to the value of 1.5 min reported 
by Schnider et al.3  whose value of ke0 was primarily based on bolus propofol administration. In the 
Schnider study, the bolus was administered in a mean time of 18 s (range, 13±24 s), which is some-
what slower than in our study (table 2). In addition, our calculated time of maximum BIS effect in the 
bolus group was 1.7 min (table 4), exactly the same as reported by Schnider et al.3 Our t½ ke0 of 2.2 
min for propofol administration by infusion is in agreement with the value computed from the valida-
tion data set of Doufas et al.5 of 2.1 min, both of which reflect fast infusions, but obviously less rapid 
than bolus injections. 
Our findings are consistent with propofol modeling studies using a conventional continuous infusion, 
which have reported propofol t½ ke0s between 2.3 and 3.5 min. In the first commercial target-
controlled infusion device (Diprifusor; AstraZeneca), the kinetic model described by Marsh et al.10
was linked to a t½ ke0 of 2.65 min as described by Schwilden et al.
13 and based on slow continuous 
infusion data. Billard et al.14 administered propofol (continuous infusion of 0.5 mg · kg-1 · min-1 until 
burst suppression) and measured the electroencephalographic effect using three different electroen-
cephalographic measures. The estimates of t½ ke0 were significantly higher (mean, 2.6 min) for delta 
power than those for spectral edge 95% (mean, 3.5 min) and Bispectral Index version 1.1 (mean, 3.5 
min). White et al.15 used midlatency auditory evoked potentials to measure propofol drug effect, when 
administered as a continuous infusion (0.5 mg · kg-1 · min-1), and calculated a ke0 of 3.5 min (mean 
value). All of these effect measures were modeled without including any delay in the electroencepha-
lographic measure. 
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Ke0 is dependent on the accuracy of the underlying pharmacokinetic model, and if the pharmacokinetic 
model is biased, the estimate of ke0 will be biased by that error. One limitation of our study is that we 
did not include measurement of propofol plasma concentrations over time in our four groups. Similar 
to previously published work,5,16±18 we applied the three-compartment model published by Schnider et 
al.6 to predict the time course of the propofol plasma concentration. In the study by Doufas et al.,5 the 
pharmacokinetic performance of the propofol pharmacokinetics reported by Schnider et al.3 was vali-
dated with rapid arterial samples and found to be accurate. Because our study was designed specifical-
ly to test the hypothesis in the Doufas article that the difference in values of ke0 might depend on the 
difference between a bolus and a continuous infusion of propofol, we did not believe it was necessary 
to collect arterial blood samples in all patients during the bolus (similar to the infusion scheme used by 
Schnider in deriving the pharmacokinetics 6) or the infusions (where the pharmacokinetics have been 
validated by both Doufas and Schnider). 
However, the literature has not documented the accuracy of the Schnider pharmacokinetic model in 
the first minutes after bolus injection. Therefore, we added the bolus validation study and documented 
that neither model performed well in the first 3 min (fig. 4). The failure of both models in the first 3 
min is an expected consequence of a flawed fundamental assumption with mammillary compartment 
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models: instantaneous mixing in the central compartment. Conventional two- and three-compartment 
mammillary compartment models assume that drug added to the central compartment is instantaneous-
ly completely mixed, and that this mixed plasma instantaneously appears in the arterial circulation. 
This is not the case, as extensively reported by Henthorn et al.19±21 and others.22,23 The reason that more 
complex models have not been integrated into target-controlled infusion systems is that incorporating 
this into target-controlled infusion algorithms introduces considerable mathematical complexity. Be-
cause the problem with model misspecification is limited to the first few minutes after bolus injection, 
there is limited incentive to develop hybrid models to correct the fundamentally flawed assumption of
instantaneous mixing. 
The initial error in the pharmacokinetic models is evident for the full 5 min with the Marsh model but 
seems to be resolving by 3 min with the Schnider model. Therefore, the Schnider model comes closest 
to fitting the bolus validation data and would be the better of the two models to use for this purpose. 
The simulation results from the bolus validation study (fig. 5) show that a t½ ke0 of 2.0 min, coupled to 
a more accurate pharmacokinetic model, predicts a peak effect site concentration of 1.9 min, as ob-
served with our bolus data (table 4). This is fairly close to the t½ ke0 of 2.2 min that we estimated for 
the three infusion groups, and demonstrates that most of the difference in ke0 between bolus and infu-
sion administration is an artifact caused by the inability of mammillary models to accurately describe 
the concentrations in the first few minutes after bolus injection. The actual rate of blood±brain equili-
bration may not differ between bolus and infusion methods of administration. 
This does not preclude the possibility that there are physiologic reasons the rate of plasma±effect site 
equilibration might change with infusion rate. Upton and Ludbrook 24,25 demonstrated that propofol 
decreases cerebral blood flow in a dose-dependent manner. This might explain why the plasma±effect
site equilibration time of propofol could change between a bolus, whose high early concentrations 
acutely decrease cerebral blood flow, and an infusion, where the changes in cerebral blood flow would 
be small. 
The rate of propofol administration influences the apparent rate of plasma±effect site equilibration. 
This is partly, and perhaps mostly, a result of the inability of conventional pharmacokinetic models to 
accurately describe the first few minutes after bolus injection. Target-controlled infusion devices need 
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to select the value of ke0 that will most accurately represent the effect site concentrations over time. 
The error in the pharmacokinetic model with rapid administration can be partly compensated for by 
the selection of ke0. If the maximum infusion rate is between 300 and 900 ml/h, this corresponds to the 
infusion rates in our three infusion groups, and the t½ ke0 should be approximately 2.2 min (ke0 = 0.32). 
However, if the infusion is closer to our bolus rate (2.5 mg/kg over 10 s almost equal to 6,300 ml/h), 
the faster t½ ke0 of 1.2 min will better approximate the time course of drug effect. These values of ke0
are for use with the Schnider pharmacokinetics. If these data are to be implemented with other phar-
macokinetics, then they should be implemented to achieve the predicted time of peak effect of 1.5 min 
if the device delivers an induction dose of propofol over a minute or less. If the pump is unable to 
infuse propofol that quickly, selecting ke0 based on a peak effect of 1.8 min is appropriate.
2
We conclude that the observation of Doufas et al. is correct, although the explanation is surprising. 
There is a difference in the apparent rate of plasma±effect site equilibration between propofol boluses 
and propofol infusions. The difference is mostly caused by misspecification in the pharmacokinetic 
model over the first few minutes after bolus injection. A pharmacokinetic model that accurately pre-
dicted propofol concentration in the first few minutes after bolus injection, and for many hours after 
infusion, might improve the accuracy of target-controlled infusion administration when targeting the 
site of drug effect. If propofol infusion rate affects the apparent ke0 even when the pharmacokinetic 
model is unbiased, there may also be a physiologic basis for dependence of ke0 on propofol infusion 
rate. 
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CHAPTER  4 
 
Study of the time course of the clinical effect of propofol 
compared  with the time course of the predicted effect-
site concentration: performance of three pharmacoki-
netic Ȃ dynamic models 
British Journal of Anaesthesia 104 (4): 452±8 (2010)
 
M. Coppens, J. G. M. Van Limmen, T. Schnider, B. Wyler, S. Bonte, F. Dewaele, M. M. R. F.
Struys and H. E. M. Vereecke
Introduction
 
In this study we investigated the performance of 3 effect-site controlled drug titration algorithms in an ASA 1 
and 2 population. One would expect that in such a population the estimated effect-site concentration has a con-
stant function with the desired clinical effect. We studied whether the respective effect-site controlled titration 
algorithms allow to maintain this desired clinical effect over time, once the corresponding effect-site concentra-
tion in the individual patient is known and targeted. We therefore expected the BIS to stay at a constant level 
corresponding with loss of response to name calling in every patient. Nevertheless this was not the case. Pa-
tients woke up (Marsh) or BIS decreased (Schnider). The models are developed in different ways, have differ-
ent parameters and hence generate different infusion rates when used in effect-site controlled TCI. 
 PK and PD estimates are closely linked to one another, they contribute to the (in-) accuracy of the estimated 
effect-site concentration to correlate with a clinical effect. Therefore optimal PK-PD model building should 
always be estimated simultaneously within one study population. 
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Study of the Time Course of the Clinical Effect of Propofol versus the Time Course of the Predicted 
Effect-site Concentration of Propofol. Performance of Three Pharmacokinetic-dynamic Models in 
Steady-State Conditions. 
Marc Coppens, MD, Jurgen Van Limmen, MD, Thomas Schnider, Prof. Dr. med., Barbara Wyler, MSc, 
Sjoert Bonte, BSc, Frank Dewaele, MD, Michel MRF Struys, Prof., M.D, PhD, Hugo EM Vereecke, MD, 
PhD
Abstract 
Background: In the ideal pharmacokinetic-dynamic (PK-PD) model for calculating the predicted effect-
site concentration of propofol (CePROP), for any CePROP the corresponding hypnotic effect should be con-
stant. We compared three PKPD models (Marsh PK with Shüttler PD, Schnider PK with fixed ke0, and 
Schnider PK with Minto PD) in their ability to maintain a constant bispectral index (BIS), while using the 
respective effect-site controlled target controlled infusion (TCI) algorithms. 
Methods: :H UDQGRPL]HGSDWLHQWV WR JURXS0 0DUVK¶VPRGHOZLWK Ne0= 0.26 min-1), Group S1 or 
JURXS66FKQLGHU¶VPRGHOZLth a fixed ke0 = 0.456 min-1 or a ke0 adapted to a fixed time to peak effect = 
1.6 min, respectively). All patients received propofol at constant rate until loss of consciousness. The cor-
responding CePROP, as calculated by the respective models, was set as target for effect-site controlled TCI. 
We observed BIS for 20min. We hypothesized that BIS remains constant if CePROP remains constant over 
time.
Results: All patients in group M woke up, one in group S1 and none in group S2.  In groups S1 and S2, 
BIS remained constant after 11 minutes of constant CePROP, at a more pronounced level of hypnotic drug 
effect than intended. 
Conclusions: Targeting CePROP at which patients lose consciousness with effect-site controlled TCI does 
not translate into an immediate constant effect. 
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Introduction 
Three compartmental pharmacokinetic (PK) models are used in  target controlled infusion (TCI) pumps to 
predict plasma-concentrations of propofol (CpPROP), based on drug input
1-4. As the plasma is not the site of 
drug effect, hysteresis exists between CpPROP and clinical effect. Extending the PK model with an effect 
compartment enables modeling of the effect-site concentration of propofol (CePROPFDOOHG³OLQNPRGHO´
RU³SKDUPDFRG\QDPLF3'PRGHO´5. The extension of the PK model with a PD model requires one addi-
tional transfer constant, called ke0. The relationship between CePROP and effect is governed by a static (time 
independent) non-linear (sigmoidal) relationship. Therefore, a change in CePROP should directly translate 
into a change of effect without time delay.  
In TCI pumps, concentrations at the effect site are calculated with different pharmacokinetic models and 
different ke0. In this study, we investigate differences in time course between CePROP and clinical effect 
between models. We compare three PK-PD models to predict CePROP corresponding with loss of response 
to name calling (LORNC). Subsequently, we use the respective effect-site controlled TCI algorithms to 
maintain a constant CePROP. We hypothesized that by targeting CePROP compatible with LORNC, the clini-
cal signs of consciousness and bispectral index (BIS) should remain constant.  
Materials and Methods 
After institutional Ethics Committee approval (University Hospital, Ghent, Belgium), informed consent 
was obtained from 60 American Society of Anesthesiologists I patients, aged between 18 and 65 years, 
scheduled for minor ambulatory surgery. Exclusion criteria were weight less than 70% or more than 130% 
of ideal body weight, neurological disorder, and recent use of psychoactive medication, including alcohol. 
All measurements for this study were performed before surgery. 
An 18 gauge intravenous line was positioned at a large forearm vein. Every patient received about 300ml 
of crystalloid fluid during the study period. No fluid load was given before induction of anesthesia. No 
patient received preoperative medication. No other drugs, including opioids, were given during the study 
period. All patients maintained spontaneous breathing with the use of a face mask delivering 100% of 
oxygen at 6 L/min. 
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Heart rate and non-invasive blood pressure, arterial oxygen saturation and capnography were recorded at 
1-min time intervals using an S-5 monitor (GE Healthcare, Helsinki, Finland). Capnography was moni-
tored by putting the side stream sample line in the face mask of the patient. This implies an error for quan-
tification of the partial pressure of carbon dioxide, but it enabled monitoring of respiratory rate and free 
airway.
During the study period, bispectral Index (BIS) was derived from the frontal electroencephalogram  (At-
Fpzt) and calculated by  a BIS® XP Monitor(version 4.0) (Aspect Medical Systems, Norwood, MA, USA) 
using a BIS-Sensor electrode (Aspect Medical Systems, Inc., Norwood, MA, USA). The smoothening 
time of the BIS monitor was set at 15 seconds.  
All data was captured using RUGLOOPII (Demed, Temse, Belgium), a computer-assisted data manage-
ment device, that simultaneously drives and controls an Asena GH Infusion Pump (Carefusion, Basing-
stoke, UK)  for the administration of propofol. At the start of the study, propofol 1% is administered at 
300 ml/h. Meanwhile, the corresponding effect-site concentration of propofol (CePROP) is calculated in a 
time synchronized way by RUGLOOPII using one of the studied PK-PD models, defined by randomiza-
tion. At any given time, the researcher was able to switch this regular propofol administration to an effect-
site controlled target controlled infusion (TCI) setting, using the same PK-PD parameters.  
Before starting the drug administration, all patients were asked to close their eyes and relax for two 
minutes. During that time, signal quality, impedance of the electrodes and the adequate capturing of all 
parameters by RUGLOOPII was verified. Propofol 1% was started at 300 ml/h. The propofol infusion was 
maintained until we observed loss of response to name calling (LORNC). At LORNC, the corresponding 
CePROP, as calculated by one of the three studied PK-PD models, was set as a target for effect-site con-
trolled TCI administration, using the same PK-PD model as defined by the randomization process. This 
effect-site controlled TCI of propofol was maintained for an additional 20 minutes if feasible. During that 
time the clinical level of consciousness was verified by repeated name calling every 15 seconds. BIS was 
also observed during the entire study period as an objective quantification of cerebral hypnotic effect.6
The study period ended after 20 minutes of measurements or when a patient regained consciousness 
(ROC) defined as a return of responsiveness on name calling. 
LORNC was defined as a transition from level 3 to 2 on the modified Observers Assessment of Alertness 
and Sedation (OAA/S) scale.6-7 To avoid inter-observer differences for defining LORNC, the methodology 
was standardized according to a predefined sequence of actions. Before induction, the patients were asked 
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EDVHG
on the RUGLOOPII case time) until no response was observed. If the patient did not respond within 5 
seconds after name calling, the name was repeated twice.  When the patient did not respond to the second 
name calling, the OAA/S was set at 2. A positive response to the second name calling was classified as 
OAA/S = 3. In that case, an additional 15 seconds delay was respected before repeating the name calling. 
We randomized all patients to one of three study groups. For Group M, the effect-site concentration was 
calculated by the PK model of Marsh extended with a ke0 = 0.26 min-1.3,4,8,9 This model has been com-
mercialized for plasma controlled TCI in the Diprifusor® Infusion module. (AstraZeneca, Brussels, Bel-
gium). In this commercialized device the calculated CePROP is only available as background information. 
The Marsh PK-PD parameters are currently not commercially available for effect-site controlled TCI, but 
RUGLOOPII overruled this limitation, and was set to allow effect-site controlled TCI with this parameter 
set.
For Group S1 and S2, the pharmacokinetic parameters as described by Schnider were used. In group S1, 
the original PK-PD model of Schnider was used. In this model ke0 is constant for all individuals (0.456 
min-1)2. This model is commercially available in the Fresenius Base Primea (Fresenius Vial Infusion Sys-
tems, Brézins, France).  
For Group S2, the pharmacokinetic parameters are identical to group S1, but CePROP was computed using 
the time-to-peak effect (TTPE) method as described by Minto et al.10 CePROP is  calculated to yield a con-
stant TTPE between individuals of 1.6 min (=101sec) after bolus injection, resulting in a individually var-
iable ke0.
10 This model is commercially available in the Asena PK pump for effect-site controlled TCI. 
(Carefusion, Basingstoke, UK) 
All parameters of the PK-PD models can be found in detail in table 1. 
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Statistical analysis 
Statistical significance was set at p<0.05 except mentioned otherwise. Differences in demographics 
between groups are tested using Anova except mentioned otherwise. All haemodynamic and electro-
encephalographic data are extracted from RUGLOOPII using LABGRAB software (Demed, Temse, 
Belgium) in 5 seconds intervals. We compared the CePROP compatible with LORNC in all groups, us-
ing Anova.
For BIS, we averaged all individual BIS values per minute and calculated the mean population BIS 
and standard deviation per minute for the duration of the study. Steady-state in BIS was defined as a 
non significant difference between the respective mean BIS over consecutive minutes, as found by a 
repeated measures ANOVA with Tukey-Kramer post hoc test.  
Results 
Demographics are shown in table 2. Groups are not significantly different for age, weight, length and 
LBM. Group S2 contains a higher number of male participants compared to group M and S1. The time 
to LORNC and the BIS compatible with LORNC were also not significantly different between groups. 
(Table 2) 
Figure 1 (A, B and C) shows the individual CpPROP and CePROP versus time for group M, S1 and S2 
respectively. The mean CePROP compatible with LORNC was significantly different between groups 
(p<0.0001), being 1.96 (+/-0.55), 5.54 (+/-0.75) and 5.08 (+/-1.20) µg/ml for group M, S1 and S2 re-
spectively. The mean CePROP at LORNC was not significantly different between groups S1 and S2. 
In group M, we found that all patients regained consciousness after a mean duration of 401 (+/-102) 
sec. In contrast, in Group S1, only one patient regained consciousness after 505 seconds of propofol 
titration and all patients remained unconscious in group S2 throughout the entire study period. 
Figure 2 shows the individual BIS measurements over time (figure 2A,C,E) and the corresponding 
mean BIS values for every minute of measurement (figure 2 B,D,F). Steady state in BIS values was 
found after respectively 6 minutes in group M, and 11 minutes in both S1 and S2. (Indicated by stars 
in figure 2B, 2D and 2E) For group M, this steady-state in BIS was only found after return of con-
sciousness occurred in all patients, at a clinically relevant lighter level of hypnotic drug effect than 
intended. For group S1 and S2,  
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Fig 1 The individual plasma-(dotted line) and effect-site concentration (full line) versus time in Group M 
0DUVK¶VPRGHO$*URXS66FKQLGHU¶Vmodel with a fixed ke0) (B), and Group S2 (6FKQLGHU¶V model with a 
fixed TTPE) (C) 
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)LJ7KHLQGLYLGXDO%,6YDOXHVYHUVXVWLPHDQGWKHLUUHVSHFWLYHPHDQ%,6YDOXHV6'LQ*URXS00DUVK¶V
PRGHO$DQG%*URXS66FKQLGHU¶VPRGHOZLWKDIL[HGNe0) (&DQG'DQG*URXS66FKQLGHU¶VPRGHO
with a fixed TTPE) (E and F).*steady state condition in BIS  (non significant BIS changes). 
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BIS showed a more pronounced hypnotic drug effect during steady-state (min 11) compared with the 
mean BIS at LORNC. (Table 3) Additionally, between minutes 11 and 20, BIS of group S1 was al-
ways significantly lower compared to BIS in group S2. (Table 3)  
Discussion 
In an accurate PK-PD model for propofol, any predicted CePROP should be time independently and 
unequivocally related to hypnotic effect. Although the estimated CePROP at LORNC was kept constant 
in our study, we found that all three studied PK-PD models failed to maintain a constant hypnotic ef-
fect over time. When using the Marsh PK-PD parameter set, all patients woke up and BIS increased 
over time. In contrast, when using two PD variations of the Schnider PK model, BIS decreased for 
several minutes, indicating a progressively intensifying hypnotic effect. Only after 11 minutes of ef-
fect-site controlled TCI titration, both CePROP and BIS remained constant over time.   
The discrepancy in performance results from differences between models, both on a PK and PD level. 
First, Schnider et al.2 estimated a smaller central compartment volume for propofol compared with 
Marsh et al. When the volume of the central compartment of any PK-PD model is decreased, a contin-
uous infusion of propofol will result in a faster increase of CpPROP, provided that the other volumes and 
equilibration constants remain identical. Therefore, the larger central compartment of the Marsh model 
might be a determinant of the slower increase in CpPROP in group M compared with groups S1 and S2. 
The significantly lower CpPROP at LORNC in group M unavoidably affects CePROP at LORNC, which 
was also significantly lower in group M compared with the other groups. 
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After LORNC, we switched to effect-site controlled TCI, using the respective predicted CePROP at 
LORNC as a target. At that time, the pump will temporarily stop infusing propofol until CpPROP and 
CePROP are in equilibrium. The time to equilibrate CpPROP and CePROP is determined both by the charac-
teristics of the three compartmental PK model and ke0. A higher ke0 reflects a more rapid equilibration 
between the central compartment and the effect-site. The fixed ke0=0.456min
-1 of group S1, and the 
variable ke0=0.362 (+/-0.04) min
-1 of group S2 are both considerably larger than the ke0=0.26 min
-1 of 
group M.8-9  Theoretically, the combination of both PK and PD model differences between groups, 
might have resulted in a comparable equilibration time. However, in our study, the pump in groups S1 
and S2 was prompted to restart propofol administration before return of consciousness could occur, 
whereas in group M, the pump did not deliver any propofol for a long time and all patients regained 
consciousness. (Table 4) 
We stopped measuring once ROC occurred, as our patients were undergoing elective surgery. We 
manually administered additional propofol after ROC to evoke anesthesia compatible with the planned 
surgery. One can only speculate what would have happened if we had continued the TCI titration in 
group M. Either patients might have remained responsive while experiencing a light level of sedation 
(in steady-state) or at the other hand,  we might equally observe patients who lose consciousness 
again, once propofol restarts, as instructed by the PK-PD model. Our study design does not allow a 
conclusive statement on this possibility. 
Comparing results in group S1 and S2, we observed a comparable behaviour in clinical observations 
and BIS. In group S1, one patient woke up after 505 sec, whereas, in group S2, all patients remained 
unconscious. Apart from the only exception in group S1, mean BIS decreased in both groups during 
11 minutes, indicating a progressively intensified hypnotic drug effect over time in most patients. This 
observation can be a reflection of inaccuracy of the PK-PD model. On the other hand it might equally 
be a FRUUHFWGHWHFWLRQRIWZRGLVWLQJXLVKDEOHFOLQLFDOFRQGLWLRQV³WKHPRPHQWXPRI/251&´YHUVXV
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³WKHFRQGLWLRQRIPDLQWDLQLQJXQFRQVFLRXVQHVVDIWHU/251&KDVoccurred´,IDSDWLHQWQHHGVDKLJKHU
concentration of propofol for falling asleep compared with maintaining the unresponsiveness, the BIS 
is expected to go down even when CePROP at LORNC is kept constant over time.  Some evidence is 
available that loss of consciousness and return of consciousness are the result of separate neuro-
physiological pathways.11 Additionally, the level of adrenergic activity in the awake might be involved 
in a higher need for propofol to evoke LORNC compared to maintaining a comparable level of unre-
sponsiveness when the adrenergic tone is suppressed. If these assumptions are confirmed in future 
studies, a temporary decrease in BIS is to be expected in our study setting. After reconsideration of 
these assumptions, we conclude that an overlapping time course of the BIS effect and CePROP as hy-
pothesized in this study is not something we can expect as a proof of accuracy of the PK-PD model. 
7KLVZLOORQO\EHWUXHLQWKHVSHFLDOFDVHWKDW³&HPROP DQGHIIHFW´UHODWHLQDFRQVWDQWIXQFWLRQUHOa-
tionship) between each other over time. (e.g. Effect = some parameter x CePROP)
A better understanding of the covariates that determine the duration of inconsistency between a con-
stant CePROP and an observed hypnotic effect could help researchers to better target anesthetic steady 
state conditions. Many covariates can be suspected that affect the time to obtain steady state.  First, a  
Table 4: Time of the pump inactivity after LORNC *P<0.001(ANOVA) between 
Groups M and S1, and Groups M and S2. 
$
P>0.05(ANOVA) between Groups S1 and S2
Group M Group S1 Group S2 
Mean pump inactivity time (s) 233* 102*$ 81*$ 
SD 105 32 20 
n 20 20 20 
high induction speed (of more than 6000 ml/h) interferes with the estimation of  ke0, as published by 
Struys et al.12 In contrast, moderate induction speeds appear to be a relevant covariate in the PK rather 
than in the PD part of the model.13 In our study, we administered propofol at moderate speed of 3000 
mg/h. The time to reach steady state could therefore be different with induction speeds other than 3000 
mg/h. Secondly, the value of the measurement of hypnotic drug effect must be considered. Different 
clinical endpoints or surrogate measures of cerebral hypnotic drug effect relate differently with CePROP
and will affect time to reach steady state. When using solitary effect-site controlled TCI of propofol, it 
remains challenging to predict the time course of a corresponding effect. It seems inevitable to use a 
surrogate quantification of cerebral hypnotic drug effect (such as BIS) to detect the exact onset time of 
the steady-state condition. Additionally, such measurements can help to readjust CePROP towards a 
predefined hypnotic drug effect. The major strength of the effect-site controlled TCI technology lies 
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not in predicting the resulting hypnotic effect in the individual patient, but rather in its ability to main-
tain the pharmacological condition once a predefined clinical effect has been reached. 
In conclusion, when targeting a constant CePROP at LORNC by means of effect-site controlled TCI 
using three different PKPD models, we observed either recovery (Marsh model) or intensifying hyp-
notic effect (Schnider PK model with fixed ke0 or fixed TTPE).  Therefore, surrogate measures of hyp-
notic drug effect, such as bispectral index (BIS), remain a valuable tool to provide the clinician with 
additional information on the correlation between time courses of CePROP versus the observed clinical 
effect. 
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CHAPTER 5 
 
An Evaluation of Using Population Pharmacokinetic 
Models to Estimate Pharmacodynamic Parameters for 
Propofol and Bispectral Index in Children 
Anesthesiology 2011;  115:83±93
Marc J. Coppens, M.D.,Douglas J. Eleveld, Ph.D., Johannes H. Proost, Pharm.D., Ph.D.,Luc A. 
M. Marks, D.D.S., Ph.D.,Jan F. P. Van Bocxlaer, Pharm.D., Ph.D.,
Hugo Vereecke, M.D., Ph.D.,Anthony R. Absalom, M.D., Michel M. R. F. Struys, M.D., Ph.D. 
Introduction
In the first study it was shown that using flawed estimated plasma concentrations could result in 
pharmacodynamic parameters of poor accuracy. 
The following article is a validation of the Kataria model. We showed that the Kataria model is biased and 
inaccurate. When the Kataria model (just like any other currently used model) is used to estimate plasma 
concentrations the PD parameters of the combined PK-PD model are also inaccurate. 
Rigouzzo used the Schnider model to estimate plasma concentrations and concluded that the Schnider 
model is accurate to describe the PD of propofol in children. We agree with Rigouzzo that the model is 
accurate in describing the PD of propofol but warn for the complete inaccuracy of the Schnider model for 
describing the PK of propofol..Additionally we propose a new combined PK-PD model for propofol TCI in 
children. 
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An Evaluation of Using Population Pharmacokinetic Models to Estimate Pharmacodynamic 
Parameters for Propofol and Bispectral Index in Children 
Marc J. Coppens, M.D., Douglas J. Eleveld, Ph.D., Johannes H. Proost, Pharm.D., Ph.D., Luc A. M. 
Marks, D.D.S., Ph.D., Jan F. P. Van Bocxlaer, Pharm.D., Ph.D., Hugo Vereecke, M.D., Ph.D., Antho-
ny R. Absalom, M.D., Michel M. R. F. Struys, M.D., Ph.D.  
ABSTRACT  
Background: To study propofol pharmacodynamics in a clinical setting a pharmacokinetic model 
must be used to predict drug plasma concentrations. Some investigators use a population pharmacoki-
netic model from existing literature and minimize the pharmacodynamic objective function. The pur-
pose of the study was to determine whether this method selects the best-performing pharmacokinetic 
model in a set and provides accurate estimates of pharmacodynamic parameters in models for 
bispectral index in children after propofol administration. 
Methods: Twenty-eight children classified as American Society of Anesthesiologists physical status 1 
who were given general anesthesia for dental treatment were studied. Anesthesia was given using tar-
get-controlled infusion of propofol based on the Kataria model. Propofol target plasma concentration 
was 7 µg/ml for 15 min, followed by 1 µg/ml for 15 min or until signs of awakening, followed by 5 
µg/ml for 15 min. Venous blood samples were taken 1, 2, 5, 10, and 15 min after each change in tar-
get. A classic pharmacokinetic-pharmacodynamic model was estimated, and the methodology of other 
studies was duplicated using pharmacokinetic models from the literature and (re-)estimating the 
pharmacodynamic models.  
Results: There is no clear relationship between pharmacokinetic precision and the pharmacodynamic 
objective function. Low pharmacodynamic objective function values are not associated with accurate 
estimation of the pharmacodynamic parameters when the pharmacokinetic model is taken from other 
sources.
Conclusion: Minimization of the pharmacodynamic objective function does not select the most accu-
rate pharmacokinetic model. Using population pharmacokinetic models from the literature
iQVWHDGRI WKH µWUXH¶SKDUPDFRNLQHWLFPRGHO FDQ OHDG WR EHWWHU SUHGLFWLRQV RI ELVSHFWUDO LQGH[ZKLOH
incorrectly estimating the pharmacodynamic parameters. 
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PROPOFOL is widely used to manage the hypnotic component of anesthesia in children because of its 
beneficial pharmacologic characteristics, although caution is warranted in relation to side effects such 
as the propofol infusion syndrome.
1
Pharmacokinetic-pharmacodynamic (PK-PD) models predicting 
the time course of drug concentration and effect might be helpful to optimize drug administration if 
found to be an accurate prediction of reality. A number of population pharmacokinetic models have 
been developed to predict propofol plasma concentrations in children for arterial blood samples,2±4
venous blood samples,5±7 or both.8 In two recent studies, Rigouzzo et al.9,10 suggested that a propofol 
model describing the PK-PD relationship in adults11,12 might be used in children. Some of these popu-
lation pharmacokinetic models are used in target-controlled infusion (TCI) regimens to modulate pre-
dicted propofol plasma concentrations. However, plasma concentrations are only of secondary im-
portance in anesthesia because plasma is not the site of drug effect. For propofol anesthesia, cerebral 
drug effects can be measured and are quantal (e.g., loss and return of consciousness, tolerance to nox-
ious stimulus) or continuous (e.g., electroencephalographic data) in nature. The Bispectral Index (BIS, 
Covidien, Norwood, IL), a quantitative parameter derived from the frontal electroencephalogram, has 
been validated as a measure of propofol cerebral drug effect in children older than 1 yr.9,10,13,14
To study propofol pharmacodynamics in a clinical setting, where dosing varies according to patient 
requirements, a pharmacokinetic model must be used to predict drug plasma concentrations. The 
methodologically best approach is the classic PK-PD approach in which population and individualized 
pharmacokinetic models are estimated using blood samples drawn from the study patients and the 
individualized pharmacokinetic model used for subsequent pharmacodynamic estimation. However, 
drawing blood samples is not always practical or possible in some clinical situations. Some investiga-
tors have instead applied what we describe in this investigation as the PK(predicted)-PD approach, 
where the individualized pharmacokinetic model is replaced by a population pharmacokinetic model 
obtained from existing literature. This fixed population model is then used to produce the pharmacoki-
netic predictions necessary to study the pharmacodynamics. In this investigation, to clarify the particu-
ODU SKDUPDFRNLQHWLFPRGHO XVHG WKHZRUG ³SUHGLFWHG´ can be changed to indicate the origin of the 
pharmacokinetic model. For example, a PK (Kataria)-PD model indicates that the Kataria model6 was 
used for pharmacokinetic predictions.
The PK (predicted)-PD approach leads to questions about the accuracy of the population predictions 
for individuals in a particular clinical situation. One approach is to simply take the accuracy for grant-
ed.15 This seems difficult to justify because a number of pharmacokinetic models 
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are available in the literature, each giving different predictions for a given situation. Another approach 
is to consider a number of pharmacokinetic models and choose the best one based on some quality of 
the corresponding pharmacodynamic estimation, such as the objective function.10,16 This approach 
assumes that the best-performing pharmacokinetic model can be identified by the lowest objective 
function from the corresponding pharmacodynamic estimation. However, this relationship has not yet 
been experimentally demonstrated. Studies using this approach also estimate important pharma-
codynamic model parameters, such as effect-site equilibration constant (ke0) or the effect-site concen-
tration for 50% effect (Ce50), by minimization of the pharmacodynamic objective function. However, 
there is no evidence that low values for the objective function are associated with accurate estimation 
of these parameters when the pharmacokinetic model is taken from other sources. It has been recently 
shown that fundamental flaws can be introduced when applying predicted instead of measured 
propofol plasma concentration when investigating the half-life for the effect-site equilibration in 
adults.17±19
The purpose of the current study was to test two hypotheses: that the PK (predicted)-PD approach 
selects the best-performing pharmacokinetic model from those considered, and that the PK (predict-
ed)-PD approach provides accurate estimates of pharmacodynamic model parameters. We performed 
propofol TCI-driven anesthesia on children and obtained propofol plasma concentrations from blood 
samples and BIS values as a measure of cerebral drug effect. From these data we estimated a classic 
PK-PD model, where both a pharmacokinetic and pharmacodynamic model is estimated. We also du-
plicated the methodology of other studies by estimating PK (predicted)-PD models, i.e., using phar-
macokinetic models from the literature and (re-)estimating only the pharmacodynamic models. By 
comparing the estimation results of the different approaches we determined the ability of the PK (pre-
dicted)-PD approach to identify the best-performing pharmacokinetic model and provide informative 
estimates for the true pharmacodynamic parameters.  
 
Materials and Methods  
 
Clinical Protocol  
 
After Ethics Committee approval (Ghent University Hospital, Gent, Belgium), clinical trial registra-
tion (EUDRACT 2005-001797-27), written informed consent of the parents or legal representative 
obtained by the dentist, and a clinical examination done by the anesthesiologist, 28 children classified 
as American Society of Anesthesiologists physical status 1 were enrolled in the study. Patients were 
divided in four groups according to age: 7 children age 3±5 yr in group 1, 7 children age 5±7 yr in 
group 2, 7 children age 7±9 yr in group 3, and 7 children age 9±11 yr in the fourth group. All children 
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Exclusion criteria were allergy to any of the constituents of propofol or local anesthetics, previous 
adverse anesthetic experience, evidence of major preexisting disease, suspected difficult airway, con-
comitant disease, or antibiotic treatment. No premedication was offered to the patients. The skin was 
locally anesthetized by applying eutectic mixture of local anesthetic cream (EMLA, AstraZeneca, 
Ukkel, Belgium) over the site of the peripheral veins 1 h before the procedure.  
Noninvasive monitoring (heart rate, noninvasive blood pressure monitoring, saturation, end-tidal car-
bon dioxide) was established before induction of anesthesia. The propofol cerebral drug effect was 
continuously monitored using the bispectral index (BIS). BIS (version 4.0, XP) was derived from the 
frontal electroencephalogram and calculated by the A-2000 BIS Monitor® (Covidien, Newton, MA) 
using three BIS-Sensor electrodes (pediatric size) or the four-sensor electrode, depending on the pa-
WLHQW¶VDJH7KH%,6YDOXHUDQJHVIURPWR7KHVPRRWKLQJ WLPHRf the BIS monitor was set to 
15s.
Venous access was established with two 20-or 22-gauge peripheral intravenous cannulae. The first 
cannula was connected to the infusion pump, and the second cannula was used for blood sampling. 
The TCI system used to control the propofol infusion comprised a syringe infusion pump (Asena, 
Carefusion, Basingstoke, United Kingdom) controlled by a computer programmed with RUGLOOPII 
(Demed, Temse, Belgium) using a pharmacokinetic model for propofol administration in children, in a 
study previously published by Kataria et al.6. Propofol was started at a target plasma concentration of 7 
µg/ml for 15 min, followed by a target concentration of 1 µg/ml for another 15 min or until signs of 
awakening (BIS more then 80, movement, eye opening). Finally, the infusion was followed by a target 
plasma concentration of 5 µg/ml for 15 min. After initial loss of consciousness a laryngeal mask was 
inserted. No opioid was administered. All children received a crystalloid infusion of 4±5 ml/kg/h dur-
ing the study. Each blood sample (2 ml per sample) was replaced by 2 ml of crystalloid solution. Dur-
ing the procedure the children were kept warm with a Bair Hugger (Arizant Healthcare, Eden Prairie, 
MN). The complete study was executed before the start of surgery.  
Venous blood samples were collected at baseline (upon placement of the cannula) and after 1, 2, 5, 10, 
and 15 min at a target of 7 µg/ml. After decreasing the target concentration to 1 µg/ml, blood was 
withdrawn after 1, 2, 5, 10, and 15 min when possible. After increasing the target concentration to 5 
µg/ml, blood samples were obtained at 1, 2, 5, 10, and 15 min. At that time the study period was com-
pleted and the anesthesia was continued at the discretion of the anesthesiologist in charge. The collect-
ed blood samples (EDTA) of each child were centrifuged, and the obtained plasma was stored in a 
refrigerator at a temperature at -80°C for further analyses. Propofol (bound and free) plasma concen-
trations were analyzed using a validated liquid chromatographic fluorescence detection method.  
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were scheduled for dental treatment under general anesthesia. 
  
In short, plasma (500 µl) was treated with 1 ml acetonitrile (containing the internal standard 2,4-di-
tert-butylfenol) to initiate plasma protein precipitation. After centrifugation, 10 µl of the clear superna-
tant is injected into the liquid chromatography system (Kontron 325 pump system, Kontron Instru-
ments, Milano, Italy) and Hitachi AS2000A autosampler (Hitachi, Tokyo, Japan). Separation was 
obtained on a Discovery C18 column (5 µm, 50 X 2.1 mm; Supelco, Sigma-Aldrich, Bornem, Bel-
gium) using a water/acetonitrile gradient. Detection was achieved using a Shimadzu RF-10AXL fluo-
rescence detector (Shimad]X.\RWR-DSDQȜH[DQGȜHPQP9DOLGDWLRQDFFRUGLQJWR)RRG
and Drug Administration guidelines: Bioanalytical Method Validation, Guidance for Industry) data 
include: limit of detection 0.0935 µg/ml; limit of quantification 0.2 µg/ml, weighted (1/x) linear re-
gression model calibration curves from 0.20 to 15.0 µg/ml (11 calibrators + blank), R2 = 0.9961 (n = 
6). Selectivity was assured on the basis of the analysis of multiple blank human plasma batches and 
injection of potential comedication standards. Independently prepared quality control samples (0.5, 
0.75, 3.5, and 12.5 µg/ml) were used to evaluate precision (repeatability 2.55± 8.37 relative SD %); 
(reproducibility 4.60±6.84 relative SD %, n = 6) and accuracy (-7.59 to -3.39 bias % relative error), 
and later to accept individual sample runs.  
Pharmacokinetic Dynamic Model  
 
A three-compartmental mammillary model with parameters V1, V2, V3, CL, Q2, and Q3 was applied 
enlarged with an effect-site. The effect-site was assumed to be linked to the central pharmacokinetic 
compartment with a first-order equilibrium constant of ke0. A classic sigmoidal maximal possible drug 
effect model (Emax) was used to describe the relationship between propofol effect-site concentration 
(Ce) and the BIS as a measure of propofol cerebral drug effect:  
Effect = E0 + (Emax ± E0)
where Effect is the measured BIS value, E0 is the baseline measurement when no drug is present, 
Emax is the maximal possible drug effect, Ce is the calculated propofol effect-site concentration, Ce50
is the Ce DVVRFLDWHGZLWKPD[LPDOGUXJHIIHFWDQGȖ is the steepness of the concentration-versus-
response relation. The delay in the reported BIS index was assumed to be 10 s as published previous-
ly.17 For the current study Emax was fixed to 0 and E0 to 95.
Unless otherwise stated, interindividual variability was assumed to be log-normally distributed:  
și  șTV . eȘL
KHUHși is the parameter value in the iWKSDWLHQWșTV is the typical value of the parameter in the 
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population, and Și is a random variable in the ith patient with a mean of 0 and D YDULDQFH RI Ȧ2.
,QWHULQGLYLGXDOYDULDELOLW\LVUHSRUWHGDVȦWKH6'RILQWKHORJGRPDLQZKLFKLVDSSUR[LPDWHO\WKH
coefficient of variation in the standard domain.  
Residual intraindividual variability for the observed propofol central compartment concentration was 
modeled using constant coefficient of variance model, and for BIS index this was modeled using an 
additive error model. Model estimation was performed using NONMEM VI 2.0 (ICON, Dublin, Ire-
land).
Classic PK-PD Approach. The sequential method20,21 was used. More specifically, a population 
SKDUPDFRNLQHWLFPRGHOZDV HVWLPDWHG XVLQJ SDWLHQWV¶ LQGLYLGXDOPHDVXUHGEORRG VDPSOHV ILUVW SUo-
ducing a population pharmacokinetic model and individual (post hoc) pharmacokinetic estimates. In 
the second stage, the pharmacodynamic model population parameters are estimated with the individual 
pharmacokinetic model parameters fixed to their post hoc estimates.  
PK (Predicted)-PD Approach. In this approach, the patient pharmacokinetic model is fixed to one of 
the previously published population pharmacokinetic models; these are shown in table 1. No pharma-
cokinetic estimation is performed because the time course of the propofol plasma concentration is 
calculated from the fixed pharmacokinetic model, the patient covariates in the model, and the given 
propofol dose per time. The pharmacodynamic model is estimated with a population approach using 
WKHSDWLHQW¶VLQGLYLGXDO%,6GDWD
Indices for Assessment  
 
For all pharmacokinetic models, goodness-of-fit plots were constructed for each data set using each 
model. The plots depict the predicted concentrations versus the observed concentrations of propofol. 
In addition, the predictive performances of the pharmacokinetic models were analyzed using predic-
tion error analysis, as described by Varvel et al.22
Prediction error (PE) for plasma concentrations was calculated using the following equation: 
 
Prediction error for BIS values was calculated using the following equation:
PE = BIS observed -BIS predicted  
PE is an indication of the bias of the achieved concentrations, and the absolute value of the PE (|PE|)
is a measure of the precision.  
101
  
PK model Parameters 
Kataria 7 V1 = 0.41 * WGT 
V2 = 0.78 * WGT _ 3.1 * AGE _ 16 
V3 = 6.9 * WGT CL _ 0.035 * WGT 
Q2 = 0.077 * WGT 
Q3 = 0.026 * WGT 
Paedfusor 
2,29
V1 = 0.4584 * WGT 
K10 = 0.1527 * WGT
-0.3
K12 = 0.114   
K21 = 0.055   
K13 = 0.0419   
K31 = 0.0033
Marsh 
5
V1 = 0.343 * WGT 
K10 = 0.1 
K12 = 0.0855 
K21 = 0.033 
K13 = 0.021 
K31 = 0.0033
Short 
8
V1 = 0.432 * WGT  
K10 = 0.0967   
K12 = 0.1413   
K21 = 0.1092   
K13 = 0.0392   
K31 = 0.0049 
Rigby-Jones 
3
V1 = 0.584 * WGT 
V2 = 1.36 * WGT   
V3 = 5.67 * WGT + 103   
CL = 0.0302 * WGT   
Q2 = 0.0160 * WGT   
Q3 = 0.0133 * WGT 
Rigby-Jones (multicenter) V1 = 7.76 * PWT 
V2 = 14.4 * PWT  
V3 = 83.9 * PWT 
CL = 0.614 * PWT
0.75
Q2 = 0.839 * PWT
0.75
Q3 = 0.252 * PWT
0.75
PWT = WGT / 15 
Schuttler 
9
V1 = 9.3 * PWT
0.71
 * (AGE / 30)
-0.39
 * (1 + BOL * 1.61) 
V2 = 44.2 * PWT
0.61
 * (1 + BOL * 0.73)   
V3 = 266   
CL = 1.44 * PWT
0.75
   
Q2 = 2.25 * PWT
0.62
 * (1 ± VEN * 0.40) * (1 + BOL * 2.02)  
Q3 = 0.92 * PWT
0.55
 * (1 + BOL * (-0.48))  
PWT = WGT / 70  
VEN = 1 (venous samples) 
BOL = 0 (infusion dosing, not bolus)
ShangGuan 
4
V1 = 7.41 * PWT 
V2 = 54.6 * PWT   
V3 = 7.2 * PWT   
CL = 0.185 * PWT
0.75 
Q2 = 0.614 * PWT
0.75 
Q3 = 0.692 * PWT
0.75
PWT = WGT / 13.7
Schnider
13,14
V1 = 4.27 
V2 = 18.9 - 0.391 * (AGE - 53) 
V3 = 238   
CL = 1.89 + 0.0456 * (WGT - 77) - 0.0681 * (LBM - 59) + 0.0264 * (HGT - 177) 
Q2 = 1.29 - 0.024 * (AGE - 53) 
Q3 = 0.836  
LBMmale = 1.1 * WGT - 128 * (WGT / HGT)
2
LBMfemale = 1.07 * WGT - 148 * (WGT / HGT)
2
Table 1 Propofol pharmacokinetic models from the literature. 
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For each individual, median prediction error (MDPE) and median absolute prediction error (MDAPE) 
were calculated as measures of the accuracy and precision of the Cplasma prediction. In the ith sub-
ject:
MDPEi = median{PEij, j  «Ni}
where Ni is the number of PE values obtained for the ith subject. Hereby, an MDPE value of 0 means 
no bias.
MDAPE indicates the precision of the Cplasma prediction. In the ith subject:
MDAPEi = median{| PEij |, j  «Ni}
where Ni is the number of PE values obtained for the ith subject. The closer to 0, the more precise is 
the model.  
To reflect the quality of the pharmacodynamic model and predictions the NONMEM objective func-
tion value was used. All of the objective function value comparisons concern estimation of the 
pharmacodynamic model using the BIS pharmacodynamic observations from the current study in con-
junction with a fixed pharmacokinetic model, so the comparisons are valid.  
Parameter units Typical value Relative standard deviation  
V1 l/kg 0.174 84% 
V2 l/kg 0.234 0 fixed 
V3 l/kg 0.951 0 fixed 
CL l/min/kg 0.0393 15.2% 
Q2 l/min/kg 0.102 0 fixed 
Q3 l/min/kg 0.0333 24.7% 
Residual SD % 18.4  
Table 2 PK model estimated from the plasma concentration observations from the current study 
Results. reasons Data from all included 28 patients were used in the analysis. In total, 443 venous 
blood samples were obtained and used for the analysis. In 5 patients, 1 blood sample was missing due 
to technical reasons (1-min sample at plasma concentration [Cp] 1 in patient 1, 1-min sample at Cp7 in 
patient 9, 15-min sample at Cp1 in patient 11, 1-min sample at Cp7 in patient 18, 1-min sample at Cp1 
in patient 21). Nineteen boys and nine girls were included.  
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Their demographics were (median [min±max]) age, 6.5 y (range, 4±11 y); weight, 21.5 kg (range, 18±
54 kg); height, 119 cm (range, 105±152 cm). All NONMEM runs successfully completed the covari-
ance step and reported a condition number less than 1,000. 
PK model PK performance PD estimation       
  MDPE MDAPE 
Objective 
function keo Ce50 SD(res) 
  (%) (%)   (1/min) ( g/ml)     
Posthoc 0.8 8.6 77385.25 0.79 3.85 1.50 7.9 
population -0.6 14.0      
asymptotic standard error    0.12 0.11 0.06 2.2 
Table 3 PK predictive performance and results from PD model estimation 
 
 
 
Classic PK-PD Approach  
 
For the classic PK-PD approach, a three-compartment model fit the data. The typical values, 
intraindividual and residual variability for the estimated population model, are shown in table 2. The 
LQWHULQGLYLGXDOYDULDQFHȦYDOXHVIRU92,V3, and Q2 were fixed to 0 to obtain a stable estimation. 
For all patients, the observed, population-predicted, and post hoc predicted plasma concentrations are 
shown in figure 1. The observed/population predicted and observed/post hoc predicted plasma concen-
trations versus time and versus observed plasma concentrations graphs are shown in figure 1. Except 
for some rather high plasma concentrations, an overall accurate fit was found as indicated by the 
smoothed curves. This is reflected by the population and post hoc median (absolute) prediction errors 
as shown in table 3.
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Fig 1 From the classic PK-PD approach, PK population and post-hoc predictions for the current study versus observed 
propofol plasma concentrations in time. 
 
Sequentially, a sigmoid Emax model was used to describe the pharmacodynamic relationship between 
concentration and cerebral effect as measured by BIS.  
For the pharmacodynamic model, the typical values and standard errors for ke0 and effect-site concen-
tration Ce50 and the NONMEM objective function for the pharmacodynamic model are shown in 
table 3. Figure 2 shows the observed, population-predicted, and post hoc predicted BIS values for all 
patients. An overall observed versus predicted analysis revealed an acceptable pharmacodynamic 
model prediction (fig. 2). We did not find any statistically significant relationship (P < 0.05) between 
patient age, height, or sex on the estimated pharmacokinetic or pharmacodynamic model parameters.  
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PK (Predicted)-PD Approach  
 
For the PK (predicted)-PD approach, the pharmacokinetic predictions are obtained from the fixed  
Fig 2 From the classic PK-PD approach, PD population and post hoc predictions for the current study vs observed BIS and 
time. Observations are marked as (+) or as (smoothed) dotted line. 
models described in table 1. For these applied pharmacokinetic models, figure 3 shows the relationship 
between predicted versus observed propofol plasma concentrations and also depicts the ratio between 
predicted/observed propofol plasma concentration versus time. The predictive performance of the 
applied pharmacokinetic models is shown in table 4. The Marsh model shows the best and the 
Schnider model the worst pharmacokinetic performance as measured by MDPE and MDAPE. We did 
not see any advantage of pharmacokinetic models developed with venous samples to predict our (ve-
nous) samples. This suggests arterial versus venous sampling is dominated by other sources of varia-
tion. Differences in assay handling23 between studies and the distinction between blood and plasma 
drug concentrations24 may also influence model performance.  
A sigmoid Emax model was used to describe the pharmacodynamic relationship between concentra-
tion and cerebral effect as measured by BIS. The typical values for ke0 and effect-site concentration 
Ce50 and the NONMEM objective function for the pharmacodynamic model are shown in table 4. The 
PK (Schnider)-PD model gave the best pharmacodynamic fit, and the PK (Rigby-Jones)-PD model 
gave the worst pharmacodynamic fit as indicated by the NONMEM objective function values.  
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Fig 3 From the PK (predicted)-PD approach, predicted versus observed graphs for propofol plasma concentrations for the PK 
(predicted) models described in table 1.
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Table 4: From the PK(predicted)-PD approach, pharmacokinetic predictive performance and results from pharmacodynamic 
model estimation. MD(A)PE is median (absolute) performance error. 
This PK (predicted)-PD approach assumes that the best-performing pharmacokinetic model can be iden-
tified by the lowest objective function from the corresponding pharmacodynamic estimation. Figure 4 
shows these relationships for the data from the current study. There does not seem to be a clear relation-
ship between MDPE or MDAPE with the objective function from pharmacodynamic estimation. Thus, 
it should not be assumed that this approach selects the best-performing pharmacokinetic model. In fact, 
in our study, it selected the worst-performing pharmacokinetic model. Alternatively, one could rank the 
models based on root mean squared error of the predictions; this can be seen as the SD of the residuals 
(SD[res]) in table 4. In this case the ranking of models is identical to that from objective function value, 
and the findings are same. Yet another ranking could be based on the MDAPE of the predictions, also 
shown in table 4. 
PK model PK performance PD estimation        
  MDPE MDAPE 
Objective 
function keo Ce50 SD(res) MDAPE 
  (%) (%)   (1/min) ( g/ml)      (BIS) 
Kataria 31.3 34.1 75619.64 0.89 2.98 1.53 7.5 5.26 
Paedfusor 10.4 19.0 75334.11 1.38 3.53 1.53 7.4 5.17 
Marsh -1.3 15.9 76976.42 0.93 3.33 1.12 7.8 5.50 
Short 17.0 23.1 76206.88 1.24 3.41 1.58 7.6 5.50 
Rigby-Jones 4.4 21.6 80904.49 2.64 3.61 1.33 8.9 6.86 
Rigby-Jones Multicenter 20.9 25.8 76001.34 1.47 3.18 1.47 7.6 5.36 
Schuttler 10.2 21.8 77214.12 0.72 2.78 1.02 7.9 5.48
ShangGuan -1.0 20.7 74351.15 3.30 4.52 2.07 7.2 4.96 
Schnider 41.4 46.9 74334.83 0.33 2.80 1.58 7.1 4.85 
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In this case the ranking of models is nearly identical, and the findings the same.  
Fig 4 For the PK (predicted)-PD approach, the relationship between objective function and MD(A)PE for the PK models as 
decribed in table 1. The point from the classic PK-PD approach is included. There is no clear relationship between PK preci-
sion and the PD objective function.  
Studies using the PK (predicted)-PD approach also estimate pharmacodynamic parameters ke0, Ce50,
DQG Ȗ E\PLQLPL]DWLRQ RI WKH SKDUPDFRG\QDPLF REMHFWLYH IXQFWLRQ+RZHYHU WKHUH LV QR HYLGHQFH
that low objective function values are associated with accurate estimation of these pharmacodynamic 
parameters when the pharmacokinetic model is taken from other sources. Figure 5 shows the relation-
ship between objective function from the PK (predicted)-PD approach and its ability to estimate the 
³WUXH´SKDUPDFRG\QDPLc parameters estimated by the classic PK-PD approach, which are marked by 
crosshairs. It seems that for the PK(predicted)-PD approach, i.e., using a population pharmacokinetic 
model taken from other sources, that minimization of the pharmacodynamic objective function does 
not necessarily result in accurate estimates of the pharmacodynamic parameters. 
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Fig 5 For the PK (predicted) ± PD approach, the relationschip between objective function (OBJN) and the estimation of PD 
parameters estimated by the classic PK-PD approach (indicated by crosshairs). Low PD objective function values are not 
associated with accurate estimation of the PD parameters when the PK model is taken from other sources.
Discussion  
 
We found that the classic PK-PD approach results in an accurate pharmacokinetic model as evidenced 
by low values for MDPE and MDAPE. Surprisingly, using a population pharmacokinetic model from 
another source, i.e., the PK (predicted)-PD approach, can lead to lower pharmacodynamic objective 
function values than the classic approach, but offers no guarantee of an accurate pharmacokinetic 
model. Interestingly, the best pharmacodynamic fit was obtained using the PK (Schnider)-PD model, 
while at the same time this model produced the worst pharmacokinetic predictions. We found that the 
PK (predicted)-PD approach does not select the best-performing  pharmacokinetic model.  
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Shafer et al. stated that the final validation of a model for TCI should be to apply it in a TCI setting 
and to measure the plasma concentration.25 These validations have been performed for adults,11,12 but
not for children. Our study is a validation of the previously applied15 Kataria model6 for propofol 
plasma-controlled, TCI-driven anesthesia on children. Similar to other models,10 we found that the 
Kataria pharmacokinetic model was biased and inaccurate, evidenced by poor MDPE and MDAPE. 
The Marsh and ShangGuan models showed low pharmacokinetic bias (MDPE) and the Marsh model 
the best precision (MDAPE). We also considered the Schnider model, despite its derivation from an 
adult population, because a recent publication suggested it may provide acceptable PK-PD perfor-
mance in children.26 However, in our study it showed pharmacokinetic bias and was inaccurate. Our 
results are in agreement with others,10 who found an MDPE and MDAPE for the Schnider model of 
44.3% and 44.3% and for the Kataria model of 52.2% and 52.5%, respectively. For the Paedfusor 
model, Absalom et al.2 found lower values for MDPE (4.1%) and MDAPE (9.7%) compared with our 
studies. This might be because of the difference between arterial and venous blood sampling in their 
study and ours, respectively. The pharmacokinetic accuracy for the Short model are worse than ex-
pected, possibly because this model was developed in Chinese children, who may have altered kinetics 
compared with the European children used in our study.7 On the other hand, the ShangGuan pharma-
cokinetic model developed in Chinese children was nearly unbiased and showed reasonable precision. 
We were able to develop a three-compartmental model from the pharmacokinetic data scaled to total 
body weight. It showed unbiased population and post hoc individual predictions with an acceptable 
accuracy.27 The difficulties we experienced in estimating the population variances for V2,V3, and Q2
may be related to the fact that the pharmacokinetic observations were made during TCI-driven anes-
thesia. TCI dosing has been mathematically proven to have lower inter-individual variability com-
pared with bolus dosing.28 This reduced uncertainty in plasma propofol observations across the popu-
lation makes the data less informative for estimation of a population pharmacokinetic model, thereby 
making the previously mentioned simplifications to the model structure necessary. 
The pharmacokinetics and dynamics of a drug should be modeled within the same patient group to 
obtain an unbiased description of the dose-response relationship of a drug,29 and the classic PK-PD 
DSSURDFK LVPHWKRGRORJLFDOO\ WKHEHVWHVWLPDWHRI WKH³WUXH´3.-PD model. In the current study we 
found a Ce50 RIJPODYDOXHVLPLODUWRWKH³PHDVXUHG´&H50 of 4.03 µg/ml found by Rigouzzo 
et al.9 Rigouzzo et al. DOVRIRXQGD³WDUJHW´&H50 using the Kataria pharmacokinetic model to be 2.94 
µg/ml, which can be compared with that from our PK (Kataria)-PD model, 2.98 µg/ml.  
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In a different study,10 the same authors found a Ce50 of 2.64 µg/ml when the Schnider pharmacokinet-
ic model was used. This value can be compared with that of our PK (Schnider)-PD model, where a 
Ce50 of 2.80 µg/ml was found. It seems that the underprediction of the Kataria and Schnider pharma-
cokinetic models leads to too-low estimates of Ce50. There does not seem to be any relationship indi-
cating any particular Ce50 value. This suggests that the PK (predicted)-PD approach does not accu-
rately estimate the true value of Ce50. The same must also apply to covariate relationships with Ce50,
although this is claimed in other studies.16
A wide variability of ke0 values between the PK (predicted)-PD models is demonstrated, clearly illus-
trating the influence of the applied pharmacokinetic model on the estimated value of ke0. There does 
not seem to be any relationship indicating any particular ke0 value. This suggests that the PK (predict-
ed)-PD approach does not accurately estimate the true value of ke0. We used a 10-s BIS delay in our 
calculations, which will influence the absolute value of ke0, a previously described approach.
17 Similar
to other studies,19 we fixed the BIS values for E0 and Emax to 0 and 95, respectively, although in oth-
er studies these values have been estimated.16
One may be tempted to argue that the limitations of the pharmacokinetic estimation may degrade the 
estimation of the true pharmacodynamic parameters, and thus the inability of the PK(predicted)-PD 
models to find the same values as the classic PK-PD approach, does not necessarily mean that the 
PK(predicted)-PD approach did not find the true pharmacodynamic parameters. However, it should be 
noted that for the PK (predicted)-PD models considered, there is no clear relationship between model 
fit (objective function or residual error) and any particular estimated pharmacodynamic parameter 
value. For example, the best two PK (predicted)-PD models estimate very different values for all of 
the pharmacodynamic parameters. Because the PK (predicted)-PD approach fails to indicate any par-
ticular pharmacodynamic value, it must also have failed at indicating the true pharmacodynamic pa-
rameter.  
It was an unexpected result that the classic PK-PD approach did not lead to the lowest objective func-
tion from pharmacodynamic estimation because it does provide the best estimates of the true pharma-
cokinetic model for each individual. The reason for this is probably the shortcomings of ke0 and the 
sigmoidal Emax model to describe the relationship between BIS and plasma compartment concentra-
tion. BIS is a complex variable measured from the brain, a very complex organ. There may be time-
dependent and/or level-dependent components to the BIS that are not properly described with the sig-
moidal Emax model. When such pharmacodynamic model misspecification is present, some specific 
pattern of misprediction of the pharmacokinetic model might lead to better pharmacodynamic predic-
WLRQVE\³FRPSHQVDWLQJ´IRUVSHcific shortcomings of the pharmacodynamic model.  
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This phenomenon may be occurring in the PK-PD models studied here. The evidence for this is that 
the PK (Schnider)-PD model performs quite well for predicting pharmacodynamic responses but poor-
ly predicts the pharmacokinetic responses. Therefore, an improved pharmacodynamic model for BIS 
may allow the PK (predicted)-PD approach to perform better, and it also would improve the classic 
PK-PD approach. Another study9 did not find pharmacodynamic model misspecification; however, 
only nearly steady-state conditions were considered. At the same time, other pharmacokinetic model 
structures, such as physiologically-based models30 or the use of transit compartments,31 may also help 
³XQLI\´SKDUPDFRNLQHWLFDnd pharmacodynamic accuracy within a single model but these need to be 
properly scaled for application in children. Rigouzzo et al.10 suggested that the adult Schnider model 
might be useful for TCI of propofol in children. Their reasoning was based on good results from the 
PK (Schnider)-PD approach, which they used in their study. The current study confirmed the good 
pharmacodynamic performance of this model but found that its pharmacokinetic accuracy in children 
is poor, worse than all other models tested. Therefore, one cannot argue for use of the Schnider phar-
macokinetic model in children on the grounds of its pharmacokinetic accuracy. On the other hand, one 
could argue that for some anesthesiologic applications, pharmacokinetic accuracy is of little im-
portance provided the pharmacodynamic accuracy is good. This approach represents a paradigm shift 
in the application of TCI systems where, instead of a target constant drug concentration, the target is 
some desired pharmacodynamic response. Drug-dosing profile is then adjusted to achieve a constant 
pharmacodynamic target, possibly requiring a non-constant time course of drug concentration. The 
good pharmacodynamic performance of the PK (Schnider)-PD model coupled with its poor pharma-
cokinetic accuracy gives us a hint that these drug dosing profiles may exist. Of course, the Schnider 
pharmacokinetic model may not be optimal for this purpose and other optimized models could be ap-
plied. Future studies may address whether this approach has any advantages to the current TCI ap-
proach in anesthesiologic applications. 
We conclude that for PK-PD models of BIS in children after propofol administration using fixed 
pharmacokinetic models from the literature and estimating the pharmacodynamic model does not en-
sure good pharmacokinetic accuracy or provide informative estimates for pharmacodynamic parame-
ters. It can, however, provide for better pharmacodynamic model fit than the classic PK-PD approach. 
It seems that there is some misspecification of the sigmoidal Emax pharmacodynamic model for BIS 
response in children. If the sigmoidal Emax pharmacodynamic model is used, then some specific pat-
tern of misprediction of the pharmacokinetic model might lead to better pharmacodynamic predic-
WLRQVE\³FRPSHQVDWLQJ´IRUVSHFLIic shortcomings of the pharmacodynamic model. For applications 
where pharmacodynamic accuracy is of primary importance these dosing profiles may prove useful.  
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CHAPTER 6 DISCUSSION  AND GENERAL CONCLUSIONS
The aim of drug titration in anaesthesia is to reach and maintain a stable therapeutic drug 
concentration at the site of drug effect. In inhalational anaesthesia the measured end-tidal 
concentration of the gaseous agent is a reliable estimate of its concentration in the brain. For propofol, 
as an intravenous anaesthetic, we have to rely on estimated/calculated concentrations. The basis for the 
estimations of propofol plasma concentrations are PK models. Furthermore we want to be in control of 
the time course and degree of the hypnotic effect of propofol which necessitates the use of PD models. 
The essential link between a PK and PD model is the ke0 the mathematical representation of the 
plasma/effect-site equilibration rate. Essential for TCI is the accuracy of the applied model. PK-PD 
models have been developed in rather low numbered populations, most often healthy volunteers, with 
limited demographic variability which limits their universal application in patients not resembling the 
typical patient.
The goal of the research we included in this thesis was to study the performance of popular and 
frequently used PK-PD models We showed that PK and PD estimations are closely linked to one 
another and that optimal PK-PD model building should always be estimated simultaneously within 
one study population. We pointed out major differences between models as choice of a wrong model 
can have detrimental consequences for the patient; either inadequate hypnotic effect or to much effect 
with potentially harmful side-effects. At the same time we warned for model inaccuracies that arise 
when models are built without blood sampling.  
In chapter 3 we hypothesized1  a different plasma-effect site equilibration time depending on the 
injection rate of propofol. To face  this problem we administered 2,5 mg/kg propofol as either a bolus 
or a rapid infusion ( duration of 1,2 or 3 minutes). BIS was measured and a PD model was developed 
(classic sigmoidal and combined fixed plus sigmoidal model). Propofol concentrations were estimated 
using the Schnider model. We initially concluded that plasma-effect site equilibration for bolus 
injection is faster than for infusions because two ke0’s , one for bolus injection  and another for the 
three infusion groups best fitted our data. Yet otherwise stated the time course of drug effect is 
different for bolus injection versus infusion.   
However one of the reviewers2 assessing the original manuscript suggested that these results were 
potentially flawed because of misspecification of propofol concentrations during the very first minutes 
after bolus administration. Additional ethics committee approval was requested for the collection of 
propofol arterial concentrations in 10 additional patients to evaluate the accuracy of the Marsh and 
Schnider PK models in the first 5 minutes after intravenous propofol bolus. We showed poor 
performance of these models to predict arterial propofol concentrations in the first minutes after 
propofol  bolus. This is not surprising as it is merely  a reflection of the misassumption that there is an 
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instantaneous mixing of drug in the central compartment. So the definitive conclusion was that the 
actual rate of blood-brain equilibration may not differ between bolus and infusion methods of 
administration. Analogous to chapter 5, this reflects the inaccuracy that arises when PD data are linked 
to PK data generated by poorly performing models.   
Masui3 and colleagues studied the front-end PK and PD of propofol and conclude that a combined 
PK/PD model consisting of a multi-compartmental model with a lag-time, presystemic compartments, 
and a sigmoidal maximum possible drug effect model accurately described the early phase 
pharmacology of propofol. 
In chapter 4 we showed4  that both the Marsh model and the Schnider model failed to maintain a 
constant hypnotic effect over time. We hypothesized that these models would be able to accurately 
estimate the Ce of propofol at loss-of-consciousness and consequently that targeting this Ce using TCI  
would result in a stable effect, i.e. unconsciousness at  the same level of anesthesia. Using the Marsh 
PK-PD parameter set all patients woke up and BIS increased over time. The opposite effect was 
observed  using two PD variations of the Schnider model; a decrease in BIS was observed for several 
minutes, indicating a progressively intensifying hypnotic effect. The question arises whether  this is 
due to inaccuracy of the PK-PD model or to a lack of understanding the exact underlying neuro-
physiological pathways. 
On a PK level there are essential differences between the Marsh and Schnider model. Marsh used slow 
infusion rates in his original population and hence found a large Vc, whereas Schnider used boluses 
and subsequently found a lower Vc. When the Vc of any PK model is decreased, a continuous infusion 
of propofol will result in a faster increase in Cp. In our study the ‘Marsh group’ and the two ‘Schnider 
groups’ were administered a continuous infusion of propofol with comparable times to loss of 
response to name calling (LORNC) and hence comparable doses. Due to the large Vc in the Marsh 
model the predicted plasma and effect-site concentrations were lower in the ‘Marsh group’. The 
plasma and effect-site concentrations were higher in the two ‘Schnider groups’ as the Vc is typically 
lower for the Schnider model. After switching to effect-site controlled TCI, PD differences arose; the 
ke0 of Marsh (0.26 min
-1) is lower then the ke0’s in our Schnider groups ( ke0 = 0.456 min
-1 and 0.362 
min-1). Therefore the equilibration between plasma and effect site concentration is slower for the 
Marsh group and so the infusion pump waits considerably longer to restart propofol infusion in the 
Marsh group. The Schnider groups started from higher Ce concentrations and together with higher 
ke0’s and hence more rapid equilibration times, this resulted in the pump to restart much earlier and 
therefore deeper levels of anesthesia.  
118
In the Schnider groups there was a progressively intensified hypnotic drug effect over time. One may 
hypothesize that the conditions to induce unconsciousness are different from those required to 
maintain unconsciousness. For instance higher  adrenergic activity in the awake may result in a higher 
need for propofol to induce LOC compared to the dose needed to maintain a comparable level of 
unconsciousness in the unresponsive patient in whom adrenergic tone is suppressed. The neural 
mechanisms that play a role in anesthesia induction and emergence are insufficiently resolved for the 
moment but are continuously under investigation5,6. It is now accepted that emergence of anesthesia is 
not simply the reverse process of induction due to the elimination of anesthetic drugs from the effect-
site concentration. At least in inhalation anesthesia, it has been shown that for sevoflurane the 
parameters of the sigmoidal EMAX model ( EC50 , slope Ȗ) are different for induction and recovery. In 
the mean time it seems inevitable to use surrogate measures of hypnotic effect such as  BIS to detect 
the exact onset time of steady-state conditions and hence keep the hypnotic effect at a constant level.
In the study, discussed in chapter 5 we validated the Kataria PK model7 for propofol in TCI for 
children. 28 children were anesthetized using TCI, plasma controlled according to the Kataria model, 
which was very popular at that time. 448 venous blood samples were drawn, and analysed for propofol 
concentration. Subsequently our own PK model was developed using NONMEM. BIS values were 
monitored and a PD model was developed. A ke0 of 0,79 min
-1 links PK and PD model. We found that 
the Kataria model was biased and inaccurate. The Coppens’ model resulted in an accurate PK 
prediction. In a next phase we estimated plasma concentrations and BIS values with PK-PD models 
found in the literature. Using the same approach Rigouzzo8 concluded that the Schnider model for 
adults is useful for TCI in children. However in our study we showed that the Schnider model in 
children was biased and inaccurate on a PK level but performed fairly well at a PD level. Other PK-
PD models were also simulated and we concluded that the use of estimates of plasma propofol 
concentrations using published PK models and estimating the PD model does not ensure good 
pharmacokinetic accuracy or provide estimates for PD parameters. An accurate estimation of ke0
demands an integrated PK-PD study, combining blood samples with frequent measurements of drug 
effect, resulting in an overall model for the dose-response behavior of the drug. The relationship 
between the effect-site concentration and clinical drug effect is thought to be governed by a static 
(time-independent), non-linear (sigmoidal) relationship. Probably the biologic reality is more complex 
and the Emax model is an oversimplification to generate a ke0 and to describe the relationship between 
BIS and plasma concentration. BIS is a complex variable from the brain, a very complex and yet not 
well understood organ. With such pharmacodynamic model misspecification, some pattern of 
misprediction of the PK model might lead to better PD predictions, by ‘compensating’ for specific 
shortcomings of the PD model. Although the literature suggest that the adult Schnider model might be 
useful for TCI of propofol in children, our study confirms the good PD performance but evenly 
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demonstrated that its PK performance in children is poor. One could argue and state that in anesthesia 
practice TCI should focus more on some desired PD response as target, rather than trying to predict 
and simulate concentrations, both plasma and effect-site concentrations. 
A way to counteract the inaccuracy of PK/PD models is the use of these models in closed-loop 
circuits9,10. A closed loop controlled drug delivery system uses a PK/PD model, which forms the basis 
for drug input. A continuous measure of drug effect (BIS) delivers feedback to the drug delivery 
device. A control system measures the error between the target and observed effects and adapts the 
drug infusion rate in a manner that is proportional to the magnitude of the error. This is a promising 
method to deal with PK/PD model inaccuracy caused by inter-individual pharmacological variability. 
The development of a ‘universal’ model covering a wide patient population ( extremes of age, co-
morbidities, obese,…) will definitely end the discussion on which model is best performing. 
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SUMMARY 
 
When the anaesthetist injects a particular dose of a hypnotic drug, he aims a specified clinical effect. 
To obtain this effect a specific therapeutic drug concentration in the blood and subsequently in the 
brain of the patient is necessary. Anaesthetists are able to gain control over the blood concentration of 
the inhalational agents by using a vaporizer to administer the volatile anaesthetic, with measured end-
tidal concentration as immediate feedback.  
For intravenous anesthesia it is impossible to measure on-line the plasma concentration so we have to 
rely on pharmacokinetic models to estimate the plasma concentration. If we want to control the time 
course of drug effect we need pharmacodynamic models, and link them with the pharmacokinetic 
models. 
PK-PD models have been studied for decades. Different models have been built in very specific pa-
tient populations and are therefore difficult to use in other patient groups. PK-PD models try to reduce 
patient intervariability by identifying and incorporating covariates. The models are used in target con-
trolled anesthesia where a plasma concentration or effect-site concentration is chosen.  
PK-PD models sometimes are inaccurate. Comparing the Marsh and Schnider models in effect site 
controlled TCI, we found significant shortcomings. When the predicted effect-site concentration was 
maintained at the moment of loss of consciousness, the patients woke up in the Marsh group, while the 
effect was even more pronounced in the Schnider group. We proved that PD models of BIS in children 
developed by predictions of plasma propofol concentrations using published PK models  and estimat-
ing the PD model does not ensure good PK accuracy or provide informative predictions for PD param-
eters. We also confirmed that three compartmental models fail to accurately predict arterial propofol 
concentrations in the first minutes following bolus administration. This is the result of the flawed as-
sumption that a drug, added to the central compartment is instantaneously and completely mixed. 
PK-PD models will be studied further in the future. Further fine-tuning of TCI will be the goal. The 
information of hypnotic-analgesic drug interactions with data from estimated drug concentration is 
used in advisory systems that provide real-time information concerning the full dose-response curve. 
These online display systems informs the anaesthetist about the anaesthetic depth, degree of sedation, 
the expected wakeup time, extent of muscle relaxation« The ultimate goal is to develop the ideal 
model that can be universally used in children, adults, obese patients, patients with comorbidities or 
critical illnesses. This will bring us to a closed-loop system completely covering the dose-effect rela-
tionship. We hopefully expect that this will make anesthesia even safer than it ever was before.  
In somno maxima securitas !   
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SAMENVATTING 
Wanneer de anesthesist een welbepaalde dosis van een hypnoticum toedient, verwacht hij een 
specifiek effect bij de patiënt. Om dit effect te bekomen moet een welbepaalde concentratie van het 
hypnoticum bereikt worden in het bloed en de hersenen. Wanneer een patiënt in slaap gedaan wordt 
met een inhalatieanestheticum kan de anesthesist zeer gemakkelijk de bloedspiegel controleren door 
middel van de verdamper en bovendien kan hij de concentratie meten in de uitgeademde lucht om 
onmiddellijk de verdamper instellingen aan te passen. 
Bij intraveneuze anesthesie is het niet mogelijk om onmiddellijk de plasmaconcentratie van het 
product te meten, en dus moeten we gebruik maken van wiskundige farmacokinetische modellen om 
de plasmaconcentratie te schatten. Als we het effect willen voorspellen in de tijd moeten we gebruik 
maken van farmacodynamische modellen en combineren met het farmacokinetisch model. 
PK-PD modellen worden reeds zeer lang bestudeerd. Een model wordt bestudeerd in een welbepaalde 
patiëntenpopulatie en is soms moeilijk te gebruiken voor een groep patiënten die sterk verschilt van de 
oorspronkelijke populatie. PK-PD modellen trachten de variabiliteit tussen verschillende patiënten te 
verminderen door rekening te houden met zoveel mogelijk patëntgebonden eigenschappen. Deze 
modellen worden JHEUXLNWLQµWDUJHW¶JHFRQWUROHHUGHWRHGLHQLQJYDQDQHVWKHWLFDGHDQHVWKHVLVWNLHVWGH
concentratie van het anestheticum die hij wil bereiken in het bloed of thv de hersenen van de patiënt. 
Een wiskundig model is soms niet voldoende accuraat. Wij vergeleken het model van Schnider met 
dat van Marsh en vonden enkele belangrijke tekortkomingen. We brachten patiënten in slaap met een 
propofol infuus tot ze het bewustzijn verloren. De concentratie thv de hersenen werd geschat met het 
Schnider of Marsh model en op het moment van bewustzijnsverlies werd de geschatte concentratie 
verder aangehouden. In de Marsh groep werden de patiënten wakker. De patiënten in de Schnider 
groep gingen nog dieper slapen. 
Wij brachten kinderen in slaap en ontwikkelden een farmacokinetisch model op basis van gemeten 
plasmaconcentraties. Tegelijk maten we de BIS waarden en gebruikten deze voor het opstellen van 
een farmacodynamisch model. Nadien schatten we de plasmaconcentratie door middel van een aantal 
IDUPDFRNLQHWLVFKHPRGHOOHQEHVFKLNEDDULQGHOLWHUDWXXU:HWRRQGHQDDQGDWGH]HµVFKDWWLQJHQ¶ niet 
in staat waren om een accuraat farmacokinetisch en farmacodynamisch model te bepalen. 
We bevestigen tevens dat drie compartimentele modellen niet in staat zijn om de arteriële 
plasmaconcentraties te schatten in de eerste minuten na propofol toediening. Deze modellen gaan er 
verkeerdelijk vanuit dat propofol zich onmiddellijk en gelijk verdeelt over het ganse bloedvolume.  
Het onderzoek naar PK-3' PRGHOOHQ ]DO RQJHWZLMIHOG YHUGHU JHYRHUG ZRUGHQ 'H µWDUJHW¶
gecontroleerde toediening van intraveneuse anesthetica zal hierdoor nog verder verfijnd worden. De 
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modellen zullen tevens gebruikt worden om voorspellingen te doen van het verloop van de 
concentratie en het bijhorend effect van het hypnoticum om het verloop van de anesthesie nog beter te 
sturen. Deze systemen zullen de anesthesist informeren over de graad van sedatie, diepte van 
DQHVWKHVLHKHWYHUPRHGHOLMNHPRPHQWYDQRQWZDNHQGHJUDDGYDQVSLHUYHUVODSSLQJ«8LWHLQGHOLMN]DO
een model ontwikkeld worden dat universeel toepasbaar is voor kinderen, volwassenen, obese 
patiënten, patiënten met co-morbiditeit, kritisch zieke patiënten«
Deze evolutie leidt naar een gesloten systeem waar de ganse dosis-effect curve gemonitord en 
automatisch gecontroleerd wordt. Hopelijk maakt dit de anesthesie nog veiliger dan ze al was.  
In somno maxima securitas. 
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- 2de jaar:  AZ Heilige Familie, Gent 
- 3de, 4de en 5de jaar: UZ Gent  
Erkenning als specialist in Anesthesie-reanimatie:  6/08/1999 
 
 
Aanvullende opleidingen 
 
-  3 Day Course on Obstetric Anaesthesia and Analgesia: 6 Ȃ 12/12/1999  
ǯȋȌǡ
London, 
 
- Cursus Basic Life Support, Automated External Defibrillation: mei 2000 
European Resuscitation Council, Antwerpen 
 
- Fellowship Obstetrische anesthesie : 10/02-30/04/2003 
 Queen Charlotte and Chelsea Hospital/ Londen, Departement van Dr. J Crowhurst,  
 
- 3 Day Course on Obstetric Anaesthesia and Analgesia: 22-24/11/2004 
OAA, Church House Conference Centre Westminster London  
 
- 3 Day Course on Obstetric Anaesthesia and Analgesia: 5-7/11/2007 
OAA, Church House Conference Centre Westminster London 
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3. BEROEPSLOOPBAAN 
 
 
- Resident Dienst Anesthesie UZGent: 1/08/1999 - 31/07/2002 
- Adjunct-kliniekhoofd UZGent: 1/08/2002 - heden 
- 1999: actief betrokken bij oprichting en dagelijks beleid Chirurgisch Dagziekenhuis (CDZ) 
   UZG, in samenwerking met het Afdelingshoofd 
    Supervisie CDZ bij afwezigheid van Afdelingshoofd 
- 2001: actief in diverse disciplines  
- specialisatie in obstetrische anesthesie 
- oftalmologische anesthesie (incl. loco-regionale) 
- beheer en organisatie van operatiezalen (OK-coördinator UZ1) 
- 2009: Afdelingshoofd Chirurgisch Dagcentrum UZGent  
- Bestuurslid BARA: Belgian Association of Regional Anesthesia 
- Bestuurslid BAAS: Belgian Association Ambulatory Surgery 
- Verslaggever LOK  
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4. ONDERWIJS 
Onderwijs UGent 
-  EHBO en Reanimatie:  medelesgever en examinator aan de 
studenten Geneeskunde,Tandheelkunde en Revalidatie en Kinesitherapeutische 
wetenschappen (REVAKI):  
Theorie en practica EHBO en Reanimatie voor  
1e ba Gen.,1e baTandhlk. en 1e ba REVAKI 
Facultatief:Toegepaste wetenschappen, Pedagogische wetenschappen,  
 Voedings- en dieetleer 
Practica EHBO en Reanimatie voor 2e, 3e ba Gen., 1e, 2e en 3e mast Gen.  
 Academiejaar 1999-2000 tot 2008-2009  
  
- Examinator examen en stationsproeven EHBO en Reanimatie voor 
 1e, 2de en 3de ba Gen, 1ste, 2de  en 3de mast Gen ; 1e ba THK 
 Academiejaar 1999-2000 tot heden 
 
- Examinator Stationsproef 4de proef Gen.  
Februari 2000, 2001, 2002 
 
- Examinator Longcases GKE, 3e mast gen, 4u, 2013 
  
- Tandheelkundige anesthesie: voor 3e ba Tandhlk. 
4 theorielessen , 4u en 2 practicalessen, 2x4u  
 1999 tot heden 
 
-  Capita Selecta 4e mast ziekenhuisarts:  
Anesthesie en Reanimatie, keuzevak  
  ǣǯǡͶ 
 
- Ǯǡabdominale en thoraco-ǯǡ
keuzevak  4e master ziekenhuisarts 
  les: Preoperatief onderzoek en anesthesie, 1u,  
 
- Medical Humanities (E-ȌǡǮǯǡʹ
 
   lessen: Wat is anesthesie en Beademingsapparaat, 3,5u, 2010-heden 
 
- Ǯǯ 
Postgraduaat Revaki 
Theorie en praktische training, 4 uur/ jaar 
Academiejaren 1999-2000, 2000-2001, 2001-2002 
 
- AVU interuniversitaire cursus voor ASO 2de opleidingsjaar: vanaf 2004 tot heden 
ǮǯǢǡʹȀͳͲȀʹͲͲͶǡͳȀͳͲȀʹͲͲͷǡ
30/09/2006; UZGent, 29/09/2007 
 
 ǮǯǢǡʹͶȀͲ͵ȀʹͲͲ͹ 
 
ǮǯǢ
13/09/2008 
ǮǣǮǯǡUZGent  13/09/2008 
 
ǮǯǡǡʹͺȀͳͳȀʹͲͲͻ 
Basic and Advanced Life Support ; VUB 16/01/2010 
 
 Basic life support and advanced life support; e-learning 2011 
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 Anesthesie voor de pathologische zwangerschap, 22/10/2011; ZOL 
 
 Basic life support and advanced life support; e-learning 2012 
 Anesthesie voor de pathologische zwangerschap, e-learning 2012 
 
- ǮǢǯǡ 
Praktijklessen ABC, nascholing voor tandartsen (organisator prof. dr. Luc Marks) 
Faculteitszaal UGent , jaarlijks van 2008 tot heden 
 
- Stagebegeleider voor een 10-tal studenten (jaarlijks) uit 1e, 2e en 4e mast Geneeskunde 
 
 
Onderwijs UZGent 
 
- Ǯ-ǯ 
Postgraduaat Anesthesie 
December 1999 
 
- Basic life support, provider 
Automated external defibrillation 
Basic life support en Automated external defibrillation, instructor 
European Resuscitation Council 
Medelesgever  
Nederoverheembeek, 8, 9 en 10/10/2000 
 
- Ǯǣ-, Keel- ǯ 
27/01/2001 
 
- Ǯ-ǯ 
Bijscholing voor verpleegkundigen 
Februari 2001 
 
- ǯǯ 
Bijscholing voor vroedvrouwen 
UZGent: 12-13/01/2002 en 24/04/2002 
 
- Ǯǣ 
´ǯ 
Bijscholing voor verpleegkundigen  
UZGent : 8/02/2002 
 
- Introductie van de cursus EHBO als onderdeel van de V-lijn op  
RUG opendeurdagen,  
Gent, 2/03/2002 
 
- Ǯǯ 
Antwerpen, september 2002 
 
- Ǯǯ 
5/10/2002, 4/10/2003, 1/10/2005 
 
- Ǯǯ 
Vorming verpleegkundigen verloskwartier en materniteit  
UZGent, 4/03/2008 
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5. WETENSCHAPPELIJK CURRICULUM 
 
 
PUBLICATIES 
 
Boeken 
 
(b1) co-auteur van boeken 
 
1. L. Versichelen, M. Coppens  
EHBO / First Aid 
Handboek voor studenten 
Academia Press, herwerkte en vernieuwde uitgave 2001 
 
2. L. Versichelen, M. Coppens 
EHBO / First Aid 
Handboek voor studenten 
Academia Press, herwerkte en vernieuwde uitgave 2002 
 
3. Versichelen L F M, Coppens MJ, et al.  
EHBO / First Aid 
Handboek voor studenten  
Academia Press, herwerkte en vernieuwde uitgave 2007 
 
 
(b2) hoofdstukken in boeken 
 
1. Coppens M  
Ǯ´ǯ 
In Jaarboek 2006 : Binnenste buiten, Intensief  bekeken.  
International centre for reproductive health, Gent: p73-80. 
 
2. Coppens M  
ǮDe  gecombineerde spinale-ǯ 
In  Reproductieve geneeskunde, gynaecologie en obstetrie anno 2007.  
Editor. Dr. E. Slager c.s., DCHG, Medische Uitgeverij: 461-4. 
 
 
 
Artikels 
a1) artikels in tijdschriften opgenomen in Science Citation Index 
 
1. V Capouet, C De Pauw, B Vernet, D Ivens, V Derijcke, L Versichelen 
H Van Aken, B Ickx, L Ritter, F Hulstaert. Acknowledgements to G Rolly,  
M Coppens  
Single dose intravenous tropisetron in the prevention of postoperative nausea and vom-
iting following gynaecological surgery: a double blind, multicentre, dose-comparison 
study. 
British Journal of Anaesthesia 1996, 76: 54-60 
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2. E Alon, E Buchser, E Herrera, F Christiaens, C De Pauw, L De Ritter,  
  F Hulstaert, V Grimaudo  
 Single dose intravenous tropisetron in the treatment of established       
postoperative nausea and vomiting: a double blind, multicentre, dose-comparison     
study. 
Co-investigator M Coppens 
Anesthesia& Analgesia 1998, 86 :617-23 
 
3. L Versichelen, G Rolly, M Struys, K Fonck, M Coppens  
Automatic online computing of delivered inhalation anaesthetics is now possible in clini-
cal practise. 
Anaesthesiology and Intensive Therapy 1999; 29:14 
 
4. Coppens M, Versichelen L, Mortier E 
Treatment of postoperative pain after ophthalmologic surgery. 
Bull Soc Belge Ophtalmol. 2002;(285):27-32 
 
5. Coppens MJ, Versichelen LFM et al.  
The mechanisms of carbon monoxide production by inhalational agents. 
 Anaesthesia 2006, 61: 462-8 
 
6. MJ Coppens, LFM Versichelen, E Mortier and M Struys  
Do we need inhaled anaesthetics to blunt arousal, haemodynamic responses to intuba-
tion after i.v. induction with propofol, remifentanil, rocuronium? 
British Journal of Anaesthesia 2006, 97(6): 835-41. 
 
7. Struys MMRF, Coppens MJ, De Neve N, Mortier EP, Doufas AG, Van Bocxlaer JFP, and 
Shafer SL  
Influence of administration rate on propofol plasma - effect site equilibration. Anesthesi-
ology 2007, 107(3): 386-96 
 
8. Femke Delporte, Kristien Roelens, Marc Coppens, Annick Viaene, Karel Everaert, Hans 
Verstraelen, Marleen Temmerman  
Obstetrisch handelen bij tetraplegische patiënte 
  Tijdschrift voor Geneeskunde. 2009 65(10). p.468-469  
 
9. Marc Coppens, Jurgen Van Limmen, Thomas Schnider, Barbara Wyler, Sjoert Bonte, 
Frank Dewaele, Michel MRF Struys, Hugo EM Vereecke.  
Study of the Time Course of the clinical effect of propofol versus the time course of  the 
predicted effect-site concentration of propofol. performance of three  pharmacoki-
netic-dynamic models in steady-state conditions. 
British Journal of Anaesthesia 2010, 104 (4):452-8 
 
10. Marc Coppens, DouglasJ Eleveld, Johannes H Proost, Luc Marks, Jan Van Bocxlaer, Hugo 
Vereecke, Anthony R Absalom and Michel Struys  
An evaluation of using population pharmacokinetic models to estimate 
pharmacodynamic parameters for propofol and bispectral index in children. 
Anesthesiology 2011; 115 (1):83-93 
 
11. Alicia Borderé, Annelies Stockman, Barbara Boone, Ann-Sophie Franki, Marc J. Coppens, 
Hilde Lapeere and Jo Lambert  
A case of anaphylaxis caused by macrogol 3350 after injection of a corticosteroid (pages 
376Ȃ378) 
Contact Dermatitis 2012,vol 67, issue 6 
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a3) artikels in nationale tijdschriften die gebruik maken van een leescomité  
1/ G. Rolly, L Versichelen, M Coppens 
Het belang van de anesthesie voor de ontwikkeling van heelkunde in dagopname. 
The role of anesthesiology in the development of ambulatory surgery. 
Tijdschrift voor Geneeskunde 2001, 57(12):854-8 
 
2/ Verbraeken H and M Coppens  
Postoperatieve zorgen en verwikkelingen bij cataractchirurgie: de rol van de huisarts na 
de daghospitalisatie. 
Tijdschrift voor Geneeskunde 2004, 60(8): 552-8 
 
3/ Pijnbestrijding gedurende de partus 
X Schyns-van den Berg, M Coppens 
A&I,nr 2, 2010 
 
 
 
a4) artikels in tijdschriften niet begrepen in (a1), (a2) en (a3) 
 
1) ǯǣǯǯǤ 
 Inge Tency, Ellen Roets, Marc Coppens,and Marleen Temmerman 
Tijdschrift voor vroedvrouwen 2010; 16(5): 279-86  
 
 
c) artikels in Proceedings van wetenschappelijke congressen 
 
1.  Single dose intravenous tropisetron in the treatment of established postoperative nausea 
and vomiting: a double-blind, multicentre, dose-comparison study. 
M Coppens, F Christiaens, C De Pauw, M Van Boven, V Capouet, B Ickx,  
L De Ritter, V Grimaudo, F Hulstaert 
Acta Anaesthesiol. Belgica 1997, 48 (3):195 
 
2. Do we need inhaled anaesthetics to blunt arousal and haemodynamic responses to intuba-
tion after intravenous induction with propofol, remifentanul and rocuronium? 
Ndjekembo Shango D, Coppens M, Versichelen L, Mortier E, Struys M  
Acta Anaesthesiologica Belgica 2007, 58(1): 75 
 
3. Comparison of the ability of two pharmacokinetic models to maintain a predicted effect-site 
concentration of propofol compatible with loss of consciousness. 
J Van Limmen, H Vereecke, M Coppens, E Mortier, M Struys 
Acta Anaesthesiologica Belgica 2008, 59 (3): 211 
 
4. Tramadol IV: influence of dose and intervals on the therapeutic accuracy and side effects 
when used for postoperative pain relief after ambulatory surgery. 
D Devriese, B Vandervennet, L Van Praet, M Coppens, E Mortier, M Struys 
Acta Anaesthesiologica Belgica 2009, 60 (2):131 
 
5. Combined spinal epidural for labor using sufentanil epidurally versus intrathecally: influ-
ence on fetal heart rate. 
N Everaert and M Coppens 
European Journal of Anaesthesiology 2012; 29 (suppl 50):172 
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WETENSCHAPPELIJKE ACTIVITEITEN  
 
(a) studieverblijf in het buitenland van langere duur (minimum 1 maand) 
 
Queen Charlotte and Chelsea Hospital/ Londen 
Departement van Dr. J Crowhurst 
Fellowship Obstetrische anesthesie: 10/02-30/04/2003 
 
(b) door mezelf georganiseerde internationale of nationale congressen en symposia 
 
ǣǮǣ
ǫǮǤǤǤ 
Gent, 18/02/2009 
 
(c) internationale congressen en lezingen waarop een actieve bijdrage 
1. ǣǮi-
ble in clinical praǯǤ 
L Versichelen, G Rolly, M Struys, K Fonck, M Coppens. 
21st Annual Meeting of the European Academy of Anaesthesiology. 
Boedapest, 26-28/08/1999  
 
2. Ǯǯǣ 
International Winter Symposium, Update in Anesthesia, Intensive Care Medicine and 
Emergency Medicine 
Leuven 10-11/01/2003 
 
3. Ǯǣǯǯ 
Chairman session 1: Anesthesia for the Obstetric patient  
20th Ǯǡǡ
ǯ 
UZ Leuven, 6/01/2005 
 
4. Ǯǯǯ 
Voordracht sessie 2 op 22nd International Winter Symposium Update in Anesthesia, In-
tensive Care Medicine, Emergency Medicine and Algology 
Leuven, 12-13/01/2007 
 
5. Ǯǯǡ 
Ǯǯ 
Ǯǯ 
Voordrachten 4th Annual Meeting of Indonesian Society of Obstetric Anesthesia  
16-17/02/2007 
 
6.  Ǯǯǣ 
Chairman Sessie 3 op 23th International Winter Symposium Update in Anesthesia, Inten-
sive Care Medicine, Emergency Medicine and Algology 
Leuven, 11-12/01/2008 
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(d)  idem voor nationale congressen en symposia 
 
1) ǣǮSingle dose intravenous tropisetron in the treatment of established postop-
erative nausea and vomiting: a double-blind, multicentre, dose-Ǥǯ 
M Coppens, F Christiaens, C De Pauw, M Van Boven, V Capouet, B Ickx,  
L De Ritter, V Grimaudo, F Hulstaert 
Annual Meeting BVAR (Belgische Vereniging voor Anesthesie en Reanimatie) 
Louvain-La-Neuve, 30 /11/1996 
 
2) ǣǯSingle dose intravenous tropisetron in the treatment of established postopera-
tive nausea and vomiting: a double-blind, multicentre, dose-Ǥǯ 
M Coppens, F Hulstaert, C De Pauw, M Van Bever, V Capouet, B Ickx,  
L De Ritter, V Grimaudo, F Christiaens. 
ǯng BVAR  
Gent, 21/06/1997 
 
3) ǣǮǤǯ 
L Versichelen, M Coppens, L Veeckman 
Annual Meeting BSAR (Belgian Society of Anesthesia and Resuscitation) : 
Women in Anesthesia, Anesthesia  for women 
Brussel, 30/11/2002 
 
4)  Abstract ǣǮe-
dicted effect-Ǥǯ 
J Van Limmen, H Vereecke, M Coppens, E Mortier, M Struys 
Research Meeting SARB  
Sint-Lambrechts Woluwe, 14/06/2008 
 
5) Ǯǣǡt-
Ǥǯͺȋ
ȌǮǯǣ ǯ 
en Chairman sessie : Miscellaneous  
Brussel, 04/10/2008 
 
6) ǣǮǣ
ǯǤ 
D Devriese, B Vandervennet, L Van Praet, M Coppens, E Mortier, M Struys 
Research meeting SARB 
Leuven, 20/06/2009 
 
7) G-ENT Rounds georganiseerd door  dienst Neus-, Keel- en Oorheelkunde van het UZGent. 
Inleiding: Basisprincipes van het pre-operatief onderzoek.  Dr. Marc Coppens. Chirurgisch 
dagcentrum. UZ Gent, Locatie: Zaal Oude Infirmerie, Het Pand, Onderbergen 1, 9000 Gent,  
26/04/2012 
 
 
e)  lezingen aan universiteiten en wetenschappelijke instellingen 
1. Ǯǯ 
Postacademische bijscholing Anesthesie UZG 
UZGent, 20/10/1999 
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2. Ǯ
Ǥǯ
Postgraduaat heelkunde UZG  
UZGent, 8/11/1999 
 
3. ǮPre-ǯǤ  
 
4. Ǯǯǡ 
Postacademische bijscholing Anesthesie UZG  
UZGent, december 1999 
 
5. Ǯǯ 
Lokgroep Anesthesie Kortrijk 
Kortrijk, oktober 2000 
Ǯ 
6. ǮǯǤǮǯ 
Postacademische bijscholing Anesthesie  UZG  
UZGent, november 2000 
 
7. Ǯǯ 
Voordracht ter gelegenheid van cursus Allergology 
15.09.2001 
 
8. ǮBehandeling van de postoperatieve pijn in oǯ 
Voordracht voor  Academia Ophtalmologica Belgica 
23.11.2001 
 
9. Ǯǯ 
Gemeenschappelijke Staffvergadering: Verloskunde Ȃ Neonatologie Ȃ Genetica - 
Anesthesie  
January 2002 
 
10. Aspecten van bifasische ǯ 
Postacademische bijscholing Anesthesie UZG 
UZ Gent, 6/03/2002 
 
11. Ǯǯ 
LOK vergadering Neus- Keel- en Oorheelkunde 
Gent, 24/04/2002 
 
12. Ǯǯ 
Perinatale stafvergadering voor verloskunde-neonatologie-genetica-anesthesie 
UZGent, 30/09/2003 
 
13. Ǯǣǯ 
Voordracht voor LOK 0703 
Gent, 16/12/2003 
 
14. Ǯǯǣ 
Ǯǯǣ 
Vlaamse Wetenschappelijke Vereniging voor Tandheelkunde - Scientific Association of 
ǣǮǯ 
Gent, 7/02/2004 
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15. Ǯǫǯ 
Perinatale stafvergadering verloskunde-neonatologie-genetica-anesthesie  
UZGent, 24/02/2004 
 
16.  Ǯ-Ǥǯ 
Perinatale stafvergadering verloskunde-neonatologie-genetica-anesthesie 
UZGent, 11/05/2004 
 
17. Ǯǯ 
Postacademische vorming Anesthesie  
UZGent, 29/09/2004 
 
18. Wintersymposium Leuven 
Ǥǯǫǯ 
7/1/2005 
 
19. Ǯǫǯ 
Postacademische vorming Anesthesie  
UZGent, 12/01/2005 
 
20. ǫǨǯ 
Perinatale stafvergadering verloskunde-neonatologie-genetica-anesthesie  
UZGent, 25/01/2005 
 
21. ǮʹͲͲͷǯ 
voordracht voor LOK 0703  
UZGent, 18/06/2005 
 
22. Ǯǣǯ 
Postacademsiche bijscholing anesthesie 
UZGent, 22/06/2005 
 
23. ǯ 
Perinatale stafvergadering verloskunde-neonatologie-genetica-anesthesie 
UZGent, 20/09/2005 
 
24. ǣǮǯ 
ǣǮǯ 
Ǯǯ
Obstetrie en Gynaecologie 
Diegem, 14-15/10/2005 
 
25. ǮǤ 
Perinatale stafvergadering verloskunde-neonatologie-genetica-anesthesie 
UZGent, 27/12/2005 
 
26. Ǯǡǯ 
Postacademische bijscholing anesthesie  
UZGent, 22/02/2006 
 
27. Ǯ
- ǯ 
Postacademische bijscholing anesthesie UZG 
UZGent, 22/03/2006 
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28. ǮNieuwe richtlijnen in ǯ 
Voordracht voor LOK 1667 
UZGent, 30/03/2006 
 
29.  ǣǯ´ǯ 
Jaarlijks congres van de Vlaamse Vereniging van Intensieve Zorgen voor 
ǣǮǡǯ 
Gent, 24/11/2006 
 
30. VǣǮǯ 
ǣǮǯ 
Vlaamse Wetenschappelijke Vereniging voor Tandheelkunde - Scientific Association of  
ǢǣǮlicaties tijdens de  
ǯ 
Gent, 25/11/2006 
 
31. Ǯǯ 
Voordracht Bara-meeting  
Tienen, 30/11/2006 
 
32. Ǯ
ǯ 
Perinatale stafvergadering verloskunde-neonatologie-genetica-anesthesie 
UZGent, 05/12/2006 
 
33. Congres Gynaecologie De Doelen Rotterdam 
ǣǯǯ 
Rotterdam 4/2007 
 
34. ǣǮ´ǯ 
102e Reeks AvondcolloquiǮǯ 
UZGent, 23/05/2007 
 
35. Ǯǯ 
Postacademische bijscholing Anesthesie  
UZ Gent, 20/06/2007 
 
36. ǮǯǮǯ 
Moderator Journal Club Assistenten - casusbesprekingen 
Postacademische bijscholing Anesthesie  
UZGent, 05/09/2007 
 
37. ǣǮǯ 
ǣǮǯ 
VVOG ( Vlaamse Vereniging voor Obstetrie en Gynecologie), cursus Praktische 
Vaardigheden in de Verloskunde 
Zemst, 23/11/2007 
 
38. Ǯǣǯ 
Voordracht KUL: Academie voor Kindertandheelkunde 
Leuven, 29/11/2007 
 
39. Ǯǯǯ 
Voordracht Perinatale stafvergadering verloskunde-neonatologie-genetica-anesthesie 
UZGent, 11/12/2007 
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40. Ǯ-ǯ 
Voordracht op uitnodiging van The Surgical Company 
Den Haag/ NL, 24/01/08 
 
41. Ǯ ǯ 
Postacademische bijscholing Anesthesie  
UZGent, 27/02/2008 
 
42. Ǯǯ 
Voordracht LOK 0703 
UZGent, 17/06/2008 
 
43. Ǯǯ 
Postacademische bijscholing Anesthesie  UZG 
UZ Gent, 24/09/2008 
 
44. Ǯǯ 
Stafvergadering ZNA Middelheim  
Antwerpen, 26/09/2008 
 
45. Ǯǯ 
Perinatale stafvergadering verloskunde-neonatologie-genetica-anesthesie 
UZGent, 14/10/2008 
 
46. Ǯǯ 
ABC voor de tandartspraktijk (organisator prof. dr. Luc Marks) 
UZ Gent, 28/11/2008 
 
47.  Ǯ
ǯ 
Postacademische bijscholing Anesthesie  
UZ Gent, 10/12/2008 
 
48. Ǯǣǯ 
Postacademische bijscholing Anesthesie  
UZ Gent, 21/01/2009 
 
49. Ǯǯ 
Postgraduaat meeting Anesthesiologie 
UZ Brussel, 30/04/2009 
 
50. Congres BARA 
Voordracht: Bloedingen in de verloskundige anesthesie 
3/9/2009 
 
51. ǮͳͲǯ 
Postacademische bijscholing Anesthesie  
UZ Gent, 21/10/2009 
 
52. Ǯǯ 
ABC voor de tandartspraktijk (organisator prof. dr. Luc Marks) 
UZ Gent, 03/12/2009 
 
53. Wintersymposium Leuven, januari 2010 
ǣǲ 
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54. Refresher course obstetrische anesthesie BARA en NVA 
Voordracht: Pijn en pijnbestrijding tijdens normale arbeid en verlossing 
19/3/2010 
 
55. Ǯǯ 
Postacademische bijscholing Anesthesie  
UZ Gent, 28/04/10 
 
56. Ǯǯ 
Postacademische bijscholing Anesthesie  
UZ Gent, 15/09/2010ǯ 
 
57. Congres reanimatie in tandheelkunde L Marks 
2/12/2010 
voordracht Medische urgenties in de tandheelkunde 
 
58. Voorstelling van het nieuw Chirurgisch DagCentrum UZGent 
voordracht voor LOK 0703 
Gent, 7/12/2010 
 
59. Openingssymposium Chirurgisch Dagcentrum 
ǣǮǯ 
19/3/2011 
 
60. Congres vroedvrouwen Oostende 
29/3/2011 
Voordracht: Nieuwe tendensen in pijnstilling na sectio 
 
61. Refresher course obstetrische anesthesie NVA en BARA 
8/4/2011 
ǣǯǯ 
 
62. Cursus lachgassedatie Tandheelkunde: 3/5/2011 
voordracht: Biologische, chemische en fysische aspecten van lachgas 
Voordracht: Medische urgenties in de tandheelkunde 
 
63. Studieclub Tandheelkunde 
voordracht medische urgenties in de tandheelkunde 
 
64. Studieclub Tandheelkunde Kortrijk 
1/9/2011 
voordracht Medische urgenties in de Tandheelkunde 
 
65. Congres Luc Marks Reanimatie in de Tandheelkunde 
1/12/2011 
voordracht: Medische urgenties in de tandheelkunde 
 
66. Cursus Lachgassedatie in de Tandheelkunde 
ǣǮǡǯ 
ǣǯ ǯ 
8/5/2012 
 
67. Ǯǯ 
voordracht voor LOK 1667 
Gent, 31/01/2012 
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68. Ǯǣ´Ǯ 
voordracht voor LOK 0703 
UZGent, 24/09/2012  
 
69. Symposium georganiseerd door  het Allergienetwerk  
ǣǮǯ 
   25/10/2012 
 
70. Ǯǯ 
Postacademische bijscholing Anesthesie  
UZ Gent, 21/11/2012 
 
71. Congres van de Royal Belgian Society for Ear Nose Throat ǯ 
ǣǯǯ 
24/11/2012 
 
72. Cursus Vlaamse Vereniging voor Wetenschappelijke Tandheelkunde 
Voordracht: Medische urgenties in de tandheelkunde 
10/11/2012 
 
73. Cursus L Marks Tandheelkunde 
Voordracht: Medische urgenties in de tandheelkunde 
6/12/2012 
 
74. Refresher course obstetrische anesthesie. Nederlandse Vereniging voor Anesthesie en 
BARA 
ǣǯǯ 
 
75. Cursus Lachgassedatie in de Tandheelkunde 
ǣǮǡǯ 
ǣǯǯ 
23/4/2013 
 
 
 
(d) promotorschap of dagelijkse leiding van scripties en doctoraatsproefschriften  
 
Co-promotor scriptie Pauline De Bruyne, 2e 
ǡǮ
ǣǤǯ
Academiejaar 2003-2004 
 
Co-promotor Tramadolstudie studenten 2e proef Gen: B Vandervennet, L Van Praet, 
Ǯpeutische accuraatheid van perorale versus intraveneuze toediening van 
ǯǤʹͲͲ͹-2008 
 
Co-promotor Tramadolstudie van Heleen Apostel, 2e mast Gen, Academiejaar 2008 -2009 
 
Begeleider van Nele Everaert voor de Z-lijn Masterproef 1 Ȃ 1ste 
ǤǡǮ
foetale bradycardie tijdens locoregionale analgesie voor bevalling: sufentanil epiduraal 
ǤǯʹͲͳͲȂ 2011 
 
Co-Ǯl: impact op epidurale anesthesie  
Van den Daele Daphne, Academiejaar 2011-2012 
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Dienstverlening  
 
Wetenschappelijke en maatschappelijke dienstverlening, adviesverlening, lidmaatschap 
wetenschappelijke commissies, editoraat wetenschappelijke tijdschriften, lidmaatschap  
beroepsorganisaties e.d. 
 
Vertegenwoordiger Stuurgroep Reanimatie UZGent vanaf 1/8/2007 
 
Werkgroep Reanimatie UZGent, lesgever ALS voor verpleegkundigen 
 
Afgevaardigde Anesthesie in de Werkgroep P3 P4, sector Man-Vrouw-Kind 2008 
 
Lid van BARA Board (Belgian Association for Regional Anesthesia), 8 oktober 2005 
 
Lid van de BVAR (Belgische Vereniging voor anesthesie en reanimatie) 
 
Lid van The European Society of Regional Anaesthesia (ESRA) 
 
Lid van the Obstetric Anaesthetists Association (OAA), UK 
 
Verslaggever LOK 1667: sinds 2005 
 
Lid Kernteam Anesthesie 
 
Lid Kernteam Chirurgisch Dagcentrum 
 
Reviewer British Journal of Anaesthesia 
 
Reviewer Acta Anaesthesiologica Belgica 
 
Lid Werkgroep Pediatrie CDZ
 
Lid Multidisciplinaire werkgroep van het project Acute Pijn bij Kinderen 
 
Lid Commissie Heelkunde 
 
Lid Werkgroep CDZ 
 
 
MEDEWERKING AAN STUDIES  
- Co-investigator bij de klinische studie: 
ǲm-
iting following gynaecological surgery: a double blind, multicentre, dose-comparison 
Ǥǳ 
V Capouet, C De Pauw, B Vernet, D Ivens, V Derijcke, L Versichelen, H Van Aken,  
B Ickx, L Ritter, F Hulstaert.
Acknowledgements to G Rolly, M Coppens etc. (BJA 1996; 76: 54-60) 
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- Co-Investigator in multicentre study: USB 31-ʹͲǣǲǡ-blind, compara-
tive study to investigate the safety and efficacy of Ultiva versus Fentanyl for patients un-
Ǥǳ 
A Moerman, M Coppens juni-december 1997. 
 
- Co-investigator klinische studie: 
ǲu-
sea and vomiting: a double blind, multicentre, dose-Ǥǳ 
E. Alon, E. Buchser, E. Herrera, F. Christiaens, C. De Pauw, L. De Ritter,  
F. Hulstaert, V. Grimaudo. (Anesthesia Analgesia 1998 ; 86 :617-23) 
 
- Co-investigator multi-centre, randomised, double blind, double dummy, placebo con-
trolled, parallel group, phase II study to evaluate the safety, efficacy and pharmacokinet-
ics of oral  (25 mg) and intravenous (3 mg and 18 mg) formulations of the neurokinin-1 
receptor antagonist, GW597599, when administered with intravenous ondansetron hy-
drochloride for the prevention of post-operative nausea and vomiting and post-
discharge nausea and vomiting in female subject with known risk factors for PONV who 
are undergoing surgical procedures associated with an increased emetogenic risk. Pro-
ject 2004/370, 2005 
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